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ABBREVIATIONS 
ACC  anterior cingulate cortex 
AMY  amygdala 
ASL  arterial spin labelling 
BET  brain extraction tool 
BOLD  blood oxygenation level dependent 
BS  brain stem 
CASL  continuous arterial spin labeling 
CBF  cerebral blood flow 
CEPH  Caucasian European, genetic HapMap population 
CES-D Center for Epidemiological Studies Depression Scale 
CEU  Caucasian European, genetic HapMap population 
CHB  Han Chinese Beijing, genetic HapMap population 
CNS  central nervous system 
CRPS  chronic regional pain syndrome 
CTA  cortical thickness analysis 
DFNS  German Research Network on Neuropathic Pain 
DNA   Deoxyribonucleic acid 
EEG  electroencephalography 
FDR   false discovery rate 
fMRI  functional magnetic resonance imaging 
FMS  fibromyalgia syndrome 
FSL  FMRIB's Software Library 
GM(D) grey matter (decreases) 
GSEA  Gene Set Enrichment Analysis 
GWA(S)  genome wide association (study) 
HapMap Haplotype Map; catalogue of common genetic variants in humans 
HIP  hippocampus 
ICC  intra-class correlation 
IMMPACT  Initiative on Methods, Measurement, and Pain Assessment in  
  Clinical Trials 
INS  insula  
KEGG Kyoto Encyclopedia of Genes and Genomes 
LES  leading edge subset, genes before the enrichment score in GSEA  
MBP   mu-opioid binding potential 
MNI   Montreal Neurological Institute 
MRC   Medical Research Council 
MRI  magnetic resonance imaging 
NICE  National Institute for Clinical Excellence 
NSAID non-steroidal anti-inflammatory drug 
OPRM 1 Mu-opioid receptor 1 
PAG  periaqueductal grey 
pCASL pseudo continuous arterial spin labeling  
rCBF  resting cerebral blood flow 
PAG  periaqueductal grey (substantia grisea centralis) 
PCC  posterior cingulate cortex 
PET  positron emission tomography 
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ROI  region of interest 
S1  somatosensory cortex I 
S2  somatosensory cortex II 
SCL-90-R  Revised Symptom Checklist 90 
SMA   supplementary motor area 
SNP   single nucleotide polymorphism  
STAQ  State-Trait Anxiety Questionnaire  
THA  thalamus 
TME  third molar extraction 
ULBP  unspecific low back pain 
VAS  visual analogue scale 
VBM  voxel-based-morphometry
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1 INTRODUCTION 
The aim and purpose of this thesis was to assess the combination of genetic 
and neuroimaging techniques and to evaluate their utility in the exploration of 
mechanisms underlying pain resulting from tissue and nervous system injury. This 
thesis adhered to the recommendations for implementing clinical trials from a 
mechanism-based perspective (Woolf & Max, 2001) in designing the two studies 
which served as the foundation for the four manuscripts comprised in this thesis.  
 
This thesis investigated three patient cohorts, i.e. dental patients with recurrent 
pericoronitis in need of third molar extraction (TME) and patients diagnosed with 
either fibromyalgia syndrome (FMS) or unspecific low back pain (ULBP) in a 
combined analysis. The first study of this thesis, which utilized TME as a model for 
tissue injury pain, included a micro-array gene expression analysis of ribonucleic acid 
(RNA) extracted from samples of peripheral whole blood taken pre and post surgery 
in combination with pre- and post-surgical functional magnetic resonance imaging 
(MRI) assessments of cerebral blood flow (CBF).  
 
The second study analysed the effect of a common single nucleotide polymorphism 
(SNP) from the mu-opioid receptor 1 ((OPRM1), rs1799971) on grey matter (GM) 
density in response to FMS and ULBP as a model of nervous system injury pain by 
means of voxel-based morphometry (VBM).    
 
This thesis will first present an overview of the general topic by providing an 
introduction to the rationale behind and advances in research towards a mechanism-
based classification of pain with special regard to the concept of biological markers. It 
will introduce essential concepts and technologies in neuroimaging and genetics 
research and the use of TME as a suitable model of post-surgical pain to provide a 
framework within which the studies conducted for this thesis can be integrated. This 
will be followed by the four manuscripts and a summary of the findings and a final 
discussion of the results.  
 
1.1 Pain Mechanisms 
The Austrian philosopher Ludwig Wittgenstein (2003) proposed a famous 
thought experiment:  
Suppose everyone had a box and inside the box was something we call 
―beetle‖. Nobody can peek into the box of another; and everybody 
claimed to know what a beetle was, from looking at their beetle. Thus it 
could be that everyone has something completely different in their box. 
One could imagine that such a thing changes constantly. But if the word 
―beetle‖ had a use? It would not be the meaning of the thing. 
(Wittgenstein, 2003) (§ 293.) 
 
While Wittgenstein‘s thought experiment can be applied to all cognitive phenomena, 
it has special resonance with reference to pain and its treatment. It highlights the 
inter-individual variability and subjective nature of the experience of pain and 
summarises the key problem for anyone involved in researching or treating it. 
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Pain is a highly subjective and complex sensation and emotion. The International 
Association for the Study of Pain defines it as a bio-psycho-social construct, ―an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage‖ (Mersky & Bogduk, 1994). 
 
The complexity of pain manifests in the variability encountered in several aspects of 
pain and its measurement. In experimental settings the noxious stimuli are clearly 
defined and applied in different modalities such as pressure (Nussbaum & Downes, 
1998), heat (Rosier, Iadarola, & Coghill, 2002; Yarnitsky, Sprecher, Zaslansky, & 
Hemli, 1995), cold (Chen, Dworkin, Haug, & Gehrig, 1989) and ischemic pain 
(Rainville, Feine, Bushnell, & Duncan, 1992), allowing for standardised measurement 
of the effects on the research participant.  
 
However, more pressing problems arise in the clinical context, where the origin of the 
pain experience is often unclear, pain may have turned chronic, the need to resolve it 
is great and judgements regarding the nature of a patient‘s pain experience for 
correct diagnosis and initiation of appropriate treatment or recommendations in 
disability and compensation claims are demanded.   
 
There is a recognized need to open the lid and take snapshots of the contents of 
Wittgenstein‘s proposed boxes (Chapman et al., 1985) that can be shared among 
clinicians and researchers as to independently arrive at the same classification of the 
individual content across medical specialties.  
 
The beetle in the box problem in pain is most strikingly illustrated by problems in 
functional pain diagnoses such as fibromyalgia and irritable bowel syndrome 
(Nimnuan, Rabe-Hesketh, Wessely, & Hotopf, 2001), which do not feature tissue 
trauma or noxious stimuli. Oftentimes the differential diagnosis relies on the 
topography of the pain phenotype in question and the medical specialty consulted 
and not on the actual pathology (Woda et al., 2005). Current descriptors of categories 
of chronic pain such as chronic vs. acute, benign vs. malign or the body part in which 
the pain occurs have limited utility in determining the real nature of the ―beetle‖ inside 
the box. These shortcomings of current classification systems in pain have stimulated 
efforts in the late 1990s and early 2000s to move towards a mechanism-based 
approach in diagnostics and treatment (Woolf et al., 1998; Woolf & Max, 2001).  
 
The search for mechanisms has special relevance with regard to the 
development of pharmaceutical interventions in pain. The developmental process of 
most pain medications in use today has followed a purely phenomenological 
approach (Bunge, 1963), in which the medication served as an input into a black box 
and pain relief was the output achieved by medications that were then successfully 
released onto the market. It has been argued that due to this approach most new 
analgesics are merely derivatives of already established drug classes such as 
nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics (Max & 
Stewart, 2008b). Mechanism-oriented research could mean a move away from 
serendipitous findings and off label prescription of drugs approved for other 
disorders, such as anti-depressant use in chronic pain (Fishbain, 2000; Jung, Staiger, 
& Sullivan, 1997). 
 
Only recently has the lid been lifted off the box containing the mechanisms of 
NSAIDs, which have been released long prior to the discovery of their mechanisms 
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(Sneader, 1997). The discovery of the inhibitory effects of cyclooxygenase-2 (COX-2) 
on pro-inflammatory mediators (Moncada, Ferreira, & Vane, 1975; Vane, 1971; Xie, 
Chipman, Robertson, Erikson, & Simmons, 1991) has enabled the development of a 
more specific type of NSAIDs, COX-2 inhibitors. However, there are still further 
unidentified contents in this box, which became apparent when the COX-2 inhibitor 
Rofecoxib was taken off the market in 2004 (Kearney et al., 2006), after findings of 
unwanted cardio-vascular complications in patients on this medication (Yu et al., 
2012). 
 
The mechanism-based approach also aims to increase reliability in diagnoses by 
using only truly functional criteria in combination with a distinct set of inclusion and 
exclusion criteria to deal with nosologic overlap between disorders. This problem 
surfaces as phenotypic heterogeneity, an issue which will be explored in more detail 
in the genetics section, as this is one of the major challenges in genetic association 
studies. To this end, the mechanism-based approach as defined by Woolf et al. 
(2000) proposes four distinct levels at which the pain experience can be 
characterised. It sets out with a disease, injury or diathesis, which affects different 
mechanisms. These mechanisms then determine the observable symptoms and 
several symptoms can then be clustered together to signify different syndromes. 
Treatment is applied at the mechanism level, while improvement or exacerbation can 
be measured at the symptom level (Woolf, 2004). 
 
As a phenomenon that is determined by social, psychological and biological 
processes, pain requires a wide array of measurements at the symptom level in order 
to encompass all relevant facets. This is reflected by efforts to establish standardised 
assessment batteries by different research consortia such as German Research 
Network on Neuropathic Pain (DFNS) (Rolke, Baron, et al., 2006a; Rolke, Magerl, et 
al., 2006) or the Initiative on Methods, Measurement, and Pain Assessment in 
Clinical Trials (IMMPACT) (Dworkin et al., 2005; Turk et al., 2003). The latter, for 
example, recommends six core outcome domains consisting of (1) pain; (2) physical 
functioning; (3) emotional functioning; (4) participant ratings of improvement and 
satisfaction with treatment; (5) symptoms and adverse events; and (6) participant 
disposition. 
 
These outcome domains mainly focus on physical/functional and psychological 
aspects of pain by making use of psychometric and psychophysical tools, which 
include numeric or visual analogue rating scales (Dworkin et al., 2005; Jensen, 
Karoly, & Braver, 1986; Price, Bush, Long, & Harkins, 1994; Victor et al., 2008) and 
questionnaires such as the McGill Pain Inventory (Melzack, 1975; Melzack, 2005), 
diagnostic questionnaires for specific disorders such as temporomandibular joint and 
other disorders (Diatchenko et al., 2005; Gonzalez et al., 2011). Other pain-
associated psycho-social and psychological constructs such as depression (Beck, 
Steer, & Carbin, 1988; Weissman, Sholomskas, Pottenger, Prusoff, & Locke, 1977), 
fear of movement or pain (McCracken, Zayfert, & Gross, 1992; Mcneil, 1998), 
catastrophising and coping (Flor, Behle, & Birbaumer, 1993; Jacobsen & Butler, 
1996; Sullivan, Bishop, & Pivik, 1995) and/or impact of pain on the quality of life such 
as the SF-36 (McHorney, Ware, & Raczek, 1993; Ware & Sherbourne, 1992) are 
often measured as well. 
 
If we are to gain insight into patients‘ Wittgensteinian boxes and with an eye towards 
patient benefit in clinical trials, these outcome measures are essential in the context 
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of clinical endpoints, which will be defined in more detail in the following chapter. 
However, they have to be complemented by biological markers such as neural 
correlates, psychophysical parameters and molecular endpoints (e.g. genetic variants 
and gene expression levels), if the aim is a comprehensive search for pain 
mechanisms. 
 
Examples of psychophysiological measures include measurements of pain 
thresholds and tolerance for different pain modalities such as pressure pain (Ohrbach 
& Gale, 1989a, 1989b), heat pain (Yarnitsky et al., 1995) and the use of 
comprehensive quantitative sensory testing batteries (Hansson, Backonja, & 
Bouhassira, 2007; Juhl, Jensen, Norholt, & Svensson, 2008; Rolke, Baron, et al., 
2006b; Rolke, Magerl, et al., 2006). 
 
The genomic revolution has also opened up new technologies in the quest for 
biomarkers (Klapa & Quackenbush, 2003), which allow for a thorough search for 
pain-related genes and their effect on pain, nociception and the effects of analgesics 
(J S Mogil, Yu, & Basbaum, 2000; Jeffrey S. Mogil, 2009). In addition, neuroimaging 
techniques such as positron emission tomography (PET) (Di Piero et al., 1991; 
Jääskeläinen et al., 2001; Jones, Watabe, Cunningham, & Jones, 2004; Willoch et 
al., 2004b), MRI (Borsook, Moulton, Schmidt, & Becerra, 2007; Davis, Kwan, 
Crawley, & Mikulis, 1998; Davis & Moayedi, 2013; Flor, Braun, Elbert, & Birbaumer, 
1997; Owen, Bureau, Thomas, Prato, & Lawrence, 2008) or electroencephalographic 
(EEG) studies (Malver et al., 2014; Prichep, John, Howard, Merkin, & Hiesiger, 2011; 
Schulz, Zherdin, Tiemann, Plant, & Ploner, 2012) promise great potential with regard 
to identifying neural correlates of pain and the mechanisms by which they are 
regulated. The aim of this study was to determine the utility of specific genetic and 
MRI markers in search of pain mechanisms.  
 
Positive aspects of the new perspective opened by a mechanism-based approach 
are that it will potentially lead to the development of drugs that target distinct 
mechanisms, inform new guidelines for experimental design in clinical research, and 
deliver more reliable and valid diagnostic tools for clinical investigation and treatment 
through selecting treatments that interact with specific mechanisms. 
 
While all of these aspects are desirable, the identification of pain-mechanisms and 
subsequent development of mechanism-based treatments faces several challenges: 
first, pain patients‘ suffering may arise from a mix of mechanisms, which may act in 
parallel or even interact. In addition, they are often diagnosed with co-morbidities, 
adding further confounding factors (Buse, Manack, Serrano, Turkel, & Lipton, 2010) 
likely to obscure potential findings in the search for pain-specific mechanisms. This 
issue greatly affects the search for pain genes and will be explored in more detail in 
the genetics chapter, where the concept of polygenicity and a distinction between 
disease and pain susceptibility genes will be elucidated. 
 
However, once identified and met by a suitable intervention, application of this 
intervention would bring relief to sufferers across different disorders in which that 
same mechanism is at work. The ability to identify the contribution of any one 
mechanism might enable the reduction of the number of contributors in multi-
mechanism pain scenarios and thus aid the discovery of further underlying 
mechanisms. 
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The disentanglement of different pain mechanisms is most likely to be achieved if 
sound quality criteria are rigorously incorporated into studies in search of pain 
mechanisms. These criteria include reliability, which means that the patient can be 
sure that the disorder and its underlying mechanisms are given the same diagnosis 
by different clinicians. Further quality criteria also include first generalizability, where 
the same mechanism is recognized for the same diagnosis in mild as well as severe 
forms and second comprehensiveness, which allows for every necessary diagnosis 
to be included in a classification system. The last quality criterion is validity, which is 
defined as the degree of achieving the objective of a study (Büttner, 1997) and 
pertains to the ability with which a diagnostic measure can answer a medical 
question. Usually this is achieved by employing a gold standard model of a disorder. 
However, since many of the mechanisms underlying pain are yet unknown, 
alternatives to a gold standard model can be found in studies of biological markers, 
history and treatment response and symptom clusters. 
 
 
1.2 Biomarkers, Clinical Endpoints and Surrogate Markers 
This section will describe different concepts of biomarker research and their 
associated strengths and limitations in general and in the context of pain. For this 
purpose this chapter will start with definitions and move on to biomarker 
classifications and the associated advantages and caveats. 
 
Definitions 
 
The term biomarker is a commonly used contraction for a biological marker. 
The biomarker concept is usually discussed in association with two other concepts: 
the clinical endpoint and surrogate endpoint.  
 
Atkinson et al. (2001) defined a biomarker as ―a characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention.‖ This definition 
has also been adopted by the National Institute of Health Biomarkers Definitions 
Working Group and represents the narrowest definition of the concept (Lesko & 
Atkinson, 2001). 
 
A clinical endpoint fulfils the same requirements as a biomarker with regard to 
objectivity and quantifiability of biological processes, but it also takes into account, 
how a participant in a clinical trial feels, functions or survives (Lesko & Atkinson, 
2001). It is thus more comprehensive, because in addition to biological and 
physiological features it also refers to psycho-social characteristics of a given 
disorder. The aforementioned IMMPACT criteria are an example of such clinical 
endpoints. It follows, that research using clinical endpoints is more likely to yield the 
most reliable results in search of pain mechanisms. Ideally biomarkers and/or 
surrogate markers should be derived from the study of clinical endpoints. However, 
acquiring extensive data sets with detailed clinical endpoints in large clinical trials is 
expensive and time consuming. 
 
The surrogate endpoint represents a compromise between a clinical endpoint and a 
biomarker. It is defined as a biomarker, which is used as an outcome in a clinical trial 
with the intent to serve as a substitute for a clinically meaningful endpoint. The 
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purpose here is to predict the effect of a therapeutic intervention (Lesko & Atkinson, 
2001).  
 
This is justified, if a biomarker consistently and accurately predicts a clinical outcome. 
It can thus be used as a stand-in for a clinical endpoint, which has several 
advantages associated with it. For example, a surrogate endpoint may occur more 
frequently than a bona fide clinical endpoint such as survival or total remission. 
Hence, the use of a surrogate endpoint allows for smaller sample sizes, more 
efficient studies and interim analyses, while a larger dataset is being acquired (e.g. 
within the framework of a longitudinal, cross-generational study) (Aronson, 2005).  
 
Biomarker classification 
 
Further differentiation between three types of biomarkers has been suggested 
(Frank & Hargreaves, 2003). Here biomarkers can range from type zero to type two. 
Within this classification, type 0 biomarkers are defined as measures of the natural 
history of disease (i.e. symptoms, which manifest over the full range of disease 
states), which also correlate longitudinally with clinical symptoms or indices. Type I 
biomarkers determine the biological effect of a therapeutic intervention with regard to 
the mechanism of action. However, the exact nature of the mechanism‘s association 
with clinical outcomes may not be known. Type II biomarkers are defined in 
differentiation from clinical endpoints. They are considered surrogate endpoints, 
because a change in a type II biomarker predicts clinical benefit.  
 
Advantages and caveats 
 
There are several advantages, but also caveats to the use of biomarkers. The 
promise of biomarkers is, that they achieve a reduction in complexity and enable an 
intervention at the mechanism level, even before the actual pathology mechanism is 
fully understood. Thus, the biomarker concept is considered to be most useful in the 
early phases of drug development, where measurement of clinical endpoints may be 
too time-consuming, cost-intensive or difficult.  
 
Biomarkers offer an economical alternative to a full clinical trial with regard to proof of 
concept or dose-ranging information in the early stages of drug and intervention 
development (Frank & Hargreaves, 2003) by reducing ever increasing opportunity 
costs (DiMasi, Hansen, & Grabowski, 2003). This reduction may free funds for the 
development of so called orphan drugs and other interventions for rare disorders of 
low interest for the private sector from a commercial perspective (Stevens et al., 
2011).  
 
At the point of care, biomarkers can help reduce the cost for diagnostic assessment 
for example by monitoring them in blood from routine blood screens and thus help 
patients forego more hazardous medical examinations such as exposure to ionizing 
radiation as part of some imaging techniques (Huckins et al., 2013).  
 
Biomarkers also serve as a screening tool for primary prevention and pre-
symptomatic treatment. An example of this is a germline mutation in BRCA1, which 
predicts an 83% cumulative risk of onset of breast cancer by the age of 70 and 
subsequent ovarian cancer in its female carriers (Ford, Easton, Bishop, Narod, & 
Goldgar, 1994). Biomarkers can also be used in the evaluation of drugs and other 
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therapeutic interventions. If appropriately validated biomarkers demonstrate them to 
be effective, they can be tested more extensively in a standard clinical trial 
procedure. In pain research one such example is the melanocortin-1 receptor, which 
was first validated as a pain-relevant genetic locus in mice (Mogil et al., 2003).  
  
Caveats of the biomarker approach stem from two sources. One is inherent in the 
approach itself: the reduction of complexity of the biomarker concept is its greatest 
advantage, but at the same time its greatest limitation. It potentially bears risks of 
producing false negative and false positive results in comparison to using 
conventional clinical endpoints.  
 
Another caveat is found in potential legal issues regarding intellectual property in 
collaborative efforts between industry and academia with regard to patenting and 
licensing, where royalties for use of patented biomarkers or biomarker identification 
procedures may be due. This may hamper or drive up the cost of biomarker research 
and development of drugs or interventions (Esmond, 2001; Stevens et al., 2011).  
 
A further caveat is a potential discrepancy between changes in biomarkers or 
surrogate endpoints and the true clinical outcome, where either false positive or false 
negative findings are possible challenges.  
 
In case of a false positive result the biomarker or surrogate endpoint does not 
necessarily predict useful clinical outcomes with regard to wellbeing or functioning of 
a patient or group of patients. There may be a positive association between the 
biomarker and the intervention, but it may fail to translate into a clinical benefit. As 
previously mentioned, the melanocortin-1 receptor was identified as a relevant 
biomarker for the efficacy of kappa-opiodergic analgesics in rodents and 
demonstrated similar effects in humans. Tachykinin NK1 receptor antagonists, which 
demonstrated inhibition of pain behaviour in rodents, however, have failed to 
demonstrate inhibitory effects on pain transmission in human (Hill, 2000). 
 
Two strategies have proven useful in controlling for these scenarios: First, biomarker 
research would ideally be designed to simultaneously measure both surrogate 
outcomes and true clinical endpoints or derive biomarkers from the study of clinical 
endpoints in demonstrating that a treatment was effective at achieving its aim and 
purpose. However, this would eliminate the time- and cost-effectiveness advantage 
of the biomarker approach.  
 
Another method for controlling for false positive and false negative results is for 
research involving biomarkers or surrogate endpoints to incorporate panels of 
biomarkers that can reflect more adequately the full spectrum of relevant potential 
therapeutic and/or harmful effects. A panel of biomarkers can increase the 
effectiveness of prediction of pathology and inform treatment allocation. One such 
example is found in the evaluation of a panel of demographic, blood serum and 
electrocardiographic biomarkers, which was evaluated with regard to chest pain as 
an indicator of an impending major adverse cardiac event (Than et al., 2011). This 
biomarker panel served to prioritise patients with regard to and correctly identify 
patients suitable for timely discharge and those who require more extensive 
treatment to prevent serious health problems.  
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The purpose of this thesis was an evaluation of a combination of genetic and 
neuroimaging biomarkers with regard to their potential to increase the probability of 
uncovering mechanisms relevant to pain and nociception. The following sections will 
provide an overview of the genetic and neuroimaging techniques and technologies 
used to provide a framework for the actual studies included in this thesis.  
 
1.3 Pain Genetics 
Overall, medical research has embraced the concept of genes as biomarkers and 
genetic methodologies and has eagerly incorporated them into their investigative 
efforts. In cancer research for example; more than 3,000 microarray studies alone 
were published in this field in 2003 (Brentani et al., 2005). Compared to cancer 
however, genetic methodologies in pain research slowly increased in the early 2000s 
(Bradshaw, Nakamura, & Chapman, 2005).  
 
One reason for this might be the late discovery of genetic contributions to pain, which 
can be attributed to several factors: First, to this day pain is often viewed in terms of 
an accompanying symptom in the context of other disorders and health problems 
such as breakthrough pain in cancer patients (Portenoy & Hagen, 1990) or pain 
resulting from surgery (Visser, 2006). In some painful disorders such as arthritis (The 
Wellcome Trust Case Control Consortium, 2007) and headaches (Allegra et al., 
2009; Gervil, Ulrich, Kyvik, Olesen, & Russell, 1999; Larsson, Bille, & Pedersen, 
1995; Spector, Cicuttini, Baker, Loughlin, & Hart, 1996), somatic aspects such as 
inflammation or vascularisation take the foreground.  
 
Second, in spite of familial clustering of some pain disorders, the pain response was 
generally not viewed in terms of a heritable trait until Devor and Raber first 
demonstrated a substantial genetic contribution to pain-related autonomy behaviours 
in a neuropathic mouse model of pain in 1990 (Devor & Raber, 1990).  
 
In addition to extensive animal research, in which heritability of pain phenotypes was 
established in different strains of rodents (LaCroix-Fralish, Ledoux, & Mogil, 2007; 
Mogil et al., 1999; Jeffrey S Mogil, 2009), studies of pain in families (Turk, Flor, & 
Rudy, 1987) demonstrated the involvement of genetic factors in addition to 
environmental conditions. Twin studies in the 1990s further supported the notion of a 
genetic component in several painful clinical disorders and response to experimental 
pain stimuli (Norbury, MacGregor, Urwin, Spector, & McMahon, 2007) in humans. 
Heritability of 50% and more has been reported for various pain phenotypes such as 
back pain (Bengtsson & Thorson, 1991), dysmenorrhoea (Treloar, Martin, & Heath, 
1998) and irritable bowel syndrome (Morris-Yates, Talley, Boyce, Nandurkar, & 
Andrews, 1998). But there was also evidence against genetic influences in some 
types of pain. An experimental twin study of pressure pain even arrived at the 
conclusion that environmental factors outweighed genetic factors (MacGregor, 
Griffiths, Baker, & Spector, 1997). 
 
Devor was also the first to coin a definition for what constitutes a pain gene (Devor, 
2010) (p.229): ―A pain gene is a gene for which there are one or more polymorphisms 
(i.e. variations in the sequence of DNA base-pairs) that affect the expression or the 
functioning of its protein product in a way that affects pain response.‖ This pain gene 
definition signifies a hypothesis-driven approach regarding the specific manifestation 
of a gene as a phenotype. This is appropriate for obvious targets such as genes 
Introduction 
 
9 
involved in central and peripheral nervous signal transduction and receptors for pain 
peptides. 
 
However, due to the close association between diseases and pain, Devor further 
distinguished between ―disease susceptibility genes‖ and ―pain susceptibility genes‖ 
in addition to ―pain genes‖. Associations with disease susceptibility genes would 
enable a more accurate estimation of epidemiological risks to develop clinically 
relevant pain for their carriers. However, these genes might not be informative 
regarding the pain itself. According to Devor, a scenario in which three different 
disorders produce the same type of neuropathic pain (wearing constricting footwear, 
pressure from tumour tissue extension, and disc herniation) (Devor, 2010) is 
possible. Among geneticists this problem is known as locus heterogeneity (Gulcher, 
Kong, & Stefansson, 2001), which means that risk variants of different genes can 
cause the same phenotype, in this case neuropathic pain.  
 
The field of genetics as such has made enormous progress and has taken less than 
100 years from the introduction of the term ―genetics‖ by William Bateson in 1905 
(Harper, 2005) to describe general principles of heritability to the publication of the 
sequence of the entire human genome in 2001 (Venter et al., 2001). Today the term 
genotype refers to the genetic constitution of an organism, which is stored internally 
as deoxyribonucleic acid (DNA), a molecule that contains an organism‘s genetic code 
and determines the hereditary potentials and limitations of that organism (Malats & 
Calafell, 2003). 
 
Complementary to the concept of the genotype, the term phenotype was first 
introduced by Wilhelm Johannsen in 1909 to describe the manifestation of the 
genotype (Churchill, 1974). More precisely, the phenotype is defined as an individual 
characteristic or a composite of an organism‘s observable characteristics or traits.  
 
Research on the association between pain genes and pain phenotypes can be 
performed on different levels. The simplest distinction is made between structural and 
functional genetic studies, and has implications with regard to the tissues and 
substrates to be investigated. Structural studies are concerned with the DNA 
sequence and its potential variations. Functional studies investigate the dynamic 
translational processes that occur en route from genotype to phenotype. These 
studies involve differences in gene expression levels dependent on various factors 
such as genotype, epigenetic changes in DNA (Holliday, 2006) or events that trigger 
transcription changes.  
 
Genetic material for such analyses can be gained from different sources and 
acqusition varies with regard to invasiveness of the sampling material and method. 
The least intrusive method is the use of saliva or buccal swab samples. A better yield 
of DNA and RNA is usually gained from blood samples, which require venepuncture, 
which was the sampling method employed for this thesis. RNA extracted from biopsy 
samples from oral mucosa have been used in previous studies to investigate gene 
expression changes in response to oral surgery and/or administration of Rofecoxib 
(Wang et al., 2007; Warburton et al., 2005). The disadvantage here is that the tissue 
will be (re-)traumatised, if the biopsy is taken post surgery, causing the participant 
discomfort in addition to the initial surgery.  
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Once heritability was established for pain phenotypes and samples are acquired, the 
next step is to identify the actual genes responsible.  
 
There are two main modes of inheritance, which inform the choice of experimental 
designs. Some pain-related genes cause rare Mendelian disorders, which follow 
inheritance patterns first described by Gregor Mendel (Mendel, 1866). The key 
features of Mendelian traits are that they are determined by just one gene and that 
the trait occurs in all carriers of that particular gene. This is referred to as complete 
penetrance. If a particular gene or a specific mutation therein, is solely responsible 
for a disorder, this disorder is classified as a ―monogenic disorder‖. Examples include 
certain congenital insensitivities to pain (Auer-Grumbach, 2008; Lafreniere et al., 
2004; Oertel & Lötsch, 2008), which are prime examples for Devor‘s pain gene 
concept. 
 
The other mode of inheritance is a polygenic pattern, where several genes and 
possible mutations therein contribute to a specific phenotype. These genes are 
referred to as quantitative trait loci (QTL) (Plomin & Crabbe, 2000). 
 
In contrast to monogenic disorders, the QTL perspective postulates that phenotypes 
follow a normal distribution due to their polygenic origin, where several genes each 
make smaller contributions to a phenotype. Other than in a Mendelian one gene one 
disorder scenario, where a disorder is either present or absent, this mode of 
inheritance enables a focus on both ends of the distribution. Genes contribute to 
normal variation, but contributions to the extreme ends of the distribution, make them 
either factors for illness, disability or vulnerability or factors for health, ability and 
resilience.  
 
In DNA analyses QTLs are best detected in case-control studies of unrelated 
individuals (Risch & Merikangas, 1996). They compare cases, i.e. patients with 
specific pain phenotypes, to matched healthy control participants. This approach has 
been used to identify risk genes in chronic pain phenotypes such as fibromyalgia, 
irritable bowel syndrome, migraine and rheumatoid arthritis (Sikander et al., 2010; S. 
Smith & Maixner, 2012; Vargas-Alarcón et al., 2009; Yu, Huang, Wu, Wu, & Tsai, 
2004). In functional analyses differential expression would be expected between 
pain-free and painful states. However, there are some pitfalls to be avoided when 
selecting populations and phenotypes.   
 
1.4 Pain Phenotypes 
The phenotype is the description of the outward appearance of the contents of the 
Wittgensteinian boxes. The more detailed the description, the better the chances of 
identifying boxes with similar or identical contents and for discovering the 
mechanisms by which these contents operate.  
 
The concepts of the phenotype and clinical endpoints greatly overlap, as they both 
measure an organism‘s characteristics. However, the phenotype definition is less 
focused on processes than the definition of the clinical endpoint. It is often a set of 
relatively static characteristics such as duration of painful episodes or their frequency, 
age of onset and common qualitative pain descriptors (e.g. searing, burning, etc.). A 
phenotype can pertain to the features or symptoms of a syndrome in clinical studies 
of a specific disorder, but can also include response to an intervention in a treatment 
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study, e.g. when looking at responders vs. non-responders to various drugs. And 
although phenotyping and measurement of clinical outcomes are usually the most 
cost- and labour-intensive aspects of any study, they are also the most crucial for the 
success of clinical trials and genetic association studies. Measurement errors 
diminish overall statistical power and can prevent the detection of true associations in 
addition to wasting funds.  
   
Characterisation of a phenotype should be as exhaustive as possible, in order to 
allow for analysis of potential mediating factors that are not rooted in the genetic 
make up of an individual (e.g. previous injuries and tissue trauma in CRPS patients 
for correct allocation to patient groups).  
 
Another option is the use of so called endophenotypes. Endophenotypes are 
hereditary characteristics that are associated with some condition, but are not a direct 
symptom of that condition. Endophenotypes are specific variants of a biomarker in 
genetic epidemiology and represent intermediate phenotypes not as readily 
observable as the symptoms of a disorder (e.g. cerebral blood flow changes). Similar 
to the biomarker, the use of an endophenotype reduces complexity at the syndrome 
level and thus increases power to detect associated genes (Gottesman & Gould, 
2003). Genetic association studies have been conducted in post-surgical pain (Kim & 
Lee, 2009; Kim, Lee, Rowan, Brahim, & Dionne, 2006), CRPS (Huehne et al., 2010), 
Fibromyalgia (Solak et al., 2014; Vargas-Alarcón et al., 2007) and other pain 
disorders.  
 
In addition, complex pain syndromes harbour potential risk of missing suitable 
genetic targets in search of mechanisms due to other confounding factors: Pain is 
usually experienced as a symptom of various diseases and disorders, thus making it 
difficult to identify pain genes as defined by Devor. The difficulty lies in distinguishing 
genes associated with a disease from those specific to the pain experience.  
 
In order to break down the level of phenotype complexity, another strategy is to 
employ standardised, evoked painful stimuli and compare patients or participants and 
their responses by genotype. For example, associations between pain phenotypes 
such as pressure sensitivity, thermal, ischemic, and mechanical stimuli with SNPs 
from the Catechol-O-methyl transferase (COMT) and OPRM1 genes (Diatchenko et 
al., 2006; Roger B Fillingim et al., 2005) have been reported. In some cases 
quantitative sensory (QST) assessments such as laser evoked potentials allow 
identification of subpopulations within patients with the same diagnosis (i.e. 
peripheral and central neuropathic pain (Cruccu et al., 2004)) and thus help to 
discover the genetic diversity underlying different types of pain. 
 
Particular attention needs to be paid to the concept of population stratification, a term 
that describes systematic differences in allele frequencies between subpopulations in 
a population due to different ancestry, known as genetic admixture. This concept is 
particularly relevant in the context of association studies with participants from 
ethnically diverse populations (Devlin & Roeder, 1999; Devlin, Roeder, & 
Wasserman, 2001). An example of this is a finding in Pima and Papago Native 
Americans with and without diabetes. The difference was the result of genetic 
admixture in the control participants from European ancestry in which these genetic 
variants are less frequent for other reasons than these genes, but in whom diabetes 
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is also less frequent than in Native Americans (Knowler, Williams, Pettitt, & 
Steinberg, 1988).  
 
The population stratification can be controlled for by utilising markers for which 
ethnicity-dependent differences in frequencies have been demonstrated in genomic 
studies, which are referred to as ancestry informative markers (Halder, Shriver, 
Thomas, Fernandez, & Frudakis, 2008). Subsequently, one can either correct 
statistically for this effect or include only one specific ethnicity in the analysis or 
perform separate analyses for each subpopulation. In candidate gene studies 
participants should be selected from ethnically uniform backgrounds. 
  
Genetic technologies have different profiles with regard to scope and resolution of a 
planned study. At the low resolution end of the spectrum, linkage studies indicate the 
location of a target gene within a section of the genome (Roberts, MacLean, Neale, 
Eaves, & Kendler, 1999) and at the high resolution end of the spectrum sequencing 
technologies provide the exact sequence of the entire genome (Mardis, 2008).  
 
What type of genetic technology to use, depends on the study design. The majority of 
genetic studies in pain have used selected candidate genes, because they were 
driven by specific hypotheses. For example, extensive work has been conducted on 
OPRM1 and, in particular, on a SNP at position 118 in the gene coding for this 
receptor. This SNP is considered to be a functional SNP, because it causes a 
substitution of the wild-type A-allele by the G-allele, which effects a difference in the 
amino acid chain of the receptor molecule (Lötsch, Geisslinger, & Tegeder, 2009a; 
Mura et al., 2013).  
 
As a primary target site for various opioid ligands, questions regarding the 
consequences of this functional change in OPRM1 have been addressed by 
employing several pharmacodynamic and pharmacokinetic phenotypes on opioid 
potency (Lötsch, Stuck, & Hummel, 2006), including metabolite toxicity, pupil dilation 
(Lötsch, Zimmermann, et al., 2002) and receptor affinity (Bond et al., 1998a). 
 
Modern high throughput microarray technology has enabled the transition beyond 
small sets of candidate genes towards a more exhaustive whole genome approach 
for both DNA and RNA in man and animals (Gillet, de Longueville, & Remacle, 2006; 
Nijman, Kuipers, Verheul, Guryev, & Cuppen, 2008). This is an advantage with 
regard to investigating common pain disorders and their progression, which are most 
likely of a poly-mechanistic and polygenic nature with many yet unidentified genes.  
 
However, due to the cost, only two of the many possible phenotypes to date, 
rheumatoid arthritis and postsurgical pain have been examined in large genome wide 
association (GWA) studies (Gregersen et al., 2009; The Wellcome Trust Case 
Control Consortium, 2007). The use of microarrays is more frequent in 
pharmacogenomic studies of RNA, where an intervention is expected to affect more 
than one marker of interest and use of panels of biomarkers for other clinical 
endpoints such as cytokines are common (Slade et al., 2011).  
 
With regard to clinical practice the study of genetic variation potentially promises 
individualised, allele-specific medicine with genotype-informed diagnoses and drug 
prescription practices. Ethnicity-dependent differences in the frequency of 
polymorphisms in genes encoding enzymes and drug transporters have been shown 
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to affect pharmacokinetic phenotypes such as metabolic capacities for various drugs. 
Hence some drugs (e.g. opioids, debrisoquine, etc.) are less effective in some 
populations than others. These pharmacogenetic differences already inform 
prescription recommendations for some medications in the USA and Japan (Ozawa 
et al., 2004).  
 
In summary, if one is to discover ―true pain-related genes‖, careful conceptualisation 
of genetic studies is of utmost importance and hinges on several components. 
Parameters to be considered when designing a genetic study include population, 
tissues, substrate, phenotype selection and scope. An endophenotype/biomarker 
approach promises reduced phenotype complexity and increased power for 
discovery of pain and pain susceptibility genes.  
 
1.5 Imaging Pain 
Wittgenstein‘s box analogy and the inability of introspection to capture objective 
features of a phenomenon resonated with the view of the behaviourists of the early 
20th century, who considered the brain a black box, since there were no technologies 
to observe the inner workings of the brain in action and in vivo apart from reaction 
(time) experiments (Watson, 1913).  
Today‘s definition of pain includes the subjective experience not by simple 
introspection, but by employing a wide variety of imaging modalities to study neural 
correlates of pain in combination with psychometric measures. Neuroimaging 
techniques can be used to explore functional and/or anatomical aspects of pain 
processing, even though this had not been the express purpose at the time of their 
development. They have opened up new vistas of the brain during the experience of 
pain (Schweinhardt & Bushnell, 2010).  
 
The use of neuroimaging techniques has undergone a development similar to that of 
genetic technologies in the context of pain research. The brain as a central 
component in pain perception had been neglected, because during the first half of 
the 20th century it was believed that pain did not have any important cortical 
representations beyond the somatosensory cortex (Head & Holmes, 1911; Wilder 
Penfield & Boldrey, 1937). The parietal operculum and posterior insula, both brain 
areas which are involved in generating painful sensations in response to electrical 
stimulation, and the thalamus received some attention (Mazzola, Isnard, Peyron, & 
Mauguire, 2012), but inspired no further interest in brain-related pain research.  
 
Neuroimaging techniques have evolved from Electroencephalography (EEG), initially 
developed in the 1920s by Hans Berger (Berger, 1938). With few EEG studies in pain 
in the 1950s, investigating headaches and migraine (Apley, Lloyd, & Turton, 1956; 
Ulett, D, & O‘Leary, 1952). EEG has high temporal, but low spatial resolution and is 
less informative with regard to subcortical structures. Then Positron Emission 
Tomography (PET) emerged in the late 1950s (Bonte, 1976) and employs a glucose 
analogue marked with a radioactive tracer. The first functional neuroimaging study in 
pain used a heat pain paradigm in healthy volunteers in combination with functional 
magnetic resonance imaging (fMRI) for better stereotactic localisation (Talbot et al., 
1991). Other radioactive tracers have enabled the study of brain functions in pain, 
such as cortical activation in response to pressure pain (Wey et al., 2014), acute pain 
post dental extraction (Derbyshire, Jones, Collins, Feinmann, & Harris, 1999), pain 
threshold testing (Vogt, Derbyshire, & Jones, 1996), opioid-binding in central post 
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stroke pain (Willoch et al., 2004b) and the role of the dopaminergic system in chronic 
pain (Jääskeläinen et al., 2001). However, this technology has low temporal 
resolution, because it takes a certain amount of time for tracer fluids such as 
flourodeoxyglucose to be absorbed by the body and to accumulate in brain areas, 
where the glucose is metabolised in response to activation (Engel et al., 1996). The 
tomographic device registers the positrons emitted by the decaying tracer. The use of 
radioactive tracers also limits the number of applications of PET as prolonged 
hazardous exposure to ionizing radiation needs to be avoided. Hence, this method is 
unsuitable for the repeated monitoring of chronic pain conditions for extended 
periods of time.  
 
Imaging post-surgical pain 
 
Acute pain is defined in contrast to chronic pain. In clinical practice three months is 
the most widely used point of division between the two (Sternbach, 1974). 
Furthermore, pain which persists past the normal time of healing is also labelled as 
chronic pain (Bonica, 1953). Within the mechanism-based taxonomy of pain the label 
―acute‖ can be allocated to two types of pain. In most cases the label acute pain 
refers to transient pain, which is nociceptive pain, defined as a response to a noxious 
stimulus, which does not produce long-term sequelae (Woolf, 2004). Within a clinical 
setting the label acute pain can also include tissue injury pain such as postoperative 
pain (Pogatzki-Zahn, Zahn, & Brennan, 2007; Clifford J. Woolf, 2004), which 
subsides once the tissue has healed. In experimental studies other on-going pain 
induced by saline solution injection (Zubieta et al., 2001b) or application of capsaicin 
(Iannetti et al., 2005) has been investigated.  
 
To date BOLD imaging is the most frequently used fMRI technique in pain research. 
It makes use of neurovascular coupling, which was first discovered by Roy and 
Sherrington in 1890 to describe the fact, that brain activity increases the activity-
related blood flow into the active brain regions (Roy & Sherrington, 1890). This 
response creates a local surplus in oxygen which represents the foundation of the 
BOLD signal, which stems from the proportion of oxy- to deoxy-haemoglobin in the 
blood (Ogawa & Lee, 1990), since oxygenated haemoglobin does not affect the 
magnetic field. 
 
BOLD fMRI has led to the identification of a distributed network of brain areas with 
distinct roles in pain and nociceptive processing for each brain region. These areas 
include the somatosensory cortex I and II (S1 & S2), anterior cingulate (ACC), 
midcingulate cortex (MCC) and insula (Apkarian, Bushnell, Treede, & Zubieta, 2005), 
prefrontal cortex (PFC), motor cortex, supplementary motor area (SMA) (Friebel, 
Eickhoff, & Lotze, 2011), and subcortically the basal ganglia, thalamus and brainstem 
(Peyron, Laurent, & García-Larrea, 2000). The most frequently used study designs in 
this context are event-related and block designs, where transient noxious stimuli are 
given and withheld.  
 
However, BOLD imaging has been largely unsuccessful in characterising background 
or on-going pain and is suffering from a range of other limitations, which diminish its 
usefulness in the context of biomarker research, as they pertain to reliability. In 
addition, loss of statistical power for BOLD fMRI studies stems from extensive signal 
variations between subjects as well as across sessions (Aguirre, Zarahn, & 
D‘esposito, 1998) for reasons yet unknown (Miezin, Maccotta, Ollinger, Petersen, & 
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Buckner, 2000). Arterial Spin Labelling on the other hand provides a biologically 
meaningful quantitative measure of perfusion without exposure to ionizing radiation 
(Apfelbaum, Chen, Mehta, & Gan, 2003). 
 
ASL represents a class of MRI scanning sequences that captures tissue perfusion. 
The tracer used in ASL is the body‘s own magnetically labelled blood water, which 
exchanges rapidly between intravascular (IV) and extravascular (EV) tissue water 
compartments. The longitudinal magnetisation of the arterial blood water is modified 
by radiofrequency (RF) pulses in the carotid and vertebral arteries en route to the 
target tissue. After it reaches the tissue, the label is observed as an alteration of the 
tissue magnetization. The label decays with time constant T1, which is 1650 
milliseconds at 3T, the field strength used in this thesis (Owen et al., 2008). Due to 
the high EV to IV ratio in the brain, the average time for arterial water to traverse from 
arterial to venous side, as opposed to a red blood cell, which takes about 1 second 
and remains intravascular, is tens of seconds. Transit delay describes the travel time 
of the blood from the labelling location to the target tissue and takes approximately 
one second and competes with T1. The key trade-off between these two factors 
constitutes the ASL measurement, as T1 favours a short delay between label 
application and image acquisition, while transit delay favours a long delay for 
complete tracer delivery prior to image acquisition. The tracer is delivered by the 
regular blood stream to capillary beds and tends to accumulate in the tissue water of 
the surrounding tissues before it becomes venous and decays (Chen, Wang, & 
Detre, 2011).  
 
The ASL variant used in the fMRI study of this thesis was pseudo-continuous arterial 
spin labelling (pCASL) due to several advantages. The first is the elimination of 
potentially large magnetisation transfer effects in pCASL, which is the transfer of 
longitudinal magnetisation from the hydrogen nuclei of restricted water bound to a 
larger molecule to the hydrogen nuclei of water that moves unrestricted in cytosol. 
This effect frequently occurs in CASL.  
 
Finally, pCASL allows for mapping of vascular territories by making use of the time 
gaps between RF pulses and applying gradient pulses, thus modulating the labelling 
across vessels within the labelling plane. In addition, pCASL has a higher signal to 
noise ration than other forms of ASL and allows for direct control over bolus duration. 
The trade off is increased sensitivity to resonance offsets (i.e. change of phase due 
to an applied field or inhomogeneity of field between two RF pulses, or from one 
pulse to the next), to which pCASL is more sensitive than CASL. 
 
In practice pCASL uses a long series of short RF and gradient pulses instead of 
continuous pulses and an approximately 10 times higher gradient amplitude during 
the RF pulse in addition to a slice selective RF pulse, which provides excitation at the 
labelling plane, where the tracer is induced (Wong, 2014). The ASL signal, is directly 
proportional to the local CBF, because the amount of tracer in a bolus of labelled 
arterial blood delivered upstream, is deposited in each voxel of the scanned target 
tissue. Thus perfusion in ASL is a measure quantified by the amount of blood 
delivered to the tissue per time unit, per unit of volume or mass of tissue for which 
reliability has been established (Tracey & Johns, 2010a; Xu et al., 2011). Thus unlike 
BOLD it is a direct and physiologically meaningful CBF measure, but comes at the 
price of lower temporal resolution, as the scan is acquired over a period of 
approximately six minutes.  
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Imaging morphological changes induced by chronic pain 
 
This thesis also investigated genotype-dependent morphodynamic changes in 
response to chronic musculoskeletal pain. In addition to short-term changes in blood 
flow and electrical activity, it has been demonstrated that the repeated or on-going 
experience of pain may have morphodynamic effects on the brain (May, 2008).  
 
Here the term morphodynamic is used in similar fashion to the geological concept of 
morphodynamics, which describes the effect of environmental gradients, such as 
tidal range, wave exposure and sediment type on the shape of a landscape (Carter & 
Woodroffe, 1997). In this thesis chronic musculoskeletal pain serves as a gradient. 
The term morphodynamic is not used in the traditional biological sense, where it 
pertains to embryonal development (Keller, Schmidt, Wittbrodt, & Stelzer, 2008).  
 
Grey matter generally decreases with age and is associated with a decline in 
cognitive capability (Ceko, Bushnell, Fitzcharles, & Schweinhardt, 2013). 
Morphological changes of the brain have been demonstrated in grey matter as well 
as white matter (Ceko et al., 2013). An inverse relationship independent of pathology 
between grey matter density and pain sensitivity with accompanying changes in 
resting state network activity has been demonstrated in participants undergoing a 
heat pain challenge (Emerson et al., 2014). Apkarian et al. (Apkarian et al., 2004) 
were the first to demonstrate grey matter decreases in response to chronic back pain. 
Since then decreases in grey matter have been demonstrated in several other 
chronic pain disorders such as FMS (Lutz et al., 2008; Robinson, Craggs, Price, 
Perlstein, & Staud, 2011), temporomandibular disorder (Moayedi et al., 2012), 
chronic low back pain ( Schmidt-Wilcke et al., 2006) and tension type headaches 
(Schmidt-Wilcke et al., 2005).  
 
These decreases were initially thought to represent permanent atrophy. However, 
this view has been challenged by reports of grey matter recovery after cessation of 
chronic pain following reconstructive surgery (Rodriguez-Raecke, Niemeier, Ihle, 
Ruether, & May, 2013a), indicating that GM density changes could potentially serve 
as a biomarker for the success of clinical interventions.  
 
The majority of studies have demonstrated decreases in grey matter in areas 
associated with persistent pain processing, whose extent corresponds to the duration 
of the pain experience. However, there are additional factors such as affect. When 
comparing three groups of 29 age-matched participants – healthy controls, FMS 
patients with affective disorder and FMS patients without affective disorder- Hsu et al. 
(Hsu et al., 2009) demonstrated no significant GM differences between the healthy 
controls and FMS patients without affective disorder.  
 
In addition, the findings of decreases also seem counterintuitive (Moseley & Flor, 
2012) considering the results from training studies, where GM volume increased in 
response to frequent use of the activated region (e.g. hippocampal areas in taxi 
drivers). It could be expected that structures involved in the perception of pain would 
increase in GM density in response. Corresponding findings were reported for striatal 
grey matter, which was increased in FMS patients in comparison to healthy controls 
(Schmidt-Wilcke et al., 2007). A recent study suggests that the relationship between 
pain and grey matter density may be more complex.  Ceko et al. (2013) investigated 
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GM density in female FMS patients and divided the sample by age. The younger 
patients demonstrated GM density increases, which were interpreted as an adaptive 
reaction resulting in amelioration of pain, while older patients demonstrated 
decreases and increased pain indicating that the plasticity changes had turned 
maladaptive.  
 
So far, little is known about the molecular factors driving these morphodynamics. 
While genetic markers are associated with changes in sensitivity to pain, genetic 
variation may also serve as a risk or protective factor for plasticity changes in pain 
patients. A recent study on the genetic contribution of the catechol-O-
methyltransferase val158met polymorphism in female migraine sufferers (Liu et al., 
2015) highlighted a significant disease by genotype interaction in the hippocampus, 
where GM was increased in val-homozygote migraine patients.  
 
This thesis took a novel approach in analysing the effects of SNP rs1799971 from the 
gene encoding mu-opioid receptor 1 on grey matter density.  
 
Voxel based morphometry (VBM) has become the methodology of choice (Ashburner 
& Friston, 2000) due to its convenience in comparison to the other two 
methodologies. It has been used to investigate differences in cortical volumes 
between groups affected by chronic mental illness such as schizophrenia and healthy 
controls (Wright et al., 1995) as well as London taxi drivers in comparison to regular 
drivers and demonstrated increases in grey matter in the posterior hippocampus in 
the taxi drivers as a result of repeatedly performing the spatial task of navigating 
through London (Maguire et al., 2000).  
 
VBM analysis uses four distinct steps: spatial normalisation, segmentation, 
smoothing and statistical analysis. During spatial normalisation the individual MRI 
images are registered to the same template image to create a template. The aim is to 
create a template consisting of the average of a large number of MR images 
registered in the same stereotactic space. First transformation parameters are 
estimated to map the individual MRI images to the template (Ashburner & Friston, 
1997). Second, global nonlinear shape differences are accounted for by minimising 
the residual squared difference between the image and the template and maximizing 
the smoothness of the anatomical differences between template and participant 
scan.  
 
During segmentation the normalised images are segmented into the different tissue 
types: grey matter, white matter, cerebrospinal fluid and three non-brain partitions. 
Then a priori probability maps of different tissues in normal subjects are combined 
with voxel intensity distributions of particular tissue types. Images then are corrected 
for intensity non-uniformity and the resulting tissue class images are binarised to 
allocate each voxel to its most probable tissue class (Ashburner & Friston, 2000). 
Images are then smoothed by an isotropic Gaussian kernel to ensure that each voxel 
in the images contains the average amount of grey or white matter from the radius of 
the smoothing kernel, to increase the validity of subsequent parametric statistical 
tests by creating more normally distributed data and to compensate for the remaining 
inaccuracies of the spatial normalisation (Mechelli, Price, Friston, & Ashburner, 
2005). The data is then ready for statistical analyses such as group comparisons.  
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In summary, so far neuroimaging techniques have afforded us new vistas into the 
neuronal processes that generate the sensation of pain by highlighting brain regions 
previously considered inconsequential in pain processing (e.g. nucleus accumbens, 
striatal areas). Apart from the intuitive targets such as the somatosensory cortex I 
and II, a network of brain areas has been proposed and is often referred to as the 
pain matrix or neuromatrix of pain (Melzack, 1999, 2001). The concept of the pain 
matrix however, has also sparked some controversy with regard to which areas are 
included in this network. There has also been critique regarding an oversimplified 
approach by treating the components of the pain matrix similar to specialised 
structures in the visual cortex for example (Iannetti & Mouraux, 2010; Legrain, 
Iannetti, Plaghki, & Mouraux, 2011), when many areas such as the anterior cingulate 
cortex and the thalamus for example also play important roles in other processes 
such as attention (Luerding, Weigand, Bogdahn, & Schmidt-Wilcke, 2008) 
 
1.6 Combining genetics and neuroimaging in search of biomarkers and 
mechanisms of pain and nociception – a rationale for this thesis 
Both genetics and neuroimaging have undergone similar, yet, mostly separate 
progressions in the development and recent application of technologies in pain. The 
past 25 years have seen a rapid proliferation of genetic and imaging techniques in 
pain research and have, also through combination, opened up new seams for mining 
in search of pain biomarkers and mechanisms.  
 
To date imaging and genetic approaches have rarely been used in combination with 
a few notable exceptions. There are three candidate gene studies, of which one 
focused on opiodergic signalling in the brain in the presence of a mutation within 
OPRM1 A118G. The first focused on genotype-dependent differences in pain-related 
brain activation measured with fMRI after administration of short pulses of gaseous 
CO2 to the nasal mucosa using the same SNP (Oertel, Preibisch, Wallenhorst, 
Hummel, Geisslinger, Lanfermann, & Loetsch, 2008). The study demonstrated 
decreased linear activation in relation to alfentanil concentrations in brain regions 
associated with the processing of the sensory intensity of pain, which was 
significantly less pronounced in OPRM1 118G carriers.  
 
Two other studies investigated the effect of the COMT val158met polymorphism in 
combination with neuroimaging phenotypes. First, an fMRI study on structural and 
functional changes in the hippocampus in female migraine patients (Liu et al., 2015) 
revealed a significant disease by genotype interaction effect, which corresponded to 
disease-related increase of GM in val/val carrying migraineurs in a VBM analysis. 
Here increased GM and decreased connectivity between the hippocampus and the 
medial prefrontal cortex was only found in val homozygote migraine patients without 
aura compared to val homozygote healthy control volunteers. In another study 
(Zubieta et al., 2003) women underwent a PET scan using the mu-opioid receptor-
selective radiotracer [11 C]carfentanil in the presence of an on-going pain stimulus 
during the early follicular phase of their menstrual cycle. The study demonstrated 
diminished regional mu-opioid system responses to pain in carriers of the met158met 
genotype of COMT compared with heterozygotes, and higher sensory and affective 
ratings of pain in addition to a more negative internal affective state. 
 
This thesis consisted of two studies in which one used genetic and imaging analyses 
in parallel and one combined both endpoints to evaluate their utility in establishing 
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novel biomarkers in search of mechanisms underlying different types of pain. The 
VBM study was driven by a specific biological hypothesis based on previous insights 
into the effects of SNP rs1799971 in OPRM1. It investigated the effect of this SNP on 
GM density in chronic musculoskeletal pain patients, for which grey matter changes 
in comparison to healthy age and gender matched control participants have been 
demonstrated (May, 2008; Schmidt-Wilcke et al., 2005; Schmidt-Wilcke, 2008).  
 
The hypothesis that OPRM1 influences GM density was based on previous 
observations that its G-allele seems to serve as a protective factor against pain in 
general and FMS in particular (Solak et al., 2014; Walter & Lötsch, 2009b). GM 
decreases in response to chronic pain have been reported for various pain conditions 
(Lutz et al., 2008; May, 2008). In addition, opiodergic signalling is altered in FMS and 
ULBP patients (Baraniuk, Whalen, Cunningham, & Clauw, 2004; Harris et al., 2007), 
thus making OPRM1 most likely a pain gene in line with Devor‘s definition and larger 
GM decreases more likely in A-allele carriers.  
 
The other study analysed RNA from peripheral whole blood and used microarrays for 
comprehensive genomic coverage. It assessed the changes in cerebral blood flow by 
means of ASL and analysed gene expression levels from peripheral whole blood pre 
and post surgery in response to TME. It employed a data-driven analysis approach in 
search for pain susceptibility genes using pre-post comparisons as well as Gene Set 
Enrichment Analysis (GSEA) to identify known molecular pathways in the context of 
post-surgical pain.  
 
TME reliably produces on-going moderate to severe post-surgical pain (Moore, 
Edwards, & McQuay, 2005). The most common indication for TME in accordance 
with NICE guidelines is recurrent pericoronitis, repeated bouts of inflammation of the 
tissues surrounding the impacted wisdom tooth (NICE/NHS, 2000).  A benefit of the 
TME model is that study participants can be assessed pain-free during asymptomatic 
periods, providing useful ‗baseline‘ information. Patients also commonly present with 
bilateral, similarly positioned wisdom teeth requiring extraction.  Similar morphology 
between left and right teeth provides a matched level of surgical difficulty and 
resulting post-surgical pain. This makes TME ideal for analgesic trials employing a 
crossover design and thus allowing for assessment of reliability, one of the key 
requirements in a biomarker.  
 
This study aimed at establishing blood as an easily accessible tissue as a proxy for 
pain-related molecular changes. It evaluated the potential of RNA derived from 
peripheral whole blood as a substrate for biomarker discovery in pain research. Blood 
is already used for immune monitoring in response to vaccines for example has been 
implemented by means of mRNA real-time polymerase chain reaction (PCR) 
(Stordeur et al., 2003) and cyclooxygenase activity (Brideau et al., 1996) among 
other indicators. Blood is routinely taken in many clinical settings in pain treatment 
and would thus lend itself well as an easily accessible substrate for biomarker 
generation in pain.  
 
Gene expression profiling has previously been applied in the context of TME and 
potentially enables extrapolation to other forms of post-surgical pain (Barden, 
Edwards, McQuay, & Moore, 2004). Performed in otherwise healthy volunteers, it 
allows for assessment of on-going pain without the plasticity changes encountered in 
chronic pain patients. Together, the studies were designed to provide coverage of as 
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many of the different aspects of successful establishment of biomarkers and pain 
measurement as possible, rooted in a mechanism-based classification of pain. 
 
Both studies were performed in humans to enable the assessment of cognitive 
components of the pain experience such as sensory and affective ratings of pain. 
These are difficult to operationalise in animals (Max & Stewart, 2008b), but are 
essential components of the human pain experience. The mechanism-based 
taxonomy of pain proposed by Woolf et al. (Woolf et al., 1998) distinguishes between 
stimulus-dependent and stimulus-independent pain, which this thesis addressed by 
investigating pain subsequent to TME with TME serving as pain stimulus. This type of 
pain also falls into the category of adaptive pain in the mechanism-based taxonomy, 
which further distinguishes between adaptive and maladaptive pain. Post surgical 
pain aids the recovery of tissue from surgical trauma and usually subsides once the 
tissue has healed.  
 
The second study of patients with chronic musculoskeletal pain suffering from FMS 
and ULBP represented a model of stimulus-independent pain, since no external 
event to precipitate its onset was identifiable. It is also classified as maladaptive, 
since it neither indicates impending tissue damage nor serves any other adaptive 
purpose such as tissue recovery. In this scenario the pain is the disease and both 
patient cohorts were grouped under the category of nervous system injury pain 
brought on by maladaptive CNS processing (Woolf, 2004) even though FMS and 
ULBP are diagnosed as separate disorders in current clinical practice (WHO, 2010).  
 
The sample in the VBM candidate gene study consisted entirely of female 
participants based on the fact that the majority of patients are female. The other 
study consisted entirely of male participants to exclude known effects of the 
menstrual cycle (Teepker, Peters, Vedder, Schepelmann, & Lautenbacher, 2010). 
Based on clinical experience of the surgeons involved in the study, the recruitment of 
post-menopausal females is near impossible, since third molars are usually removed 
by the age of 35 in most patients. Both studies were conducted in Caucasian 
participants to prevent population stratification or and to control for its potential 
effects on gene expression.  
 
This thesis aimed to achieve an assessment with well-characterised, controlled, 
clinically relevant pain endophenotypes that are robust, yet relatively easy to acquire. 
This was done with the intention to maximise the chances of identifying genetic 
targets for clarifying the underlying molecular mechanisms and to generate suitable 
tools for the development of diagnostic procedures and evaluation of therapeutic 
success.  
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2 MANUSCRIPTS 
2.1 Manuscript I: Beyond Patient Reported Pain: Perfusion Magnetic Resonance 
Imaging Demonstrates Reproducible Cerebral Representation of Ongoing Post-
Surgical Pain1 
 
 
 
Abstract 
 
Development of treatments for acute and chronic pain conditions remains a 
challenge, with an unmet need for improved sensitivity and reproducibility in 
measuring pain in patients. Here we used pulsed-continuous arterial spin-labelling 
[pCASL], a relatively novel perfusion magnetic-resonance imaging technique, in 
conjunction with a commonly-used post-surgical model, to measure changes in 
regional cerebral blood flow [rCBF] associated with the experience of being in 
ongoing pain. We demonstrate repeatable, reproducible assessment of ongoing pain 
that is independent of patient self-report. In a cross- over trial design, 16 participants 
requiring bilateral removal of lower-jaw third molars underwent pain-free pre-surgical 
pCASL scans. Following extraction of either left or right tooth, repeat scans were 
acquired during post-operative ongoing pain. When pain-free following surgical 
recovery, the pre/post-surgical scanning procedure was repeated for the remaining 
tooth. Voxelwise statistical comparison of pre and post-surgical scans was performed 
to reveal rCBF changes representing ongoing pain. In addition, rCBF values in 
predefined pain and control brain regions were obtained. rCBF increases (5–10%) 
representing post-surgical ongoing pain were identified bilaterally in a network 
including primary and secondary somatosensory, insula and cingulate cortices, 
thalamus, amygdala, hippocampus, midbrain and brainstem (including trigeminal 
                                            
1 Author contributions listed the author of this thesis for three types of contributions: ―Performed the 
experiments‖, where she contributed 80% of recruitment, phone and psychometric screenings, MRI 
data acquisitions, sample collection, storage, randomisation and shipping arrangements and liaison 
with the lab that processed RNA and micorarrays. ―Analyzed the data‖ included manual check of all 
acquired slices for artefacts for 20 participants * 5 visits * 6 cASL scans, pre-processing including brain 
extraction and mask generation from T1 scans for inclusion in the main analysis (40%). ―Wrote the 
paper‖ included contributing passages to the introduction, methods section and discussion (10%).  
 
Reference:  
 
Howard MA, Krause K, Khawaja N, Massat N, Zelaya F, Schumann G, et al. 
(2011) Beyond Patient Reported Pain: Perfusion Magnetic Resonance 
Imaging Demonstrates Reproducible Cerebral Representation of 
Ongoing Post-Surgical Pain. PLoS ONE 6(2): e17096. 
doi:10.1371/journal.pone.0017096  
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ganglion and principal-sensory nucleus), but not in a control region in visual cortex. 
rCBF changes were reproducible, with no rCBF differences identified across scans 
within-session or between post-surgical pain sessions. This is the first report of the 
cerebral representation of ongoing post-surgical pain without the need for exogenous 
tracers. Regions of rCBF increases are plausibly associated with pain and the 
technique is reproducible, providing an attractive proposition for testing interventions 
for ongoing pain that do not rely solely on patient self-report. Our findings have the 
potential to improve our understanding of the cerebral representation of persistent 
painful conditions, leading to improved identification of specific patient sub-types and 
implementation of mechanism-based treatments.  
 
Introduction 
 
As many as 80% of individuals experience moderate to severe post-operative 
pain (Apfelbaum et al., 2003) and intractable pain in patients with cancer, diabetes 
and HIV is a major healthcare concern (Pöpping et al., 2008). The breadth of 
available treatments for pain control remains limited with an over-reliance on opiate-
based medication (Woodcock, Witter, & Dionne, 2007). Without a record- able 
biological marker for pain, decades of analgesic trials have relied largely on patients‘ 
own reports to describe location, intensity and quality of their pain. Standardised 
psychometric techniques have been developed, but inter-individual variability in pain 
reporting has often been incorrectly viewed as artefactual (Chizh, Priestley, 
Rowbotham, & Schaffler, 2009), rather than representing true differences in pain 
experience. According to a bio-psychosocial interpretation of pain (Melzack & Casey, 
1968), individual differences in pain response are likely to include effects of 
concurrent pathophysiology, cognitive and affective strategies and confounding 
effects of co-medications (Coghill, McHaffie, & Yen, 2003). Compounded by a failure 
to report null findings, the search for novel analgesics remains slow and expensive. It 
has been suggested that performance issues inherent in traditional analgesic 
development have been stymied by continuing to use the ‗‗evaluation tools and 
infrastructure of the last century to develop this century‘s drug therapy‘‘(Woodcock et 
al., 2007). With this in mind, novel indices for measuring pain are required; ideally 
they should relate to an underlying aspect of pain transduction, take account of bio-
psycho-social factors and translate between human and preclinical studies (Coghill et 
al., 2003).  
 
Modern neuroimaging techniques, such as Positron Emission Tomography (PET) 
and functional Magnetic Resonance Imaging (fMRI), show great promise in the 
development of novel measurement techniques, allowing non-invasive investigation 
of the cerebral mechanisms underpinning the pain experience. Many imaging studies 
to date, however, have relied on ‗experimental pain‘ models using healthy volunteers 
to derive brain responses to acute, repeated, short-duration nociceptive stimuli 
(reviewed in (Apkarian et al., 2005; Peyron et al., 2000)). For ethical reasons, human 
experimental pain paradigms are often expressly designed to provide a highly 
controllable, psychophysically constrained stimulus that minimises tissue damage. As 
a result, brain responses to such stimuli are highly unlikely to account for the 
physiological changes that result from tissue trauma (Pogatzki-Zahn et al., 2007). In 
addition, neurological sequelae that relate uniquely to individual chronic pain 
conditions (Apkarian et al., 2004; Maihofner, Handwerker, Neundorfer, & Birklein, 
2004; May, 2008) are largely impossible to represent in experimental models of pain 
in healthy controls; a fact reflected in the increasing reports of neuroimaging 
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investigations in patients with persistent pain (Tracey & Bushnell, 2009b). Both post-
traumatic pain and chronic painful conditions are perceived as having an ongoing 
painful component. By contrast, the majority of pain-imaging studies have relied on 
the statistical comparison of a repeated nociceptive event with interspersed ‗rest‘ or 
‗control‘ states derived within the same experimental session. As a result, many of 
these studies to date have been ill-suited to investigation of ongoing pain that cannot 
be modulated under experimental control within-session (Tracey & Johns, 2010b).  
 
Compared to studies examining responses to evoked pain, there are relatively few 
neuroimaging reports describing the cerebral representation of ongoing pain; fewer 
still describe clinical ongoing pain. There are several reports using PET, for example 
(Derbyshire et al., 1994; Derbyshire & Jones, 1998; Derbyshire et al., 1999; Di Piero 
et al., 1991; Jääskeläinen et al., 2001) but rather than examining the ongoing clinical 
pain per se, several of these studies have examined CBF changes in response to an 
experimentally-derived nociceptive stimulus in addition to any ongoing background 
pain. Further, safety considerations, availability, expense, small group sizes and 
inferior temporal and spatial resolution (compared to fMRI), have limited the impact of 
their findings. Similarly, reports using Blood Oxygenation Level Dependent [BOLD] 
fMRI, for example (Apkarian, Krauss, Fredrickson, & Szeverenyi, 2001; Pogatzki-
Zahn et al., 2010), have examined the relationship between changes in participants‘ 
self-reported pain and BOLD signal intensity, rather than examination of the BOLD 
signal alone, producing results confounded by motor responses underpinning 
participants‘ continuous online pain ratings. Others have used BOLD fMRI to 
examine inter-relationships in resting-state BOLD signal time series information 
between brain regions, known as functional connectivity analysis (Cauda et al., 2009; 
Cauda et al., 2009). Perhaps most importantly, conventional BOLD-fMRI paradigms 
are most sensitive to signal changes over several seconds and are less suitable for 
examining pain responses lasting many minutes (Thunberg et al., 2005) or for 
monitoring long-term treatment effects (Cahana, Carota, Montadon, & Annoni, 2004). 
By contrast, perfusion MRI methodologies such as arterial spin labelling (ASL) 
(Petersen, Zimine, Ho, & Golay, 2006; Williams, Detre, Leigh, & Koretsky, 1992) may 
be preferable for the study of behaviours or states over the course of minutes as 
opposed to seconds. ASL has already been documented as an ideal methodology for 
the central investigation of ongoing, non-paroxysmal pain (Tracey & Johns, 2010b). 
The methodology provides quantitative, reproducible rCBF measurements throughout 
the brain and has superior noise-power characteristics, compared to fMRI, in within-
subject designs with a task periodicity of 120 seconds or greater (Aguirre, Detre, 
Zarahn, & Alsop, 2002). The application of ASL to the study of pain remains in its 
infancy (Owen et al., 2008; Owen, Clarke, Ganapathy, Prato, & St. Lawrence, 2010); 
to the best of our knowledge there has yet to be a report of the application of ASL to 
ongoing, clinically-relevant pain.  
 
Here we assess the validity of pulsed-continuous ASL [pCASL] (Dai, Garcia, De 
Bazelaire, & Alsop, 2008) as a quantitative, reproducible marker of ongoing post- 
surgical pain. We applied the most commonly employed clinical pain model used in 
trials of analgesics such as non-steroidal anti- inflammatory drugs and opiates, the 
third molar extraction (TME) model (Barden et al., 2004; Chen, Elliott, & Ashcroft, 
2004). In the TME model, healthy participants, with no prior history of chronic painful 
disease other than recurrent, intermittent pericoronitis of their third molars, are 
recruited. As a result, participants are unaffected by confounding variables such as 
heterogeneity in pain distribution, concomitant medication and pathology and 
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participants can be initially assessed while asymptomatic and completely pain-free. 
Often bilateral, similarly-positioned wisdom teeth require extraction that are matched 
for surgical difficulty, resulting in reproducible amounts of moderate- to-severe post-
surgical pain following each unilateral extraction (Szmyd, Shannon, & Mohnac, 
1965). Reproducibility of pain response renders the model ideal for ‗cross-over‘ 
placebo-controlled analgesic trials. In addition a recent meta-analysis reported that 
TME-derived assessments of analgesic efficacy could be extrapolated to other forms 
of post- surgical pain (Barden et al., 2004), demonstrating the broad utility of the 
model.  
 
In this study we applied pCASL to the challenge of representing the cerebral basis of 
ongoing pain. We imposed three constraints, namely that the ongoing pain 
experience was induced by genuine tissue damage, could not be modulated by the 
experimenter within a single session, and that assessments of ongoing pain could be 
repeated to fulfil the requirements of a cross-over trial design. We demonstrate 
quantitative, reproducible rCBF increases that represent the experience of being in 
ongoing pain following TME including those in a network of brain regions specified a 
priori. Further, we provide novel insights into the central representation of post-
surgical trigeminal pain in humans. Our findings are discussed in terms of their 
potential impact on development of novel interventions for treatment of acute and 
chronic pain conditions and how the pCASL technique might be utilised in 
translational research.  
 
Ethics Statement  
 
This study was approved by Kings College Hospital Research Ethics Committee 
(REC Reference 07/H0808/115).  
 
Subjects and Materials 
 
 
16 right-handed, healthy male volunteers aged 20–41, (mean=26.4 years) provided 
informed consent to participate in the study. Females were excluded due to potential 
variability in the phase of the menstrual cycle affecting reproducibility of the response 
to post-surgical pain (Teepker et al., 2010). All participants presented with bilateral 
recurrent pericoronitis and fulfilled NICE guidelines for extraction of lower-jaw left and 
right third molars (NICE/NHS, 2000).  
 
Experimental Design  
 
Participants were scanned on five separate occasions (S1–S5); 
screening/familiarisation (S1), pre-surgical (S2) and post-surgical sessions (S3) for 
the first extraction and pre-surgical (S4) and post- surgical (S5) sessions for the 
second extraction. An interval of at least two weeks separated S3 and S4, following 
complete recovery from the first surgery. Order of left and right tooth extraction was 
balanced and pseudo-randomised across the group. At each session, pulse rate and 
blood pressure were recorded, an alcohol and drug-screen performed and a 
psychometric assessment completed. Analgesic medication (1000 mg paracetamol & 
400 mg ibuprofen) was provided to participants immediately following scanning 
during S3 & S5.  
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Procedure  
 
At S1, standardised screening questionnaires were administered to assess presence 
of any pain and baseline psychometric information (see Baseline Psychometry). A 
short MR examination was performed for familiarisation with the imaging environment 
and participants received training on using a computerised, joystick-operated visual 
analogue scale (VAS). MR examinations during sessions S2–S6 were identical, each 
comprised of six separate consecutive pCASL scans, each lasting six minutes. 
Participants were instructed to lie still with their eyes open. Prior to and following 
acquisition of each rCBF map, participants subjectively rated pain intensity and 
alertness using a computerised VAS.  
 
Baseline Psychometry  
 
Baseline psychometric screening assessments were performed for all participants 
prior to scanning at S1. Screening for depression was performed using the Centre for 
Epidemiological Studies Depression Scale [CES-D] (Weissman et al., 1977), and trait 
and state anxiety using the State-Trait Anxiety Questionnaire [STAQ] (Spielberger, 
1983). Changes in state anxiety relating to surgery were assessed at the beginning 
of each session. Screening for general mental health status was assessed using the 
Revised Symptom Checklist 90 [SCL-90-R] (Derogatis, 2005), and for alcohol and 
drug abuse using sections 11 and 12 of the Schedules for Clinical Assessment in 
Neuropsychiatry [SCAN] (Wing et al., 1990). Finally, the Cognitive Coping Strategies 
Inventory [CCSI] (Butler, Damarin, Beaulieu, Schwebel, & et al, 1989) was 
administered in order to assess participant coping strategies for pain. Participants 
with psycho- metric data outside published normative limits for each test were not 
included in the study.  
 
Surgery  
 
Unilateral TME was performed under local anaesthesia (4.4 ml Lignospan Special, 
Septodont) using a standardised technique. Surgical difficulty was rated on a 1-5 
scale (Renton, Smeeton, & McGurk, 2001). Following surgery, participants were 
supervised for up to six hours before their post- surgical scan, during which time 
ratings of pain intensity were recorded using a pen-and-paper 100mm VAS. 
Scanning commenced when three consecutive VAS scores greater than 30/100 mm 
were provided within a 30-minute period.  
 
Imaging Procedure  
 
Imaging was performed on a 3 Tesla Signa HDx whole-body MR imaging system 
(General Electric, USA) fitted with an 8- channel, phased-array receive-only head 
coil. High-resolution T1- and T2-weighted MR structural sequences were acquired for 
radiological assessment and image registration. Resting-state rCBF measurements 
were made using pCASL (Dai et al., 2008), using an irradiation time of 1.5 s and 
post-labelling delay of 1.5 s. pCASL images were acquired using a single-shot, Fast 
Spin Echo readout resulting in whole-brain blood flow maps, with a spatial resolution 
of 16163 mm.  
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Image Preprocessing  
 
Preprocessing and analysis were performed using FSL v4.1.0 
[http://www.fmrib.ox.ac.uk/fsl] (Smith et al., 2004). Preprocessing prior to voxelwise 
analysis using a General Linear Model (GLM), consisted of skull stripping [BET], 
registration to the Montreal Neurological Institute (MNI) template [FLIRT] and a non-
linear noise- reduction algorithm [SUSAN] to improve signal-to-noise ratio and 
condition the data for statistical analysis.  
 
Surgical and Behavioural data analysis  
 
All surgical and behavioural data analyses were computed using GenStat v11.1 
(http://www.vsni.co.uk/). Variability in perceived surgical difficulty and surgery-to-scan 
time between left and right tooth extractions were assessed using student‘s t-tests. 
VAS estimates of pain and alertness were fitted to a mixed effect model, with 
Participant and Participant-by-Session as random effects, and Session-pair (Pair 
1[S2,S3]/Pair 2[S4,S5]), Surgery (Pre-surgery/Left/Right tooth post-surgery), 
Timepoint, and Surgery by Timepoint as fixed effects. A first-order auto-regressive 
(AR(1)) covariance structure was specified for the repeated measures Timepoint. 
Significance thresholds for all behavioural analyses were at the p<0.05 level.  
 
Whole brain voxel-wise analysis  
 
Statistical analysis of pCASL data was applied at two levels using a voxelwise 
optimised GLM [FLAMEO]. First-level analyses were computed for each subject to 
create grey-matter only mean and variance images of the six individual pCASL scans 
acquired at each of sessions S2–S6. These images were used in a higher-level 
mixed effects analysis with Participant, Surgery (Presurgery/Left/ Right tooth surgery) 
and Session-pair (Pair 1[S2,S3]/Pair 2[S4,S5]) as model terms, to assess changes in 
rCBF relating to post-surgical pain and rCBF differences following left, compared to 
right TME. Z-statistic images were thresholded using clusters determined by Z>2.3 
and a corrected cluster-significance threshold of p = 0.05 according to random field 
theory (Worsley, Evans, Marrett, & Neelin, 1992).  
 
ROI Creation  
 
Anatomical ROIs in MNI-template space were derived from Harvard-Oxford 
Cortical/Subcortical and Juelich-Histological Atlases. Based on a priori information 
regarding brain activation related to pain, ROIs were created for anterior cingulate 
cortex [ACC], primary [S1], and secondary [SII] somatosensory cortices, insula [INS], 
thalamus [THAL], amygdala [AMY] and hippocampus [HIP] in each cerebral 
hemisphere. Finally, an ROI was created for V5/MT, an a priori-defined, comparably-
sized control ROI involved in visual motion perception and eye movements (Born & 
Bradley, 2005). We hypothesised that rCBF in V5/MT would not be modulated by 
post-surgical pain.  
 
ROI Data Extraction  
 
Two ROI datasets were created. In both datasets, the mean of the 20% voxels with 
greatest CBF values was computed (Mitsis, Iannetti, Smart, Tracey, & Wise, 2008) as 
a summary measure. In set one, ROIs were extracted from each individual CBF map 
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acquired at for each participant at each session; these data were used to examine 
temporal variation in rCBF response to post-surgical pain. In set two, ROIs for each 
hemisphere at each session were extracted from mean images created following first 
level voxelwise analyses.  
 
ROI Analysis  
 
All ROI analyses were performed using GenStat v11.1. Temporal variation within-
session rCBF values extracted from set one were plotted to examine temporal 
variation in rCBF value within a single session. For each ROI in each hemisphere, 
rCBF estimates from each pCASL scan were fitted to a mixed effect model, with 
Participant, Participant-by-Session, Participant-by- Session-by-Time and Participant-
by-Session-by-Hemisphere as random effects, Session-Pair (Pair 1/Pair 2) as fixed 
effect, and a 3-way factorial of Surgery (Pre-surgery/Left/Right tooth Post- surgery) 
Hemisphere (Left/Right) and Timepoint (1–6). P-values were Bonferroni corrected for 
multiple comparisons.  
Pre/Post-surgical differences  
 
For each ROI in each hemisphere, rCBF values for each subject in each session 
were fitted to a mixed effect model. Participant and Participant-by-Session were fitted 
as random effects, and Surgery (Pre-surgery/Left/Right-tooth post-surgery), Session-
pair (Pair 1[S2,S3]/Pair 2[S4,S5]) and Hemisphere (Left/Right) were fitted as fixed 
effects. Significance thresholds were imposed after Bonferroni correction.  
 
Correlation Analysis  
 
For each ROI, an ANCOVA model was fitted to rCBF values obtained from each 
hemisphere in set two. Subject was fitted as a fixed effect and VAS estimate of pain 
[VAS] fitted as a covariate. The model was used to calculate intra-subject correlation 
co-efficients (rw) for each ROI (Bland & Altman, 1995). Due to the exploratory nature 
of these correlation analyses, multiple comparison correction was not employed.  
 
Results 
 
Surgical Outcome  
 
There were no differences relating to site of surgery (left versus right). Perceived 
surgical difficulty and time taken from local anaesthesia to first CBF map did not differ 
between left and right surgeries (Difficulty: Left = 3.29, Right = 3.47; paired-t, p = 
0.44; Time taken: Left = 210 minutes, Right = 204 minutes; paired-t, p = 0.738).  
 
Psychometric Outcomes  
 
Mean alertness ratings did not differ between pre- and post- surgical MRIs (Pre-
surgery = 62.36, Post-surgery = 66.4; p = 0.35), (Figure 1a). There was no session 
order effect (p = 0.592). Mean post-surgical pain ratings were increased compared to 
pre-surgical visits (Figure 1b) (Pre-surgery = 1.8, Post-surgery = 56.5; F[1,39.6] = 
432.99, p<0.001), but there were no differences following extraction of left, compared 
to right, third molars (p = 0.97). There was no session order effect (p = 0.55).  
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Figure I-1: Within-scanner time courses of VAS indices of (a) perceived alertness and (b) pain 
experienced pre/post each pCASL scan. Each visit is plotted separately (Left tooth = Grey, Right 
Tooth = White; Filled circles = Post-surgical visit, Unfilled circles = Pre-surgical visit; Error bars 
indicate  1 Standard Deviation. 
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Neuroimaging  
 
A distributed network of brain regions demonstrated significant increases in rCBF 
relating to pain following extraction of left and right third molars, compared to pain-
free pre-surgical periods in the same subjects. Table 1 details each cluster in brain 
regions we hypothesised a priori would demonstrate CBF changes during post- 
surgical pain; for brevity, only clusters with highest Z-scores per anatomical region 
have been reported. We did not observe any post-surgical decreases in CBF in these 
regions or elsewhere. In particular, bilateral increases in rCBF during post-surgical 
pain were identified in postcentral gyrus, specifically the somatotopic region of S1 
relating to the face/jaw (Penfield & Rasmussen, 1950; Weigelt, Terekhin, 
Kemppainen, Dörfler, & Forster, 2010) (Figure 2; 3a), in SII (Figure 3b), extending 
ventrally towards posterior insula cortex and in mid/anterior insula cortices, extending 
towards the frontal operculum.  
 
 
 
Figure I-2: Post-surgical CBF changes in S1 relate to the classical somatotopic representation of the 
jaw (adapted from (Weigelt et al., 2010)). CBF increases coded in red illustrates mask image of 
clusters significant at the p<0.05 (corrected) level. Yellow mask illustrates S1 ROI in left and right 
cerebral hemispheres. 
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Structure Left Hemisphere Right Hemisphere 
 Zstat x y  z Zstat x y  Z 
Primary Somatosensory Cortex  3.41 -62 -16 42 3.17 42 -16 42 
Secondary Somatosensory Cortex 3.29 -56 -14 14 3.36 54 -14 16 
Thalamus 3.46 -20 -28 16 3.76 16 -36 6 
Pons 2.98 -18 -28 -32 3.11 14 -30 -26 
Trigeminal System     3.53 -18 -18 -32 
Midbrain 3.22 -16 -22 -8 3.54 4 -24 -14 
Posterior Cingulate Gyrus                 3.02 -8 -64 12 3.38 24 -70 6 
Cingulate Gyrus                     3.03 -4 -32 24 3.25 10 -42 26 
Mid-anterior Cingulate Gyrus 3.26 -12 6 36 3.38 14 -12 44 
Anterior Cingulate                        3.13 6 36 6 
Hippocampus/Parahippocampus               4.05 -28 -50 -6 4.00 26 -44 -4 
Amygdala 3.80 -30 2 -26 4.32 24 0 -14 
Insula                            3.47 -44 -10 6 4.10 40 -12 14 
Table I-1: Regions of increased post-surgical CBF specified a priori to underpin cerebral processing 
of pain. 
At midline, clusters were observed bilaterally in mid-anterior cingulate cortices, 
(Figure I-3c) extending towards perigenual cingulate cortex, and in posterior cingulate 
gyrus close to the splenium of the corpus callosum. In the temporal lobe, clusters 
were identified in amygdala (Figure I-3d), extending dorsally through 
hippocampal/parahippocampal cortices (Figure I-3e). In the thalamus, a single, 
bilateral interconnected cluster was identified which included pulvinar, ventral 
posterior, ventromedial and anterior regions at midline, extending inferiorly to include 
the hypothalamus (Figure I-3f).  
 
ROI 
Estimated Marginal 
Means 
Pre-surgery vs. 
Post-surgery 
Post-surgery  
(left vs. right) 
Hemispher
e Session Pair 
 
Pre-
surger
y 
Post-
surgery 
[L] 
Post-
surgery 
[R] 
Mean 
differen
ce 
F-
ratio p 
Mean 
differen
ce 
F-
ratio p 
F-
ratio p F-ratio P 
AMY 56.6 60.2 61.3 4.2 14.45 0.00 1.1 0.47 0.49 18.87 0.00 0.04 0.85 
HIP 59.3 62.1 63.4 3.5 10.47 0.00 1.3 0.73 0.40 0.57 0.45 0.08 0.78 
Insula 81.0 85.4 87.5 5.4 10.38 0.00 2.1 0.79 0.38 27.23 0.00 0.00 0.99 
S1 66.6 71.2 71.2 4.6 5.28 0.03 0 0.00 0.99 69.58 0.00 0.01 0.91 
S2 71.9 76.2 77.2 4.8 11.02 0.00 1.1 0.27 0.61 32.05 0.00 0.04 0.85 
ACC 93.3 97.0 100.2 5.3 6.80 0.01 3.2 1.27 0.27 
157.0
4 0.00 0.12 0.73 
PCC 103.1 105.7 108.6 3.9 4.01 0.05 2.9 1.11 0.30 73.98 0.00 0.01 0.92 
Thalamu
s 67.4 71.5 74.2 5.5 15.35 0.00 2.8 1.98 0.17 18.34 0.00 0.03 0.85 
V5 76.4 77.3 77.9 1.2 0.39 0.53 0.6 0.04 0.84 
159.9
8 0.00 0.01 0.91 
 
Table I-3: Summary table: Pre and post-surgical estimated means, and ANOVA outputs for each pre-
specified ROI. 
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Figure I-3: (a–f) Time courses of post-surgical rCBF increases relating to pain in each a priori-
defined ROI. Cluster-corrected (p<0.05) Z-statistic map (red) indicates regional post-surgical 
increases in CBF relating to pain. In each row, a priori ROI masks are outlined in yellow. Plots at far 
right of each row indicate time courses of post-surgical increases in CBF (ml/100 g/min) for each ROI 
extracted from each individual pCASL scan (Red = left hemisphere, Blue = right hemisphere; Error 
bars represent  1 Standard Error). 
 
Further regions of increased post-surgical rCBF (Table 2) were identified in addition 
to those specified a priori. In the frontal lobe, clusters were identified in superior, 
middle, medial and orbital-frontal cortices, in precentral gyrus and superior and 
inferior parietal lobules bilaterally. In the temporal lobe, bilateral regions of increased 
CBF were identified in superior, middle inferior temporal and fusiform gyri, and in the 
lingual gyrus and precuneus in the occipital lobe. In the basal ganglia, clusters were 
identified in caudate and lentiform nuclei bilaterally. In the brainstem, increased post-
surgical CBF was identified bilaterally adjacent to the lateral mid-pons, approximating 
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to the trigeminal ganglion/ roots (Figure 4), with further continuous regions of 
increased rCBF in mid-pons identified as principal sensory trigeminal nucleus (Vp), 
extending posteriorly towards bilateral anterior cerebellar hemi- spheres and vermis. 
Superior to Vp, a single cluster was observed encompassing the pontine reticular 
formation, ascending superiorly into midbrain reticular formation including much of 
the tegmentum including substantia nigra, ventral tegmental area and red nucleus, 
and tectum including quadrigeminal body and periaqueductal grey.  
 
 
 
Figure I-4: Anatomical and Functional Localisation of the Trigeminal Ganglion. (left) High 
resolution axial T2-weighted image illustrates Meckel’s cave (magenta), the anatomical location of the 
trigeminal ganglion. (right) Post-surgical rCBF increases in trigeminal ganglion. 
 
ROI Analysis: Temporal Variation Within Session  
 
The anatomical location of each ROI, post-surgical CBF change and associated time 
courses is illustrated in Figure I-3 (a2f). Mixed effect model analyses in each a priori 
ROI demonstrated that no significant variation in rCBF across scans (Time) was 
identified within a single session. There were no other significant second or third 
order interactions of Time with Hemisphere, or Surgery, indicating that within-session 
temporal variation across pCASL scans did not differ between cerebral hemispheres, 
either in pre-surgical or post-surgical scanning sessions following either left or right 
TME. In the light of these findings, assessment of between session variation in rCBF 
was studied using ROIs derived from set two, the average of all 6 cASL maps 
acquired within a single session.  
Pre/Post surgery differences  
 
Mixed effect models were computed for all pain and control ROIs. Main effects and 
interactions for ROIs are summarised in Table I-3. In each pain-related ROI, rCBF 
increases between 5-10% were identified following TME. Following correction for 
multiple comparisons, significant increases in post-surgical rCBF were observed in 
AMY, HIP, SII, THAL, & INS ROIs, with strong trends in the same direction identified 
in S1 and ACC, but not in control region V5/ MT. There was no effect of side of first 
tooth removal. A main effect of hemisphere was observed in all ROIs, including 
control region V5/ MT but excluding HIP, which indicated that both pre- and post- 
Manuscripts 
 
33 
surgical rCBF values for ROIs were increased in right, compared to left hemisphere. 
There were no significant interactions of hemisphere with surgery side across all 
ROIs, meaning that surgery effects had the same impact on each hemisphere 
independently of whether left or right third molar was removed.  
 
Structure Left Hemisphere Right Hemisphere 
 Zstat x y  z Zstat x y  z 
Medial Frontal Gyrus                 2.66 -12 38 24 2.71 8 -8 60 
Superior Frontal Gyrus 2.74 -20 -4 68 2.91 34 56 28 
Middle Frontal Gyrus 3.12 -34 2 66 2.78 24 -2 46 
Inferior Frontal Gyrus             3.77 -36 8 -16 3.20 42 32 -12 
Orbital Gyrus                            2.95 4 42 -22 
Rectal Gyrus                             2.95 12 42 -18 
Rectal Gyrus                          2.86 6 32 -24 
Precentral Gyrus                   3.92 -60 10 0 3.49 64 8 10 
Postcentral Gyrus                  2.70 -28 -48 72 3.22 22 -34 66 
Paracentral Lobule                  3.46 10 -32 62 3.15 6 -42 72 
Superior Parietal Lobule           2.92 -22 -60 56 3.20 26 -66 56 
Inferior Parietal Lobule             2.64 -2 -94 26 3.35 24 -62 30 
Superior Temporal Gyrus            3.78 -64 -6 4 3.77 36 8 -20 
Middle Temporal Gyrus                 3.25 64 -40 -10 
Inferior Temporal Gyrus                3.49 38 -6 -28 
Fusiform Gyrus                    3.32 -36 -34 -22 3.61 36 -40 -18 
Supramarginal Gyrus                 2.84 -28 -46 38 
Superior Occipital Gyrus              2.74 34 -88 22 
Precuneus                           3.22 -18 -62 30 3.42 22 -86 42 
Lingual Gyrus                   2.68 -20 -78 -4 3.69 18 -84 -6 
Lentiform Nucleus                  4.55 -26 2 -4 4.24 30 -12 2 
Caudate                            3.78 -10 20 6 4.71 6 4 2 
Internal Capsule 4.26 -18 20 -6 4.49 30 6 -4 
Claustrum                                4.31 32 0 8 
Cerebellum 3.25 -20 -46 -32 3.23 12 -56 -26 
Cerebellar Lingual                      3.90 2 -46 -24 
Declive                       3.29 50 -50 -26 
Cuneus                         3.17 -14 -74 16 3.01 0 -100 4 
Culmen                              3.20 -12 -70 -12 3.68 12 -44 -24 
 
Table I-2: Additional regions of increased post-surgical CBF not specified a priori to underpin central 
processing of pain. 
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Relationships Between VAS Pain Estimates and rCBF  
 
Within-subject correlation co-efficients (rw) were computed for each ROI in each 
hemisphere to assess the relationship between post-surgical pain rCBF and patients‘ 
self-reported pain VAS scores. Significant linear relationships were identified in AMY, 
HIP, S1, SII, THAL, INS, PCC & ACC ROIs, (Table I-4) but not in control region 
V5/MT.  
 
ROI Structure Left 
Hemisphere 
 Right 
Hemisphere 
 
 ρw F-prob ρw F-prob 
Amygdala 0.41 0.004 0.51 0.000 
Brainstem 0.40 0.005 0.44 0.002 
Hippocampal 
Formation 
0.42 0.003 0.46 0.001 
Insula 0.35 0.014 0.48 0.001 
S1 0.36 0.011 0.41 0.003 
S2 0.38 0.008 0.46 0.001 
ACC 0.37 0.009 0.37 0.009 
Thalamus 0.47 0.001 0.46 0.001 
V5 0.15 0.304 0.23 0.122 
 
Table I-4:  Within-subject correlation co-efficients (ρw) between mean rCBF in each region in each 
hemisphere and mean self-reported pain. 
 
Discussion 
 
Using pCASL, we have demonstrated reproducible, rCBF- derived markers of 
ongoing, clinically-relevant pain. Increases in rCBF were established following 
surgery, compared to pain-free pre-surgical periods, in an unbiased voxel-wise 
analysis and in a priori hypothesised regions inherent in the central processing of 
pain, but not in control brain regions hypothesised to be unchanged by pain. rCBF 
assessments were stable within a single session and there were no between-session 
differences in post- surgical rCBF following extraction of left, compared to right, teeth, 
indicating a viable test-retest paradigm. Post-surgical CBF changes correlated with 
VAS estimates of self-reported pain, but only in brain regions known to underpin the 
processing of pain and not in a control brain region. Quantitative changes in rCBF 
that represent ongoing pain have potential as markers of treatment efficacy for acute 
and persistent painful conditions.  
 
Our findings of rCBF increases during pain following TME provide valuable new 
insights into the representation of ongoing post-surgical trigeminal pain. 
Independently of site of removal, the pain resulting from tooth extraction is 
represented by a largely bilateral pattern of rCBF changes throughout the brain. No 
hemispheric differences in rCBF changes related to extraction were found. These 
findings differ from earlier pain studies using PET imaging, which have largely 
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reported rCBF changes contralateral to the painful body-site, for example, 
contralateral increases in rCBF in PFC, insula cortex, and lentiform nucleus were 
reported following a composite third molar extraction and thermal heat pain challenge 
(Derbyshire et al., 1999). To the best of our knowledge, this is the only other 
neuroimaging study of pain following third molar extraction, but is difficult to relate to 
our findings due to the confounding effect of a nociceptive heat stimulus applied to 
the hand contralateral to the extracted tooth. Two recent reports using experimental 
pain models have highlighted the potential of ASL in pain research (Owen et al., 
2008; Owen et al., 2010). Several findings in those studies were concordant with our 
own, namely, similar magnitude of CBF values in grey matter and resulting rCBF 
changes in response to pain in bilateral insula cortex, SII, cingulate cortex and 
supplementary motor area, as well as responses in S1 and thalamus. However, 
contrary to our own findings, responses to a tonic painful hypertonic saline stimulus 
produced a CBF decrease in S1, while several additional regions demonstrated a 
reduction in magnitude of the CBF change over the time course of the saline infusion. 
We speculate that such CBF decay characteristics may relate to differences not only 
in physiological response but also in terms of the threat value of an experimentally 
evoked stimulus, compared to a genuine post-surgical tissue trauma (Pogatzki-Zahn 
et al., 2010; DD Price, 1999; Weigelt et al., 2010). Differences in ASL implementation 
in those studies precluded further examination of CBF changes inferior to the 
thalamus and provided a lower spatial resolution than reported here, and further 
comparisons are difficult due paradigm design, body-site differences, and potentially 
confounding CBF changes relating to patient introspection and movements derived 
from providing VAS estimates of perceived pain throughout image acquisition.  
 
Our finding of bilateral post-surgical rCBF increases in S1 is supported by primate 
electrophysiological studies of S1 neurones with bilateral receptive fields (Lin, 
Murray, & Sessle, 1993), and other imaging reports of evoked painful and non-painful 
stimulation of the trigeminal nerve, e.g. (Jantsch, Kemppainen, Ringler, Handwerker, 
& Forster, 2005; Weigelt et al., 2010). Our observations of bilateral rCBF changes in 
thalamus most likely relate particularly to representation of pain by the trigeminal 
system. In particular, crossed and uncrossed somatosensory and nociceptive 
afferents project from the trigeminal ganglion, via the principal sensory nucleus and 
nucleus caudalis respectively, terminating at the ventral medial and lateral posterior 
regions of the thalamus. Both these thalamic regions contain bilateral representations 
of the intra-oral cavity (Nieuwenhuys, Voogd, & Van Huijzen, 2008). In addition, 
extensive interconnections in thalamus and hypothalamus (Pogatzki-Zahn et al., 
2007) are likely to underpin bilateral changes in post-surgical thalamic rCBF and may 
represent changes in arousal as well as the experience of ongoing pain (De Leeuw, 
Albuquerque, Okeson, & Carlson, 2005).  
 
Demonstration of local increases in CBF in Vp during post- surgical, ongoing 
trigeminal pain echo recent reports of changes in brain activation in Vp in preclinical 
studies (Dessem, Moritani, & Ambalavanar, 2007), following hypertonic saline 
injection to the masseter muscle (Nash, Macefield, Klineberg, Murray, & Henderson, 
2009) and following noxious electrical stimulation of the tooth pulp (Weigelt et al., 
2010). These findings challenge the traditional belief that Vp is associated only with 
somatosensation, with nociceptive trigeminal afferents processed only via nucleus 
caudalis of the trigeminal nerve (Nieuwenhuys et al., 2008) and provide evidence that 
Vp plays a role in pain processing. We could not identify rCBF changes in trigeminal 
nucleus caudalis; this region of hindbrain was inferior to the ASL imaging volume 
Manuscripts 
 
36 
prescribed. Further methodological development is required to include these regions 
within the imaging volume. We speculate that extended brainstem coverage is likely 
to improve our ability to detect significant bilateral post-surgical CBF increases in the 
trigeminal ganglion (TG). While we report a cluster of significant CBF increase in left 
TG only, CBF increases in right TG were slightly below statistical cluster threshold 
and are likely to be explained by type-II error. Our findings of CBF changes in 
response to pain in the mandibular branch of TG are contrary to a recent report using 
BOLD-fMRI, which reported signal changes in the maxillary branch of TG only 
(Weigelt et al., 2010).  
 
Taken together, our findings have potential to impact positively upon the role of 
neuroimaging in assessing novel treatments for pain (Borsook et al., 2008). We 
conjecture that in future, pCASL-derived rCBF measures might be used as 
prospective independent endpoints for pain assessment, rather than an adjunct to 
patient self-reported pain. We acknowledge such a statement is likely to provoke 
considerable controversy within the field (Derbyshire, 2006). In common with 
previous reports, for example (Derbyshire et al., 1997), our findings of correlations 
between post-surgical rCBF and VAS estimates of self-reported pain, limited only to 
brain regions known to underpin the pain experience, demonstrate that our results 
are physiologically plausible and relate (at least in part) to the pain experience. 
Caution should be exercised, however, in over-interpretation of VAS pain-estimate 
relationships with individual ROIs; first, given the multi-dimensional nature of the pain 
experience (Melzack, 2001) multivariate regression analyses are likely to provide 
better predictions of verbal response (Marquand et al., 2010); secondly, seeking only 
to replicate patient-self reported endpoints using neuroimaging obviates its use. 
Arguably imaging-based markers of ongoing pain should be considered in terms of 
their ability to add value over and above self-report (Borsook et al., 2008).  
 
Our finding of reproducible rCBF data, within and between sessions, makes ‗cross-
over‘ assessments of pain treatments tenable. A critical next step to develop ASL as 
a methodology for assessing modulation of ongoing pain will be to demonstrate pain-
related CBF changes that are attenuated by an analgesic of known efficacy. 
Successful demonstration of analgesic-modulated CBF changes should provide the 
evidence necessary to refine decision- making techniques for assessing efficacy of 
novel interventions. We envisage several potential uses for the pCASL methodology 
(Borsook et al., 2008); central effects of pain medications unrelated to their analgesic 
action could be assessed in pain-free participants (Wagner et al., 2001); putative 
mechanisms of action for novel analgesics might be investigated and possible new 
indications for existing compounds in related therapeutic areas uncovered; 
examinations of differential efficacy across pharmacological classes and doses could 
be realistic applications. In addition, availability of ASL in preclinical MRI should 
facilitate translational research; ASL studies might potentially illustrate new insights in 
ongoing pain in preclinical cohorts in which examination of simple behavioural 
endpoints in response to evoked pain has predominated to date (Mogil, 2009).  
 
Improved knowledge of acute ongoing pain should impact upon understanding the 
central representation of chronic pain; bridging this gap might facilitate developing 
new medications for intractable pain conditions that are often resistant to currently 
approved analgesics (Kupers & Kehlet, 2006). Given increasing evidence for 
changes in brain function and structure relating to chronicity of pain (May, 2008), a 
better understanding of disease-specific ‗neurosignatures‘ will be imperative. The 
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ROI-based methodology described here is appropriate to examining post-surgical 
pain in healthy volunteers, but cannot be applied universally to all persistent pain 
states; instead, selecting a set of a priori ROIs based on previous knowledge of the 
specific pain condition should be preferred. While we believe ASL has utility in 
analgesic trials, the method should be equally applicable to assessing changes in 
ongoing pain in other, non-pharmaceutical scenarios; for example, pain modulation 
following cognitive behavioural therapy (Eccleston, Williams, & Morley, 2009). 
Additional applications might include assessing pain in individuals less able to 
verbalise self-reported pain, for example children (Eccleston et al., 2012) or 
potentially, patients with consciousness disorders (Owen & Coleman, 2008).  
 
In summary, using perfusion MRI, in concert with the TME model, we have described 
a network of rCBF increases representing ongoing post-surgical pain. Post-surgical 
CBF changes are reproducible within- and between sessions. Our findings represent 
the beginning of a novel approach to measure ongoing pain as an alternative to self-
report. The approach is stable and provides robust, repeatable results in a relatively 
small group of participants, compared to conventional studies solely using self-
reported pain as endpoints (Moore, Gavaghan, Tramèr, Collins, & McQuay, 1998). 
Reduction in study numbers is likely to provide benefits in the early phase 
assessment of putative analgesics and other interventions, both in terms of cost and 
time. While we have focussed upon assessment of acute, ongoing post-surgical pain, 
we believe that developing the methodology for examining pain in patients with 
persistent painful conditions will be valuable for pioneering much-needed new 
therapies.  
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2.2 Manuscript II: Quantifying the test-retest reliability of cerebral blood flow 
measurements in a clinical model of on-going post-surgical pain: A study using 
pseudo-continuous arterial spin labelling2 
  
 
 
Abstract 
 
Arterial spin labelling (ASL) is increasingly being applied to study the cerebral 
response to pain in both experimental human models and patients with persistent 
pain. Despite its advantages, scanning time and reliability remain important issues in 
the clinical applicability of ASL. Here we present the test–retest analysis of 
concurrent pseudo-continuous ASL (pCASL) and visual analogue scale (VAS), in a 
clinical model of ongoing pain following third molar extraction (TME). Using ICC 
performance measures, we were able to quantify the reliability of the post-surgical 
pain state and ΔCBF (change in CBF), both at the group and individual case level. 
Within-subject, the inter- and intra-session reliability of the post-surgical pain state 
was ranked good-to-excellent (ICC N 0.6) across both pCASL and VAS modalities. 
The parameter ΔCBF (change in CBF between pre- and post-surgical states) 
performed reliably (ICC N 0.4), provided that a single baseline condition (or the mean 
of more than one baseline) was used for subtraction. Between-subjects, the pCASL 
measurements in the post-surgical pain state and ΔCBF were both characterised as 
reliable (ICC N 0.4). However, the subjective VAS pain ratings demonstrated a 
significant contribution of pain state variability, which suggests diminished utility for 
inter-individual comparisons. These analyses indicate that the pCASL imaging 
technique has considerable potential for the comparison of within- and between-
subjects differences associated with pain-induced state changes and baseline 
differences in regional CBF. They also suggest that differences in baseline perfusion 
and functional lateralisation characteristics may play an important role in the overall 
reliability of the estimated changes in CBF. Repeated measures designs have the 
important advantage that they provide good reliability for comparing condition effects 
because all sources of variability between subjects are excluded from the 
experimental error. The ability to elicit reliable neural correlates of ongoing pain using 
quantitative perfusion imaging may help support the conclusions derived from 
subjective self-report. 
                                            
2
 Author Contributions to Idea/Experimental Hypothesis: 5%, Experimental Design: 5% Data 
Collection: 80%, Data Analysis: 20%, Writing: 5%, Interpretation: 5%  
 
 
Reference: 
Hodkinson, D. J., Krause, K., Khawaja, N., Renton, T. F., Huggins, J. P., 
Vennart, W., … Howard, M. a. (2013). Quantifying the test–retest reliability 
of cerebral blood flow measurements in a clinical model of on-going post-
surgical pain: A study using pseudo-continuous arterial spin labelling. 
NeuroImage: Clinical, 3, 301–310. http://doi.org/10.1016/j.nicl.2013.09.004 
 
Manuscripts 
 
39 
Introduction 
 
Pain is a complex, multidimensional experience that includes sensory and affective 
components. Within this context, pain is subjective and is not readily quantifiable. For 
humans, pain assessment strategies may include self-rating scales, observational 
scales, and other behavioural tools (Katz & Melzack, 1999). One of the most 
commonly used methods for assessing pain in the clinic is the visual analogue scale 
(VAS). While this assessment is by definition, highly subjective, these scales are of 
most value when looking at changes within individuals, and are of less value for 
comparing across a group of individuals at one particular time (Steingrímsdóttir, 
Vøllestad, Røe, & Knardahl, 2004; Victor et al., 2008). Critically, there is an 
acknowledged, unmet need for more reliable endpoints of the pain experience 
(Kupers & Kehlet, 2006). The identification of robust and quantifiable measurement 
tools is likely to improve the diagnosis and management of chronic pain conditions, 
and help provide a better evaluation of the mechanisms of analgesic drugs. 
 
Neuroimaging techniques have demonstrated that a large, distributed brain network 
underpins nociceptive processing. In the past, authors have referred to this network 
as the ―pain matrix‖ (Brooks & Tracey, 2005); however this concept has been 
challenged, as relevant salient or behavioural stimuli have been shown to engage a 
similar network (Downar, Mikulis, & Davis, 2003; G. D. Iannetti & Mouraux, 2010). 
For acute pain experiences, commonly activated areas include the primary and 
secondary somatosensory cortices, insular, anterior cingulate, prefrontal cortex, and 
the thalamus (Apkarian et al., 2005; Tracey & Bushnell, 2009a). Depending on the 
nociceptive stimulus and experimental paradigm, other brain regions including the 
basal ganglia, cerebellum, amygdalae, hippocampus, and areas within the parietal 
and temporal cortices may also be recruited. By contrast, the mechanisms that 
contribute to the generation and maintenance of chronic clinical pain states are more 
complex. Several groups have reported consistent activation in the pre- frontal, 
frontal, and anterior insular cortices that may be important in the maintenance of 
chronic pain conditions (Apkarian, Baliki, & Geha, 2009; Howard et al., 2012; 
Schweinhardt & Bushnell, 2010; Wasan et al., 2011). However, it is still unclear if 
these markers of activity directly predict the underlying clinical pathology, or 
represent other contextual aspects of the patients' experiences. 
 
Owing to the advent of arterial spin labelling (ASL) MRI techniques, the 
representation of ongoing or spontaneous pain states has rightly received attention in 
neuroimaging (Howard et al., 2011; Maleki, Brawn, Barmettler, Borsook, & Becerra, 
2013; Owen et al., 2008; Owen et al., 2010; Tracey & Johns, 2010b). Our group 
recently reported a study using pseudo-continuous ASL (pCASL) (Dai et al., 2008), in 
conjunction with a commonly used post-surgical model, to demonstrate changes in 
regional cerebral blood flow (CBF) associated with the experience of being in 
ongoing pain after third molar extraction (TME) (Howard et al., 2011). This study 
identified a number of the anatomical regions consistent with pain response patterns 
detected using ASL in other experiments (reviewed in Maleki et al., 2013 (Maleki et 
al., 2013)). Pain following TME has become the most frequently used model in acute 
pain trials, particularly for regulatory purposes (Barden et al., 2004). However, in the 
present literature, there is limited information available on the reliability of quantitative 
perfusion measures for the study of ongoing pain in experimental volunteers and 
patients using ASL methodologies. 
 
Manuscripts 
 
40 
A well-established measure of reliability is the intra-class correlation coefficient (ICC) 
(Shrout & Fleiss, 1979). ICC has classically been described in the context of 
consistency or agreement between ratings given by different judges; however, it can 
also be used to assess the reliability of ratings across different testing sessions and 
to assess the reliability of imaging methods over time (Bennett & Miller, 2010; 
Caceres, Hall, Zelaya, Williams, & Mehta, 2009). Several groups have conducted re- 
liability studies of resting CBF measurements employing different ASL labelling 
schemes (Çavuşoǧlu, Pfeuffer, Uǧurbil, & Uludaǧ, 2009; Y. Chen et al., 2011; Floyd, 
Ratcliffe, Wang, Resch, & Detre, 2003; Gevers, Majoie, Van Den Tweel, Lavini, & 
Nederveen, 2009a; Gevers et al., 2011; Hermes et al., 2007; Jahng et al., 2005; Jain 
et al., 2012; Jiang et al., 2010; Parkes, Rashid, Chard, & Tofts, 2004; Petersen, 
Mouridsen, & Golay, 2010; Tjandra et al., 2005; Xu et al., 2010; Yen et al., 2002). 
These studies converge on the conclusion that ASL reliability is comparable to other 
perfusion imaging techniques such as PET or SPECT; however, the extracted CBF 
values are often constrained to the cortical grey matter (GM), flow territories, brain 
lobes, or targeted regions-of-interest (ROIs). Two recent studies assessed the 
feasibility of ASL for pharmacological research, conducting test–retest evaluations of 
citalopram and fentanyl drug challenges (Klomp, Caan, Denys, Nederveen, & 
Reneman, 2012; Zelaya et al., 2012). To our knowledge, there have been no reports 
confirming the reliability of ASL-based perfusion measurements for the study of on- 
going pain states in experimental volunteers or chronic pain patients. Similarly, there 
have been no ‗head-to-head‘ comparisons of the ASL technique with traditional 
behavioural assessments of pain. 
To confidently compare CBF values across different cohorts of a population (i.e. pain 
patients vs. healthy controls) and across repeated measurements on the same 
individual (such as in longitudinal cross-over studies and drug trials), it is important to 
consider the between- and within-subject variability. In this study, we sought to 
quantify the test–retest reliability of concurrent pCASL and VAS in a clinical model of 
ongoing pain following TME. Reliability was examined at three levels; (1) inter-
subject, (2) inter-session, and (3) intra-session. Within each of these categories, we 
calculated the ICCs for the pre- and post-surgical states, together with the change in 
CBF (ΔCBF) between conditions. The principal aim of this work was to inform on the 
reliability of the pCASL technique versus VAS subjective pain ratings, and help pro- 
vide a framework to support future use of ASL methodologies for the study of chronic 
pain conditions and experimental ongoing pain states. 
 
Methods 
 
Ethical approval and consent 
 
All procedures were approved by the Kings College Hospital Research Ethics 
Committee (REC Reference 07/H0808/115). Informed, written consent was provided 
by all participants. 
 
Inclusion criteria 
 
Sixteen right-handed, healthy male volunteers (age range: 18– 50 years) were 
selected for the study. Participants presented with bilateral recurrent pericoronitis and 
fulfilled NICE guidelines for extraction of lower-jaw left and right third molars 
(NICE/NHS, 2000). Females were not included in the study due to potential variability 
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in the phase of the menstrual cycle affecting reproducibility of the post-surgical pain 
(Teepker et al., 2010). 
 
Study design 
 
Data were pooled from the previously published work of Howard et al. (2011) 
(Howard et al., 2011). Briefly, sixteen subjects were assessed on five separate 
occasions, screening/familiarisation (S1), pre-surgical scan (S2), post-surgical scan 
following the first tooth extraction (S3), pre-surgical scan (S4), and postsurgical scan 
following the second tooth extraction (S5) (Fig. 1). Scanning commenced at S3 and 
S5 when three consecutive VAS scores greater than 30/100 mm were provided 
within a 30-minute period. Order of left and right tooth extraction was balanced and 
pseudo-randomised across the group. A minimum of two-week interval separated 
S3/S4, and participants were assessed based on individual report of pain cessation 
to ensure complete recovery from the surgery. The rescue medication of 1000 mg 
paracetamol/400 mg ibuprofen was provided to participants immediately following 
scanning during S3 & S5. Full alcohol and drug-screens were performed at every 
visit, including psychometric assessment. 
 
Perfusion MRI 
 
Participants were scanned on a 3 T whole-body MRI scanner (GE Signa HDX) fitted 
with a receive-only 8-channel, phased-array head coil. For image registration 
purposes, a high resolution T2-weighted Fast Spin Echo (FSE) image was acquired. 
Perfusion measurements were made using a pseudo-continuous arterial spin 
labelling (pCASL) sequence (Dai et al., 2008). Labelling was performed using a train 
of Hanning RF pulses; 500 μs duration, peak-to-peak gap 1500 μs, and a total 
labelling duration of 1.5 s. After a post-labelling delay of 1.5 s, the image was 
acquired with a 3D FSE inter-leaved spiral readout (8 shots, TE/TR = 32/5500 ms, 
ETL = 64, 3 tag–control pairs). Pre- saturation of the image volume, followed by 
selective inversion pulses for background suppression, was also acquired in order to 
minimise the static signal. Two reference images (fluid suppressed and both fluid and 
white matter suppressed); as well as a coil sensitivity map, were used for the 
computation of the CBF maps in physiological units (ml blood per 100 g of tissue per 
min). The ASL time series comprised 6 pCASL scans, lasting 6 min each. 
Participants were instructed to lie still with their eyes open. Full details of the pCASL 
sequence and absolute quantification of CBF are available in Supplementary 
information. 
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Figure II-1: Study design for the assessment of reliability of the pCASL and VAS modalities in the clinical model of 
ongoing post-surgical pain. The data was pooled from two pre- and post- surgical visits to assess group-level 
inter-subject consistency, and the within-subject inter- and intra-session reliability. 
 
 
 
Visual analogue scales 
 
Concurrent with the MRI examination, subjects were asked to rate their perceived 
levels of pain and alertness using a visual analogue scale (VAS). The VAS 
measurements were performed according to an established protocol (Howard et al., 
2011) which consisted of a computerised line anchored with ―no pain‖/―worst 
imaginable pain‖ and ―very sleepy‖/―wide awake‖. Participants subjectively rated their 
experience following each of the six pCASL scans using a computerised VAS and 
button-box. 
 
Image pre-processing 
 
The quantitative CBF data were pre-processed using FSL (http:// 
www.fmrib.ox.ac.uk/fsl) (S. M. Smith et al., 2004). The pipeline consisted of skull 
stripping [BET], affine registration of each subject's T2 to the Montreal Neurological 
Institute (MNI) ICBM152 non-linear asymmetric T2- weighted template with 
resampling to 2 × 2 × 2 mm3 [FLIRT], and non-linear noise reduction [SUSAN: λ = 5 
mm full-width half maxi- mum]. Statistical analysis was performed under the 
framework of the general linear model (GLM) [FLAMEO]. First-level analyses were 
computed for each subject to create grey-matter (GM) only mean images of the six 
individual pCASL scans acquired at each of the sessions S2–S5. For the second-
level analysis, changes in the CBF relating to post-surgical pain were obtained using 
a mixed-effects two-way ANOVA of the combined session-pairs (i.e. Pair 
1[S2,S3]/Pair 2[S4, S5]) and a t-threshold equivalent to p < 0.01 (z = 2.3, t = 2.41, dof 
= 45). Factorial designs are powerful, because the interaction between various 
cognitive components (factors) is explicitly modelled in the analyses (Friston et al., 
1996). However, an anticipated problem with calculating the change in CBF between 
pre- and post-surgical states (ΔCBF) is that arithmetic subtraction between these two 
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conditions will not take account of the error variance. To examine these effects, 
images of ΔCBF (change in CBF) were calculated in four separate ways: (1) 
arithmetic subtraction of the pre- and post-surgical session- pairs (ΔCBFPairs), (2) 
subtraction of the post-surgical sessions from the combined mean of the pre-surgery 
sessions (ΔCBFMean), (3) subtraction of the post-surgical sessions from the first pre-
surgery session only (ΔCBFS2), and (4) subtraction of the post-surgical sessions 
from the second pre-surgery session only (ΔCBFS4). The same contrast images, for 
the pre- and post-surgical sessions only, were used to extract the reliability of the 
independent states (see Figure II-1). 
 
Regions of interest 
 
To assess CBF reliability between subjects and sessions, regions of interest (ROIs) 
were defined a priori based upon previously implicated areas in pain processing 
measured with arterial spin labelling (reviewed in Maleki et al. (2013) (Maleki et al., 
2013)). ROIs were anatomically defined in standard MNI space from the Harvard–
Oxford cortical and subcortical structural atlases, with probabilistic images 
thresholded at 20% and binarised to create exclusive ROI masks. These were 
anterior cingulate cortex (ACC), posterior cingulate cortex (PCC), anterior insula 
(aINS), posterior insula (pINS), somatosensory cortex (primary, S1 and secondary, 
S2), thalamus (THAL), hippocampus (HIP), amygdala (AMY), and brainstem (BS). 
 
Statistical methods 
 
To systematically evaluate the test–retest performance of the TME post-surgical pain 
model, we examined the inter-subject, inter-session, and intra-session variability of 
CBF and VAS measurements (Fig. II-1). These reliability estimates were calculated 
using the third ICC defined by Shrout and Fleiss (1979) (Shrout & Fleiss, 1979) 
 
   (   )  
       
    (   )   
 
 
where BMS is the between-targets mean square, EMS is the error mean square, and 
k is the number of repeated sessions (here two). All ICC values were calculated in 
MATLAB 7.1 (The Mathworks Inc.) and the statistical toolbox produced by (Caceres 
et al., 2009) (ICC Toolbox is available for download at:   
http://www.kcl.ac.uk/iop/depts/neuroimaging/research/imaginganalysis/Software/ICC-
Toolbox.aspx). We denote ICC values < 0.4 as poor, 0.4–0.59 as fair, 0.60–0.74 as 
good, and > 0.75 as excellent (Fleiss, Levin, & Paik, 2003). However, these ranges 
should be interpreted with caution as they do not take into account the confidence 
intervals of the ICC. 
Coefficient of variation (CV) is defined as the ratio of the standard deviation σ to the 
mean σ := 
 
 
 . 
 
Reliability of the behavioural measures 
 
We examined behavioural changes using the VAS self-report of subjective alertness 
and pain. Inter-subject consistency was compared using all ratings from the post-
surgical pain sessions. Within-subjects the VAS measurements from left and right-
side post-surgical pain sessions were used to assess inter-session reliability. Intra-
session stability was evaluated using the six VAS measures from either left or right-
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side post-surgical sessions independently. The parameter ΔVAS (change in VAS) 
could not be assessed due to a floor effect (i.e. scores of zero) in the pre-surgery 
VAS condition. 
 
 
Figure II-2: Concurrent VAS ratings of perceived alertness (A) and pain (B). Participants subjectively rated their 
experience following each of the six pCASL scans. Data represents the mean (± S.E.M.) of all subjects' ratings. 
 
 
Inter-subject reliability of the CBF measurements 
 
Inter-subject consistency of the ASL data was compared using an ICC approach 
previously described in the literature (Caceres et al., 2009). This was performed as a 
voxel-wise calculation of ICC, based upon the medians of ICC distributions (med 
ICC). We demonstrate the reliability of the pain network, whole GM volume, and 
targeted ROIs. 
 
Inter- and intra-session reliability of the CBF measurements 
 
Inter- and intra-session reliability of the ASL data was compared using an intra-voxel 
ICC measurement (ICCv) (Caceres et al., 2009; Raemaekers et al., 2007; Specht, 
Willmes, Shah, & Jancke, 2003). This was calculated by extracting the CBF 
amplitudes of each voxel, and assessing the distribution of ICC values across voxels 
of each ROI (Caceres et al., 2009). Comparisons between the session pairs were 
used to assess inter-session reliability. For intra-session reliability, the CBF values of 
the first and third, and first and sixth pCASL scans were examined independently. 
These scans were chosen as they represent the start, mid-point, and end of the 
dynamic time-series, hence should reflect any temporal variations in CBF between 
the repeated measurements. 
 
 
Results 
 
Behavioural results 
 
The VAS self-reported measures of alertness and pain are shown in Figure 2. There 
were no significant differences in alertness between the pre- and post-surgical 
sessions (p = 0.35), indicating that voluntary attention was consistent across the 
group. Participants' subjective ratings of pain were significantly higher in the post-
surgical sessions as com- pared to the pre-surgical sessions (p < 0.001). There were 
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no significant differences in the VAS scores relating to the left or right third molar 
extraction (p = 0.97). The ICC performance measures of alertness and pain VAS 
ratings demonstrated the highest reliability within-subjects. Both inter- and intra-
session ICCs were consistently above 0.6 and 0.8 with a low coefficient of variation 
(CV), indicating that the test–retest reliability of the pain and alertness ratings was 
good-to-excellent. At the group level, inter-subject VAS ratings of alertness indicated 
a good level of reliability (ICC = 0.664). However, the pain ratings demonstrated only 
fair reliability between-subjects (ICC = 0.456), which indicates a significant 
contribution of pain state variability. The ICC results are summarised in Table II-1. 
 
VAS reliability    
Visual analogue scales Inter-subject Inter-session Intra-session 
 Left vs right Left Right 
 ICC CV ICC CV ICC CV ICC CV 
Pain intensity 0.456 0.285 0.602 0.200 0.830 0.300 0.861 0.267 
Alertness 0.664 0.359 0.640 0.203 0.800 0.390 0.940 0.320 
Table II-1: Reliability measures for the subjective behavioural ratings of pain and alertness. ICC, 
intraclass correlation coefficients; CV, coefficient of variation. 
 
Group-level inter-subject consistency of the CBF measurements 
 
Univariate GLM analysis of the pre- and post-surgical sessions showed significant 
CBF increases in the respective anatomical target regions (Figure II-3) (see 
Supplementary information Table II-1 for ROI values).  
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Figure II-3: Group-level univariate and ICC analysis of pre- and post-surgical sessions, and ΔCBF. 
 
Having confirmed that a network of rCBF increases is present during pain processing 
in the TME model, these data were used to assess the reliability of the pre- and post-
surgical states together with the stability of the observed pain response (ΔCBF). The 
resulting ICC (3,1) maps for these conditions are depicted in Fig. II-3. ICC values 
across the pre- and post-surgical states were high (0.763/0.746 and 0.744/0.731; 
[pain network/total GM]), which confirms high reliability across the individuals. 
Estimates of the reliability associated with the different ΔCBF calculations were less 
consistent: the between-subjects ICC was smallest in the ΔCBFPair (0.325/0.343), 
slightly higher using the mean of the two pre-surgical sessions (ΔCBFMean 
0.469/0.440), and greatest with the ΔCBFS2 (0.542/0.494) or ΔCBFS4 (0.604/0.589). 
The voxel-wise ICC values for individual ROIs can be found in Fig. II-4A.  
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Figure II-4. Inter-subject (A) and inter-session (B) reliability for the cortical grey-matter (GM), pain 
network, and targeted ROIs. Stacked columns represent the reliability magnitude including labels 
inside end. ICC values were calculated at a voxel-wise level. Abbreviations: amygdala (AMY), 
hippocampus (HIPP), brainstem (BS), thalamus (THAL), anterior insula (aINS), posterior insula (pINS), 
somatosensory cortex (primary, S1 and secondary, S2), posterior cingulate cortex (PCC), anterior 
cingulate cortex (ACC). 
 
 
Examining the ICC distributions, plots of the relative number of voxels against ICC 
score are shown in Fig. II-5. The profiles of the pre- and post-surgical states (Fig. II-
5A) both demonstrate a pronounced negative skew in the ICC distribution, with the 
mass of the distribution concentrated on the right of the figure. There were relatively 
few low ICC values. For the parameter ΔCBF (Fig. II-5B), the profiles of the four 
baseline calculation methods were considerably different. The negative skew was 
largest with ΔCBFS2 or ΔCBFS4, slightly smaller with the ΔCBFMean, and smallest with 
the ΔCBFPair baseline. Importantly, in the ΔCBFS2 or ΔCBFS4 comparisons, voxels of 
the pain network were visibly more detached from the ICC values of the total GM 
volume. 
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Figure II-5. ICC distributions of the pre- and post-surgical states (A) together with the ΔCBF (change 
in CBF) (B). Plots show the relative number of activated voxels against ICC score for the grey matter 
(dotted lines) and activated pain network (solid lines). 
 
 
Within-subject inter-session reliability of the CBF measurements 
 
Figure II-4B shows the regional inter-session ICC values for the pre- and post-
surgical states together with the change in CBF (ΔCBF). For the pre- and post-
surgical states, a high level of agreement was found in all ROIs of the pain network. 
These voxel-based ICCs (ICCv) were consistently above 0.90 for each subject, 
demonstrating that the rCBF measurements have excellent inter-session 
reproducibility. By contrast, the ICC values for the ΔCBF images were much more 
varied with the ΔCBFPair and ΔCBFMean ranking poor-to-fair reliability, and ΔCBFS2 or 
ΔCBFS4 classified as fair to good. 
 
Within-subject intra-session reliability of the CBF measurements 
 
Intra-session reliability was reported for the post-surgical states. Sequential 
comparisons of the pCASL scans revealed that the voxel-based ICCs in all ROIs 
were consistently above 0.90 for every subject (irrespective of surgery-side) (Table II-
2). This suggests that the CBF measurements have excellent time-course 
reproducibility, and are stable from scan-to-scan.  
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pCASL intra-session reliability   
ROI Left-side post-surgical state Right-side post-surgical state 
 
pCASL 1 vs 3 
 
pCASL 1 vs 6 
 
pCASL 1 vs 3 
 
pCASL 1 vs 6 
 
 CCv SEM ICCv SEM ICCv SEM ICCv SEM 
ACC 0.965 0.006 0.962 0.006 0.968 0.003 0.966 0.006 
AMY 0.937 0.009 0.921 0.017 0.944 0.004 0.938 0.007 
alNS 0.967 0.005 0.959 0.004 0.970 0.005 0.964 0.004 
BS 0.974 0.003 0.970 0.004 0.974 0.003 0.970 0.002 
HIPP 0.931 0.008 0.923 0.010 0.938 0.004 0.938 0.004 
PCC 0.974 0.007 0.973 0.007 0.977 0.005 0.972 0.006 
pINS 0.958 0.005 0.951 0.007 0.963 0.003 0.961 0.005 
S1 0.957 0.004 0.952 0.007 0.953 0.008 0.947 0.007 
S2 0.974 0.004 0.968 0.003 0.976 0.003 0.971 0.004 
THAL 0.955 0.006 0.945 0.012 0.957 0.005 0.955 0.012 
 
Table II-2: Intra-session reliability of the representative pain ROIs. ICC values are compared between 
first and third, and first and sixth pCASL scans in the post-surgical pain states (ICCv; the intra-voxel 
reliability; SEM, standard error from measurement). 
 
Discussion 
Summary 
 
In the current literature there is very limited information available on the reliability of 
quantitative cerebral perfusion measures for the study of ongoing pain in 
experimental volunteers and patients. Here we present the test–retest analysis of 
concurrent pCASL and VAS measurements in a clinical model of ongoing pain after 
third molar extraction (TME). 
 
The key findings of this study are: 
 
1) Within-subject, the inter- and intra-session reliability of the post- surgical pain 
state was ranked good-to-excellent across both pCASL and VAS modalities. 
The parameter ΔCBF (change in CBF between pre- and post-surgical states) 
performed reliably, provided that a single baseline condition (or the mean of 
more than one baseline) was used for subtraction. 
 
2) Between-subjects, the pCASL measurements in the post-surgical pain state 
and ΔCBF were both characterised as reliable. However, the subjective VAS 
pain ratings demonstrated a significant contribution of pain state variability, 
which suggests diminished utility for inter-individual comparisons. 
 
Reliability at the behavioural level 
 
Of the various methods for measuring pain, the visual analogue scale (VAS) is 
regarded the most sensitive. In the present study, inter- and intra-session reliability of 
VAS was consistently above 0.60, which indicates good-to-excellent levels of 
sensitivity to the changes in pain intensity within-subjects. As anticipated, the group- 
level pain scores demonstrated only fair reliability, reflecting a significant contribution 
of pain state variability. A likely reason for this numerical discrepancy is that the ICC 
measures are particularly sensitive to the small number of observations. One could 
argue that higher numbers of subjects may be required to detect a more robust 
behavioural response to pain. However, the VAS measures of alertness appeared 
not to suffer from this affect, suggesting that the variation in reliability could be 
explained by the influence of other contextual aspects of the patients' environment, 
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which are known to separately influence pain perception (Tracey, 2010). A potential 
weakness of pain VAS is that each scale is one-dimensional and does not capture 
the full complexities of an individual's pain experience (Schiavenato & Craig, 2010). 
This remains a contentious issue in pain research (Davis, Racine, & Collett, 2012; 
Robinson, Staud, & Price, 2013); however our paper focuses on the opportunities 
afforded through combining novel neuroimaging endpoints of pain with subjective 
self-report. 
 
Group-level inter-subject consistency of the CBF measurements 
 
Reliability and agreement are important issues in the conduct of clinical studies as 
they provide information about the amount of error inherent in any diagnosis, score, 
or measurement. In the present study, ICC values for the pre- and post-surgical 
states were characterised as good-to-excellent, while the reliability of ΔCBF ranged 
from poor-to-good depending on the method of ΔCBF calculation. These findings 
support the use of perfusion MRI measures for the study of ongoing pain states and 
induced CBF responses. However, we demonstrate that measurement of more than 
one pre- and post-surgical CBF map has a profound effect on the reliability of the 
ΔCBF parameter. 
 
ICC reliability indexes are not fixed characteristics of a measurement instrument. 
Factors associated with the study design (e.g. time-intervals between sessions and 
session order), the study cohort (e.g. age, gender, emotional status, and cognitive 
level), surgical interventions, etc., might all influence the magnitude of the variance 
between subjects as well as the error variance. To minimise the impact of these 
effects, we employed a counterbalanced within-subject study design, including strict 
inclusion and exclusion criteria as a means of establishing precision in the cohort. 
However, our reliability tests suggest that the cognitive or physiological contexts of 
the pre- and post-surgical states are not entirely independent or free of both 
functional and psychological interactions. Issues with pure insertion are common in 
studies that employ cognitive subtraction, and it is has been shown that factorial 
designs are generally more powerful in the analysis of cognitive processes (Friston et 
al., 1996). These effects were recently demonstrated by Klomp et al. (2012), who 
reported issues in detecting reliable drug-induced CBF changes with ASL using the 
test–retest method. With this in mind, we demonstrate that using a single baseline 
condition (or the mean of more than one baseline) may give more precise estimations 
of ICCs, and we suggest taking this innovation into account when designing future 
test–retest studies involving repeated measures, particularly in the context of a drug 
study. 
 
We also observed that the high ICC values do not necessarily follow the high values 
of t (see Figure II-3). This discrepancy may originate from differences in the spatial 
distribution of the CBF response to pain, or from differences in intrinsic physiological 
factors between the individuals. Under normal resting conditions, perfusion has the 
potential to fluctuate considerably (Petersen et al., 2010) depending on the level of 
brain activity (Wenzel et al., 1996). Also, variations in blood T1, neuronal density or 
number, and arousal (Parkes et al., 2004) may cause individual differences in the 
perfusion estimate. Given that we carried out pCASL measurements at 3 T rather 
than 1.5 T, we had the advantage of longer T1, higher SNR, and improved spatial 
and temporal resolution. Uncertainties regarding the cerebrovascular kinetics or 
blood equilibrium magnetisation might potentially bias the calculation of absolute CBF 
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values; however, this would not affect the conclusions of the current paper regarding 
reliability of the on-going pain state. The ICC is clearly dependent on the 
heterogeneity of the sample and fluctuations in physiology induced by the pain state. 
We therefore conclude that any spatial non-uniformity of reliability in the CBF 
measurements may be driven by physiological variability rather than potential 
limitations of the pCASL technique. Further reliability studies in patient populations 
relevant for pain clinical trials will be important for the future use of ASL 
methodologies for assessing the cerebrovascular response to pain. Our results 
provide a framework for such assessments. 
 
Within-subject inter-session reliability of the CBF measurements 
 
Within-subject reliability is principally a longitudinal phenomenon. In the current 
study, the pre- and post-surgical states demonstrated excellent levels of reliability 
following a minimum two week interval in the TME model (see Figure II-4), which is 
comparable with previous studies into the longitudinal reliability of ASL in healthy 
volunteers (Chen et al., 2011; Gevers et al., 2009a; Gevers et al., 2011; Jain et al., 
2012; Parkes et al., 2004) and neurological patients (Xu et al., 2010). The reliability 
of ΔCBF was acceptable depending on the method of the ΔCBF calculation. More 
specifically, the ICC values were smaller with ΔCBFPair and ΔCBFMean than with 
ΔCBFS2 or ΔCBFS4. We suggest that this highlights once again the inadequacy of the 
simple insertion model, which may be an intrinsic problem with testing reliability by 
the test–retest method at the individual subject level. It must be stressed that our 
study design did not allow us to perform the pre-surgical scans immediately before 
surgery, but were instead performed on different days. This limitation was considered 
when interpreting the results of this reliability assessment; however we found no 
relationship between interval length and ICC values (see Supplementary information 
— Figure II-S2). 
 
There may also be intrinsic physiological differences in lateralisation of anatomy 
and/or function within-subjects. Initial assessments of lateralisation (Howard et al., 
2011) revealed that the surgical pain appeared to have the same impact on each 
hemisphere, independent of whether the left or right third molar was removed. 
Bilateral activations in S1, S2, and the insular cortex have also been reported in two 
previous studies employing painful (Jantsch et al., 2005) and non-painful (Ettlin et al., 
2004) dental stimulations. This has important implications for follow-up studies and 
crossover trials, as the ability to demonstrate low variation across repeated measures 
enables the detection of small alterations in CBF indices to monitor disease 
progression or the effect of therapeutic interventions. Other advantages of the ASL 
technique are that it is less invasive and less expensive than existing perfusion 
imaging approaches using radioactive tracers or paramagnetic contrast agents 
(Petersen et al., 2006). As ASL sequences become more widely used, evaluations of 
their reliability across the course of longitudinal studies will be important for 
understanding the advantages they offer in clinical pain research. 
 
Within-subject intra-session reliability of the CBF measurements 
 
Potential variability in the CBF measurements could be attributed to temporal 
variation. The temporal stability of the ASL signal was investigated with respect to the 
duration of scanning for each subject. Since the pCASL scans were repeated without 
repositioning, the potential error from aligning the acquisition and labelling plane was 
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averted. Theoretically, this should minimise the operator-related variability, and begin 
to approach reproducibility values that are completely physiology dependent. As 
anticipated, the ICC values between pCASL scans were higher than those between 
sessions (Figure II-4 & Table 2), confirming that the CBF measurements within the 
on-going pain state have excellent time-course stability. The relative stability of these 
perfusion measurements to sustained temporal effects makes pCASL an attractive 
method to study naturalistic responses to pain. Furthermore, it allows within-subject 
investigations of spontaneous fluctuations in pain state, over relatively long-time 
intervals. 
Conclusion 
 
Here we present the test–retest analysis of concurrent pCASL and VAS 
measurements in a clinical model of on-going pain after third molar extraction (TME). 
Using ICC performance measures, we were able to quantify the reliability of the pain 
response and the on-going pain state, both at the group and individual case level. 
Within-subject, the inter- and intra-session reliability of the post-surgical pain state 
was characterised as good-to-excellent across both pCASL and VAS modalities. The 
parameter ΔCBF (change in CBF between pre- and post- surgical states) performed 
reliably, provided that a single baseline condition (or the mean of more than one 
baseline) was used for subtraction. Between-subjects, the pCASL measurements in 
the post-surgical pain state and ΔCBF were both characterised as reliable. However, 
the subjective VAS pain ratings demonstrated a significant contribution of pain state 
variability, which suggests diminished utility for inter-individual comparisons. These 
analyses indicate that the pCASL imaging technique has considerable potential for 
the comparison of within- and between-subjects differences associated with pain-
induced state changes and baseline differences in regional CBF. They also suggest 
that differences in baseline perfusion and functional lateralisation characteristics may 
play an important role in the overall reliability of the estimated changes in CBF. 
Repeated measures designs have the important advantage that they provide good 
reliability for comparing condition effects, because all sources of variability between 
subjects are excluded from the experimental error. The ability to elicit reliable neural 
correlates of ongoing pain using quantitative perfusion imaging might help support 
the conclusions derived from subjective self-report. 
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2.3 Manuscript III: Molecular Characterisation of blood-based Response to Surgical 
Trauma reveals Enriched Expression in Pain-Relevant Signaling Pathways3 
 
 
 
 
Abstract 
 
   Genome-wide gene expression levels in peripheral whole blood pre- and post 
third molar extraction with added bioinformatic pathway analysis yielded a list of 
potential biomarkers in inflammatory post-surgical pain in humans. Several of the 
genes showed numerous associations with various pain disorders and coded for 
members of protein groups with known pain modulatory functions (e.g. zinc finger 
proteins, interleukins and enkephalinases). The high number of associations with 
various pain phenotypes might facilitate future identification of shared mechanisms 
between pain disorders of different clinical manifestations and promote the 
development of novel analgesics and drug classes within a mechanism based 
framework of pain and its treatment.   
 
Introduction 
 
 To date genotyping individuals with rare Mendelian disorders has led to the 
discovery of genes, which dramatically affect the pain response by causing severe in-
/sensititvity to pain (Auer-Grumbach, 2008; Einarsdottir et al., 2004; Lafreniere et al., 
2004; Wada et al., 2002). In addition, several candidate gene studies have 
investigated various single nucleotide polymorphisms (SNPs) in specific pain 
populations or experimental pain paradigms (Diatchenko et al., 2006; Kim, Mittal, 
Iadarola, & Dionne, 2006; Vargas-Alarcón et al., 2007) based on prior knowledge 
about pain physiology. For example, in the clinical context the effects of opioid 
analgesics in conjunction with their primary target, the mu-opioid receptor and 
mutations therein, have received much attention (J Lötsch & Geisslinger, 2006; 
Walter & Lötsch, 2009a).  
 
The majority of pain disorders seen in clinical practice, however, is most likely of 
polygenic origin (Kalow, 2006; Max & Stewart, 2008a) with genes from a target 
selection whose full extent is still undetermined. The genes involved may also vary 
between disorders, since our knowledge of molecular pain mechanisms is still 
                                            
3
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incomplete (Max, 2000; Woolf & Max, 2001). A pure candidate gene approach is 
time-consuming and prone to overlook potentially relevant targets.  
 
Recent advances in genomic technologies have enabled the simultaneous 
assessment of the expression patterns of a multitude of genes. These technologies 
are increasingly employed in a wide range of clinically relevant pain disorders and 
nociception (Galicia, Henson, Parker, & Khan, 2016; Sjöstrand et al., 2006).  
This study assessed gene expression patterns at whole-genome level in human 
participants pre and post third molar extraction (TME) in order to identify genes 
indicated in acute inflammatory pain. TME represents a clinically relevant pain 
challenge and has been utilised successfully in genetic association studies in 
humans in association with gene expression in oral mucosa wound repair (Warburton 
et al., 2005), in a DNA association study on post-surgical pain tolerance (Kim, 
Ramsay, Lee, Wahl, & Dionne, 2009) and has also produced useful results in the 
assessment of inflammatory pain (Barden et al., 2004). Results are also likely to 
translate to other post-surgical pain experiences (Hyungsuk Kim et al., 2009). This 
investigation used gene expression levels in peripheral whole blood as a clinical 
endpoint in search of candidate genes for post-surgical pain in a TME paradigm. 
Blood was selected due to its involvement in pain modulation by delivering 
inflammatory mediators to damaged tissues such as histamine, bradykinin and 
opioid-peptides from leukocytes (Busch-Dienstfertig & Stein, 2010; Dray, 1995).  
TME tissue trauma triggers several cascades of molecular responses including an 
immune response in order to protect the body from pathogens likely to enter through 
the lesion, tissue repair functions to restore protective tissue boundaries and a 
nociceptive response to alert the organism to this threat, prevent further damage and 
to modify behaviour in order to support the latter two responses. As a result an 
extensive list of differentially expressed genes with involvement in these different 
responses emerges in comparisons of samples collected in painful and pain-free 
states. The particular challenge was to identify those genes differentially expressed 
after surgery with a primary association with post-surgical pain. 
Gene Set Enrichment Analysis (GSEA) of gene expression data takes into account 
prior biological knowledge in evaluating microarray data by operating at the level of 
gene sets rather than individual genes or gene lists simply ordered by statistical 
significance and fold change (Mootha et al., 2003; Subramanian, Tamayo, & Mootha, 
2014). These gene sets are organised maps generated manually from current 
scientific literature on molecular interaction and reaction networks. One such 
database is the Kyoto Encyclopedia of Genes and Genomes (KEGG), which provides 
seven different categories of pathways (1. metabolism, 2. genetic information 
processing, 3. environmental information processing, 4. cellular processes, 5. 
organismal systems, 6. human diseases and a structure relationship map for 7. drug 
development). This study used GSEA to test for significant enrichment of the list of 
genes with significant up- and down-regulation post surgery in any of the established 
KEGG pathways.  
GSEA potentially facilitates the discovery of known molecular pathways in novel 
contexts with post-surgical pain. In addition, novel sets of genes might emerge, which 
could highlight hitherto unknown molecular pathways and mechanisms of pain 
regulation. This in turn might enable a much needed expansion in the number of 
molecules that have so far been considered targets in pain treatment (Belfer et al., 
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2004; Max & Stewart, 2008a) and may thus improve analgesic development, 
treatment allocation and increase patient benefit (Max, 2000; Woolf et al., 1998).  
 
 
Methods 
 
Ethics Statement 
This study was approved by Kings College Hospital Research Ethics 
Committee (REC Reference 07/H0808/115).  
 
Subjects and Materials 
 
 Informed consent was provided by all participants prior to study procedures. 
Removal of both wisdom teeth in the lower jaw was necessitated by bilateral 
intermittently recurring pericoronitis, diagnosed in accordance with NICE guidelines 
(NICE/NHS, 2000). Impact of the wisdom teeth on the second molars and gum tissue 
was confirmed by an experienced clinician based on x-ray images. Surgeries were 
performed while pericoronitis was in remission and participants were pain-free.  
 
In total 22 right-handed, healthy male volunteers aged 20–41, (Mean=26.44, 
SD=5.49) were assessed. Since the study was conceived as a proof of concept 
study, potential variability was controlled for by excluding female participants as 
menstrual cycle status interferes with reproducibility of the post-surgical pain 
response (Teepker et al., 2010).  
 
Study Design & Procedure 
 
 Teeth were removed separately on two of a total of one familiarisation and five 
study visits (T2 & T4).  This created a cross-over study design with pain-free baseline 
measurements to use in contrast the post-surgical measurements (see figure III-1). 
Due to the similar placement and surgical difficulty level, the surgery on the side 
opposite to the initial surgery site can be used akin to a repeated measure. A 
modified version of this design was used in a follow up study to compare the effect of 
a drug vs. placebo (Hodkinson, Khawaja, et al., 2015b). 
 
Time point Labels description 
T0 Sample A familiarisation 
T1 Sample B non-surgical baseline 
T2 Sample C1 pre tooth extraction 
T2 Sample C2 post tooth extraction 
T3 Sample D non-surgical baseline 
T4 Sample E1 pre tooth extraction 
T4 Sample E2 post tooth extraction 
T5 Sample F non-surgical baseline 
 
Table III-1: Sampling time points and labels 
 
The order of left and right tooth extraction was balanced and pseudo-randomised 
across the group, to account for occasions where one tooth had to be removed 
before the other due to clinical need. There was a minimum of three weeks between 
T2 and T3 to allow for recovery from the first surgery such that participants did not 
report any on-going pain at T3. The same interval was applied for post-surgical 
recovery from T4 before T5.  For each tooth there was a minimum of a week and a 
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maximum of three weeks between pre-surgical and post-surgical sessions. 
Peripheral whole blood was collected on each of the visits. 
 
A total of eight peripheral whole blood samples were taken from each subject, out of 
which seven per participant were included in the analysis (T1-T7). Baselines B, D 
and F were taken after the MRI assessment on T1, T4 and T5. Pre-surgical samples 
C1 and E1 were taken before surgery on T2 and T4. Post-surgical samples C2 and 
E2 were taken after the MRI assessments on the same visits. Table III-1 contains an 
overview of the all sampling time points and labels. A sample was taken after the 
scan on the familiarisation session T0 was not included in the analysis due to lack of 
corresponding MRI data. 
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Figure III-1: Flow chart for study recruitment & analysis of the gene expression samples 
 
 
Baseline Psychometry 
 
Baseline psychometric screening assessments were performed for all participants at 
T0 to ensure participants scored within normal limits in measures of mental health, as 
depression, substance use and chronic anxiety are knowon to alter response to 
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painful stimuli (Bair, Wu, Damush, Sutherland, & Kroenke, 2008; Carr, Thomas, & 
Wilson-Barnet, 2005).For a full list of screening questionnaires and interviews see 
Howard et al., 2011 (Howard et al., 2011).  
 
Surgeries 
 
 Unilateral TME under local anesthetic was performed by one of three 
experienced oral surgeons using a frequently performed, standardised technique 
(NICE/NHS, 2000; Renton et al., 2001).  Briefly, local anesthetic was administered 
via an inferior alveolar block and long buccal infiltration using 4.4ml lignospan (2% 
lidocaine, 1:80,000 adrenaline). A buccal mucoperiosteal flap was raised and a gutter 
of bone buccal to the lower third molar removed using a fissure bur.  Following 
decoronation and root sectioning with a fissure bur, tooth fragments were elevated 
and extracted. The surgical site was closed using 1-2 vicryl 3/0 rapide sutures.  
Surgical difficulty was rated by the surgeon on a 1-5 scale (Renton et al., 2001).  
 
Following haemostasis and issuing of post-operative instructions, patients were 
escorted back to the MRI facility and supervised for up to six hours before returning 
to the MRI scanner for a post-surgical MRI scan. During the supervision period, 
participants provided ratings of pain intensity every 30 minutes using a pen-and-
paper 100mm VAS (Katz & Melzack, 1999). The frequency of VAS responses 
increased to every ten minutes at the first indication of a VAS score greater than 20 
out of 100 mm. Scanning commenced when three consecutive VAS scores greater 
than 30 out of 100 mm were provided by the participant. 
 
RNA Extraction and Array Hybridisation 
 
 Peripheral blood for RNA extraction and a full blood count (FBC) were sampled 
using one 4.5ml EDTA K3 tube and two 2.5ml PAXgene tubes at each time point. 
RNA was sampled immediately after each MRI scan, and further samples were 
obtained before administration of the local anesthetic on each of the surgical visits. 
PAXgene tubes were left at room temperature for 2 hours to allow fixation of the 
transcripts in the stabiliser solution and were then stored at -80 degrees Celsius until 
further processing.  
 
RNA extractions   
 
 Samples were randomised prior to shipping on dry ice to prevent batch effects. 
The cooling chain was uninterrupted. Total RNA was isolated from PAXgene-
collected blood samples by Asuragen, Inc., according to the company‘s standard 
operating procedures.   
 
A pilot of ten samples, randomised across the different conditions, was run to ensure 
the quality of the automated extraction protocol by extraction reagents manufacturer 
NuGen Inc. . The protocol was implemented on a robot for the first time at the lab. 
RNA integrity, cDNA conversion and hybridisation results on the Exon arrays yielded 
acceptable results and hybridised arrays passed standard quality controls.  
 
The purity and quantity of total RNA samples were determined by absorbance 
readings at 260 and 280 nm using a NanoDrop ND-1000 UV spectrophotometer.  
The integrity of total RNA was qualified by Agilent Bioanalyzer 2100 capillary 
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electrophoresis. RNA integrity numbers (RIN) were reported and 11 samples fell 
short of the standard of 7.0. Replication tubes were shipped on dry ice for a second 
extraction. All samples were used for hybridsation onto Affymetrix Exon 1.0 ST 
arrays. Final RIN for the repeat samples were between 5.4 and 7.4. All samples were 
included and arrays with RNA of an RIN of less than 7 were flagged up for additional 
quality control. None of the arrays showed signs of errors attributable to low quality 
RNA.  
 
Gene expression profiling  
 
 Biotin-labeled sense strand cDNA was prepared from 50 ng total RNA per 
sample using the WT-Ovation Pico RNA amplification system, WT-Ovation Exon 
Module, and FL-Ovation cDNA Biotin Module V2, according to the manufacturer‘s 
protocols (NuGEN, Inc.). Intermediate cRNA and resulting cDNA yields were 
quantified by spectrophotometry.  Fragmentation and labeling of cDNA was 
performed using 5 µg for Exon Arrays.  Hybridisation to arrays was carried out at 
45oC for 16 hours in an Affymetrix Model 640 hybridisation oven. Affymetrix Human 
Exon 1.0 ST arrays were washed and stained on an Affymetrix FS450 fluidics station. 
The arrays were scanned on an Affymetrix GeneChip Scanner 3000 7G.  For every 
array scanned, .DAT, .CEL, .GRD, .jpg, and .xml flat files were provided.  In addition, 
robust multi-chip average (RMA) normalised data was provided for the core dataset 
and the corresponding QC information. RMA data captures metrics including Area 
Under the Curve (AUC) and polyA spikes generated using Affymetrix Expression 
Console. 
 
Statistical and Pathway Analysis 
 
Statistical analysis was performed using JMP Genomics 
(http://www.jmp.com/en_us/software/jmp-genomics.html) developed for SAS 
software, version 9.1.3 of the SAS System for Windows. GSEA and viusalisations 
were performed using the GSEA software suite by the Broad Institute (Mootha et al., 
2003; Subramanian et al., 2014) (http://software.broadinstitute.org/gsea/index.jsp). 
Pathway visualisations were rendered in the R/Bioconductor package 
https://www.bioconductor.org/pub/RBioinf/ Pathview (Luo & Brouwer, 2013). 
 
Array Pre-processing and Normalisation 
 
Probe intensities of 126 Exon Arrays (18 individuals, 7 RNA arrays from T1 
through T5) were normalised using quantile normalisation and summarised to gene 
level expression intensities using the robust multi-chip average (RMA)(Bolstad et al., 
2003; Irizarry, Bolstad, et al., 2003; Irizarry, Hobbs, et al., 2003). Gene definition was 
implemented by applying the definition of the core probeset provided by the 
Affymetrix annotation system. Quality assessment and exploratory analysis of 126 
chips were within normal limits, thus all samples were included in the analysis.  
 
Array Data Analysis 
 
Normalised gene level expression intensities were –log10 transformed. A 
repeated measures ANOVA was implemented to identify the differentially expressed 
transcripts across the samples contrasting all samples from non-surgical visits with 
those acquired at the two post-surgical sampling time points, when participants 
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emerged from the MRI scanner and reported a VAS-score of 3/10 or above. False 
discovery rate (FDR) was applied and p-values were corrected for multiple 
comparisons at FDR < 0.05.  
 
 
Results 
 
Gene expression results 
 
The repeated measures ANOVA identified 837 probesets that were 
significantly differentially expressed between the non- and post-surgical conditions 
(see supplementary materials for gene list).  
 
 
Fig III-2: Plot of differences in gene expression levels between non- and post-surgical samples: 
The X-axis represents log-tranformed expression levels, while the Y-axis displays the p-values at -log 
10; a horizontal reference line was drawn at –log(10) = 2.764 
 
Manuscripts 
 
61 
Examining the top 20 genes with the most significant differences in expression 
revealed eight genes with explicit associations in the context of pain and nociceptive 
signaling (see table III-2). ZNF106 emerged as the most significantly up-regulated 
gene post surgery, but has no prior associations with phenotypes in pain or 
nociception. As a group of proteins 11 additional zinc finger proteins (ZNF 37A, 319, 
337, 438, 460, 573, 586, 655, 705G, 829 and 844) demonstrated significant 
differential expression post surgery. 
 
Gene Gene name  Associated pain phenotypes or mechanims 
ZNF106 zinc finger protein 106 UP No previous association with pain or nociception,  
BMX 
BMX non-receptor 
tyrosine kinase 
UP Signaling and control processed during the proliferation of 
cells (Chau et al., 2002), involvement in chronic inflammation 
and angiogenesis in the skin via cytokine-mediated 
recruitment of inflammatory cells (Paavonen et al., 2004), 
rheumatoid arthritis (Palmer, Mutch, Page, Horwood, & 
Foxwell, 2008) 
PADI4 
peptidyl arginine 
deiminase, type IV 
UP Association with susceptibility to rheumatoid arthritis in Asian 
populations (Gandjbakhch et al., 2009).  
ARL4C 
ADP ribosylation factor 
like GTPase 4C 
DOWN Association with and positive predictor for Chronic Fatigue 
Syndrome (CFS), which is accompanied by pervasive with 
joint and muscle pain (Frampton, Kerr, Harrison, & Kellam, 
2011; Kerr, 2008). 
LMTK2 lemur tyrosine kinase 2 
UP Interacts with Cyclin-Dependent Kinase 5 (CDK5) 
(Kesavapany et al., 2003), which phosphorylates TRPV1 
(Chalovich & Eisenberg, 2009) and is expressed in nociceptive 
neurons (Pareek et al., 2006) 
MME 
membrane metallo-
endopeptidase 
UP One of the major enzymes for enkephalin degradation, cleaves 
peptides at the amino side of hydrophobic residues and 
inactivates pain-relevant peptides such as enkephalins, 
substance P, neurotensin, oxytocin, and bradykinin.(Comings 
et al., 2000) 
PAK1 
p21 protein 
(Cdc42/Rac)-activated 
kinase 1 
UP Its expression is increased by Lidocaine and inhibits fibroblast 
multiplication, which may interfere with wound healing (Desai, 
Kojima, Vacanti, & Kodama, 2008). 
PELI2 
pellino E3 ubiquitin 
protein ligase family 
member 2 
UP Shown to promote microglia-mediated CNS inflammation by 
regulating Traf3 degradation (Xiao et al., 2014). 
LRRC4 
leucine rich repeat 
containing 4 
UP MAP kinase signalling influenced by competitive inhibition of 
MEK/ERK activation in glioma cells by D domain of LRRC4, 
(Z. Wang et al., 2016)(Ji, Gereau, Malcangio, & Strichartz, 
2009)  
 
Table III-2: The 20 genes with the most significant differential expression. Genes from exclusive 
association profiles with previous associations in pain and nociception 
 
Gene Set Enrichment Analysis 
 
GSEA demonstrated significant enrichment of differentially expressed genes 
from this analysis in a total of 280 significant KEGG pathways out of which 171 were 
up-regulated and the remaining 109 were down-regulated. Across six of the seven 
main pathway categories, categories 1, 5 and 6 (metabolism, organismal systems 
and human diseases) revealed the largest number of significantly enriched gene sets 
(see Figure III-3a).  
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Fig III-3a: Main groups of significantly enriched pathways: Total number of significantly enriched 
pathways within each main group  
 
The subgroups within the metabolism pathways enriched for differentially expressed 
genes were subgroups involved in glycan biosynthesis and metabolism (N=11), and 
lipid (N=13), carbohydrate (N=14) and amino acid metabolism (N=11) (Figure III-3b). 
The subgroups of organismal systems pathways with significantly enriched pathways 
were the endocrine (N=19), immune (N=16), digestive (N=9) and nervous system 
(N=10) (Figure III-3c). The subgroups within the main group of human diseases 
pathways with the greatest number of significantly enriched pathways were the 
pathways for specific cancers (N=14) and infectious bacterial diseases (N=10)  
(Figure III-3d). 
 
 
 
Fig III-3b: Main category: 1. Metabolism. Number of metabolism pathways subgroups enriched with 
genes differentially expressed between non- and post-surgical samples 
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Main Category: 1. Metabolism 
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Fig III-3c: Main category: 5. Organismal Systems. Number of organismal systems pathways 
subgroups enriched with genes differentially expressed between non- and post-surgical samples 
 
 
 
Fig III-3d: Main category: 6. Human Diseases. Number of human diease pathways subgroups 
enriched with genes differentially expressed between non- and post-surgical samples 
 
 
GSEA revealed pronounced up-regulation of genes involved in the MAP Kinase 
(enrichment score (ES) = 0.348; normalised enrichment score (NES) = 1.479; 
nominal p-value = 0.002; FDR q-value = 0.129) and chemokine signaling pathways 
(ES = 0.397; NES = 1.632; nominal p-value = 0.0; FDR q-value = 0.058), and 
osteoclast differentiation pathway (ES = 0.517; NES = 2.003; nominal p-value = 0.0; 
FDR q-value = 0.007) in peripheral whole blood in patients in pain compared to the 
pain-free condition.  
Enrichment plots illustrated the running ES for each of the pathway-specific gene 
ontologies as the analysis went down each of the ranked lists of differentially 
expressed genes. The peak value of the running ES represented the final ES. Genes 
before the ES contain the leading edge subset (LES) correlated with painful post-
surgical state. 
0 2 4 6 8 10 12 14 16 18 20
5.1 Immune system
5.2 Endocrine system
5.3 Circulatory system
5.4 Digestive system
5.5 Excretory system
5.6 Nervous system
5.7 Sensory system
5.8 Development
5.9 Aging
5.9 Environmental adaptation
Main Category: 5. Organismal Systems 
0 2 4 6 8 10 12 14 16 18 20
6.1 Cancers: Overview
6.10 Infectious diseases: Parasitic
6.2 Cancers: Specific types
6.3 Immune diseases
6.4 Neurodegenerative diseases
6.5 Substance dependence
6.6 Cardiovascular diseases
6.7 Endocrine and metabolic diseases
6.8 Infectious diseases: Bacterial
6.9 Infectious diseases: Viral
Main Category: 6. Human Diseases 
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The heatmaps illustrated that samples from both post-surgical sampling time points 
revealed an expression pattern across patients that was markedly different from the 
non-surgical time points for the MAP Kinase and chemokine signaling pathways, and 
osteoclast differentiation pathway (see Figure III-6a-c). Tables listing genes with their 
individual ranks within the list, rank metric score and running ES are listed in the 
appendix (Supplementary tables III-2a-c). 
 
 
 
 
Figure III-4a-c: Enrichment plots for the MAP Kinase and chemokine signaling pathways, and 
osteoclast differentiation pathway. Profile of the running ES and positions of gene set members on the 
rank ordered list. Green line: running ES for pathway-specific gene ontologies. The peak value of the 
running ES represents the final ES. Genes before the ES represent the Leading Edge Subset 
correlated with painful post-surgical state. 
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Figure III-5a: Non- and post-surgical expression intensities for gene set members of the MAP Kinase 
Signaling Pathway. Samples post-surgery (Samples C2 and E2) for all 18 participants are highlighted 
in grey, while non-surgical samples (Samples B, C1, D, E1 & F) for all 18 participants are highlighted 
in yellow. A full list of the genes and expression values is found in the appendix (see Table III-2a). 
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Figure III-5b: Non- and post-surgical expression intensities for gene set members of the Osteoclast 
Differentiation Pathway. Samples post-surgery (Samples C2 and E2) for all 18 participants are 
highlighted in grey, while non-surgical samples (Samples B, C1, D, E1 & F) for all 18 participants are 
highlighted in yellow. A full list of the genes and expression values is found in the appendix (see Table 
III-2b). 
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Figure III-5c: Non- and post-surgical expression intensities for gene set members of the Chemokine 
Signaling Pathway. Samples post-surgery (Samples C2 and E2) for all 18 participants are highlighted 
in grey, while non-surgical samples (Samples B, C1, D, E1 & F) for all 18 participants are highlighted 
in yellow. A full list of the genes and expression values is found in the appendix (see Table III-3c). 
 
 
Enriched pathway maps 
 
The most significantly enriched pathway for up-regulated genes was the pathway for 
osteoclast differentiation (see Figure III-6a; NES=2.0, p=0.007 FDR corrected), 
closely followed by the pathway for toll-like receptor signalling (NES=1.96, p=0.007 
FDR corrected). The most significant pathway for down-regulated genes was the 
pathway for Ribosome (NES=-3.12, p<0.0001).
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Figure III-6a: KEGG Pathway results: Osteoclast differentiation (genes highlighted in green dark red = up-regulated genes at p < 0.05, light red = up-regulated 
genes at p > 0.05, dark green = down-regulated genes p < 0.05, light green = down-regulated genes p > 0.05); Other maps connected to this pathway include 
Pi3K-Akt-, NF kappa B-, MAP Kinase-, Calcium- and Jak-STAT signaling pathways. 
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Figure III-6b: KEGG Pathway results : MAP Kinase Signaling Pathway (genes highlighted in green dark red = up-regulated genes at p < 0.05, light red = up-
regulated genes at p > 0.05, dark green = down-regulated genes p < 0.05, light green = down-regulated genes p > 0.05); Other maps connected to this pathway 
include the Phosphatidylinositol, p53, Wnt signaling pathways with further connections to apoptosis and cell cycle and JNK, p38 MAP Kinase and ERK5 
pathways. 
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Figure III-6c: KEGG Pathway results :Inflammatory mediators of TRP channels (genes highlighted in green dark red = up-regulated genes at p < 0.05, light red 
= up-regulated genes at p > 0.05, dark green = down-regulated genes p < 0.05, light green = down-regulated genes p > 0.05); Other maps connected to this 
pathway include the Arachidonic acid metabolism, MAP Kinase-, Calcium signaling pathways. TRP channels involved in thermal transduction feature highly 
significant up-regulation of TRPV4 between painful and pain-free conditions and highly significant down-regulation of TRPV2
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Discussion 
 
The aim of this study was to evaluate the augmentation of the utility of the 
TME paradigm beyond mere psychometric assessment of nociception, pain and 
discomfort post surgery. For this purpose this study employed TME in combination 
with a gene expression phenotype in the assessment of inflammatory post-surgical 
pain. It investigated RNA extracted from peripheral whole blood in conjunction with 
biological pathway enrichment analysis in search of potential pain- and nociception-
related biomarkers. 
 
A significant surgery effect on gene expression levels in peripheral whole blood was 
established. When checking the first 20 genes on the list of differentially expressed 
genes ordered by significance, nearly half of them featured explicit previous 
associations with various pain- and nociception related phenotypes. Furthermore, 
GSEA highlighted gene sets from known pathways with significant enrichment for the 
differentially expressed genes from this study. Among the pathways of particular 
importance were the osteoclast differentiation, MAP Kinase siganling, chemokine 
signaling and inflammatory mediator regulation of TRP channels pathways.  
 
In particular, the osteoclast differentiation pathway makes for a very biologically 
plausible result as restructuring of the bone occurs following tooth extraction. 
Osteoclasts are involved alveolar crest resorbtion in the mandible, while the fundic 
part of the bony socket fills with connective tissue and bone (Pietrokovski & Massler, 
1967; Schropp, Wenzel, Kostopoulos, & Karring, 2003). Participants anecdotally 
commented on the speed at which the „hole― left in the jaw post surgery disappeared 
at the follow up visits. To be able to show this pathway in blood without the use of 
tissue from the surgery site, where one might rather expect to see an increase in this 
cell type (Boyle, Simonet, & Lacey, 2003), could represent an opportunity to 
investigate mechanisms over the course of the healing process in traumatised tissue 
without having to re-traumatise it with biopsies.  
 
Surgical trauma causes inflammatory pain, but also triggers gene expression events 
related to other biological processes such as tissue repair and immune response 
functions, which due to genetic pleiotropy may or may not be relevant to 
inflammatory pain. Hence, the challenge was to extract a list of candidate genes with 
primary relevance with regard to inflammatory pain signalling and processing. The 
large number of pathways relevant in metabolism represented an additional activated 
class of biological pathways concurrently activated with pain- and nociception-related 
pathways. Their strong representation can be attributed to a factor inherent in the 
design, which created considerable variability in food intake. Although patients were 
instructed to eat a light breakfast before the surgery, some patients reported that they 
were too anxious or were afraid of queasiness during the surgery to eat. Even though 
participants were offered a standardised soft lunch, several participants declined the 
lunch for fear of perturbing the sutures, biting into anaethetised mucosal tissue or 
lack of appetite. In addition, the study did not adhere to a sampling schedule with 
fixed time intervals, but was event-related where scans were initiated in response to 
the patients‘ reported pain levels of at least 30/100. Thus the metabolism-related 
differences would have persisted in spite of fixed time points for food intake as the 
timing of the increases in VAS ratings varied between patients and could not be 
predicted reliably. 
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The most significantly up-regulated gene in this study (ZNF106) has no prior 
associations with other nociception and pain phenotypes. It encodes a zinc finger 
protein, a class of proteins, which bind to DNA, RNA and can serve as transcription 
factors. Due to their regulative functions, engineered zinc finger-based factors have 
been discussed as novel therapeutics in humans (Gommans, Haisma, & Rots, 2005; 
Papworth, Kolasinska, & Minczuk, 2006). Zinc-finger proteins also play an essential 
role in mu-opioid signalling (Rodríguez-Muñoz & Garzón, 2013). In neuropathic pain, 
myeloid zinc finger protein 1 has been shown to increase excitability in dorsal root 
ganglion (DRG) neurons by altering KCNA2 antisense RNA expression (Zhao et al., 
2013) and ZNF641 is involved in MAP Kinase-mediated signalling (K. Luo et al., 
2006). 
 
Further convergent evidence for the validity of the approach in this study arose from 
the fact zinc finger protein genes also featured strongly in two other studies, which 
also employed the TME model. One investigated gene expression in oral mucosa 
tissue (Warburton et al., 2005) and one performed a GWAS in DNA (Hyungsuk Kim 
& Lee, 2009). The later used the maximum post-operative pain rating, post-operative 
pain onset time and the analgesic onset time after administering ketorolac as 
phenotypes of pain and analgesia and found a significant association with a SNP 
(rs2562456) from an uncharacterised gene in linkage disequlibrium with ZNF 429. 
The other study demonstrated differential gene expression in ZNF 9 and ZNF36, 
C3H type-like1 post surgery. However, there was no overlap between zinc finger 
protein genes from the two other studies using TME, which may also be due to the 
differences in substrates and sampling time points.  
 
Highly prominent among the enriched known pathways was the MAP Kinase 
pathway, which is an umbrella term for three major subgroups of kinase pathways 
including extracellular signal-regulated kinases (ERK), p38, and c-Jun N- terminal 
kinase (JNK) (Ji et al., 2009). Out of these p38 MAP Kinase has already received 
attention as a target for a specific inhibitor (Anand et al., 2011). 
 
The lack of gene sets specific to various pain phenotypes was not so much a 
limitation of the applied analysis strategy, but highlights the demand of further 
research into pain- and nociception-specific molecular signalling cascades. The 
inflammatory mediator regulation of TRP channels pathway was not part of the 
KEGG database, but a custom designed pathway. However, considering that genetic 
research in pain and nociception is still in the early stages (Bradshaw et al., 2005), 
the relatively large number of genes with specific associations with pain (e.g. 
rheumatoid arthritis  (Alsaleh et al., 2010; Joosten et al., 2006)) and nociceptive 
signalling from the top of the gene list retrieved in this study strongly supports the 
validity of this approach. Reliable establishment of pain and nociception-specific 
pathways will benefit from the use of replication samples and larger sample sizes 
(Tsai, Wang, Chen, & Chen, 2005).  
 
GSEA-based gene expression analysis has been applied to research on painful 
pulpal inflammation, which compared pulpal tissue from pulpitis patients with pulpal 
tissue from teeth extracted for other medical reasons (Galicia et al., 2016). This 
between-subjects comparison revealed a specific pattern of pathway activations 
involved in immune response activation, maintaining cellular function and cell-to-cell 
interaction. An additional advantage of the TME model is, that it enables within-
subject comparisons, which could be applied in future studies of additional samples 
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taken after successful application of an analgesic to further specify their impact on 
blood-borne inflammatory mediators and their molecular mechanism of action. 
 
Similar gains might be achieved from analysing data from the participants who fail to 
experience relevant pain post surgery. However, since this only applied to two 
participants in this study, no separate analysis was performed. An extension of the 
model to other types of surgery beyond TME might highlight shared pain-mediating 
molecular pathways.  
 
One of the greatest criticisms of analgesic development has been, that analgesics 
released in the past decades are merely variations of existing classes of analgesics 
such as opioids and NSAIDs (Max, 2000; Woolf & Max, 2001). Further research will 
have to demonstrate if inhibitors of membrane metalloendopeptidase (MME) for 
example, an enzyme which cleaves enkephalins, is a suitable target in analgesic 
development. Thus, instead of introducing agonists and antagonists such as 
synthetic opioids, which bind to pain and nociception-relevant receptors, a new class 
of drugs which achieves analgesic effects by promoting the body‘s own peripheral 
opioid and cannabinoid analgesia, might emerge. This type of analgesic would 
increase the levels of inhibiting the enzymes that inactivate enkephalins. Similar 
drugs are already being tested. The two main groups - dual enkephalinase inhibitors, 
which inactivate neprilysin (NEP) and aminopeptidase N (APN) and fatty acid amide 
hydrolase (FAAH) inhibitors- have demonstrated analgesic effects in various models 
of inflammatory and neuropathic pain (Roques, Fournié-Zaluski, & Wurm, 2012). 
APN and NEP are provided by peripheral nerves and leukocytes in inflamed tissue 
(Schreiter et al., 2012), a cell type also abundant in peripheral whole blood.  
  
Overall, this study represents another step towards a more comprehensive molecular 
characterisation of phenotypes in pain and nociception. It also ties in with other 
efforts to utilise genome-wide mapping approaches in finding pain-relevant pathways 
(Neely et al., 2012) and to employ data science approaches for identification of 
candidate genes (Ultsch, Kringel, Kalso, & Mogil, 2016). The findings support the use 
of RNA derived from peripheral blood as an economically viable substrate in pain- 
and nociception-related biomarker research.  
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2.4 Manuscript IV: Negative Association Between Grey Matter Density and Sensory 
and Affective Pain Scores in Female Carriers of the OPRM1 118A SNP with 
Chronic Musculoskeletal Pain4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
In this study a genotype-specific voxel-based morphometric (VBM) 
investigation of chronic musculoskeletal pain in relation to the single nucleotid 
polymorphism rs1799971 (118A/G) in the gene coding for mu-opioid receptor 1 
(OPRM 1) was performed. A total of 22 patients with either fibromyalgia syndrome 
(FMS) or unspecific lower back pain (ULBP) – with both groups reporting comparable 
levels of pain - were combined for analysis assuming a shared mechanism of 
maladaptive plasticity of the central nervous system. A genotype-dependent 
permutation-based comparison of grey matter density (GMD) revealed an inherent 
risk of relative hypertrophy in pain processing regions of the brain associated with the 
A-allele of SNP rs1799971. These effects became more pronounced when 
controlling for age and duration of pain. Findings potentially indicate a compensatory 
response to genotype-specific impairment of endogenous endorphine-mediated 
analgesia. A correlation analysis showed inverse relationships between mean GMD 
in pain-relevant regions of interest (e.g. putamen, pallidum, paracingulate, posterior 
cingulate) and sensory and affective pain scores. The inverse associations were 
more numerous for the 118A-carriers than for the 118G-carriers. There were no 
significant relationships when carriers of the 118A- and G-carriers were entered into 
the correlation analysis together. The putative mechanism of action may be rooted in 
impaired endogenous opioid binding in 118A-carriers, which suggests the 118A allele 
as a risk factor and informative biomarker for chronic musculoskeletal pain in female 
patients. 
 
 
 
 
 
Introduction 
                                            
4 Author contributions included Idea/Experimental Hypothesis: 50% for SNP selection, Experimental 
Design: 70% for set up of the VBM analysis in conjunction with genotype, Data Collection: 10% 
shipping and arrangement with genotyping facility in London, Writing: 80%, Interpretation: 70%. 
 
Reference: 
Krause, K., Clarke T. C., Witt, S., Thieme, K., Diers, M., Ridder, S., Josef Frank, 
J., Rietschel, M., Schumann, G., Flor, H. (in preparation). Negative 
Association Between Grey Matter Density and Sensory and Affective Pain 
Scores in Female Carriers of the OPRM1 118A SNP with Chronic 
Musculoskeletal Pain.  
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Opioid signalling is a key modulator of pain-suppression. Pain is modulated by 
means of endogenous opioid peptide release (e.g. beta-endorphins, enkephalins and 
dynorphin (Basbaum & Fields, 1978)) in response to noxious stimulation (Zangen, 
Herzberg, Vogel, & Yadid, 1998; Zubieta et al., 2001a). Mu-opioid receptor-mediated 
neurotransmission is also activated as part of the placebo effect (Zubieta et al., 
2005). Reduced opioid binding (Harris et al., 2007; Maarrawi et al., 2007; Willoch et 
al., 2004a) and elevated levels of opioid peptides in patients‘ cerebro spinal fluid 
(Baraniuk et al., 2004) have been demonstrated in different chronic pain patient 
cohorts. This is indicative of altered opiodergic signalling in the CNS of these 
populations. The exact explanations for these findings are yet to be determined, but a 
decrease in opioid receptor bearing neurons (Jones et al., 2004) has been discussed 
and is in line with findings of decreases in grey matter density (GMD) in various 
populations of chronic pain patients in contrast to age and sex matched control 
subjects in morphometric studies of the brain (Apkarian et al., 2004; May, 2008; 
Schmidt-Wilcke et al., 2005, 2007). In order to obtain a more comprehensive 
understanding of the role of opioid mechanisms in chronic pain, it is important not 
only to look at morphological changes, but also to try to combine morphometric 
endpoints with other endpoints such as genetics.   
 
This study investigated the influence of a common genetic polymorphism (118A>G, 
rs1799971) and its effects on GMD in the presence of prolonged pain by means of 
voxel based morphometry (VBM) (Ashburner & Friston, 2000). This was implemented 
in a cohort of unmedicated female chronic musculoskeletal pain patients suffering 
from either FMS or ULBP. Said SNP is part of the gene that encodes OPRM1, which 
is a target site for endogenous opioid ligands and various opioid analgesics  
 
FMS is characterised by chronic widespread pain, fatigue and tenderness at speciﬁc 
body sites. Prevalence is relatively high with diagnoses given to more than 10% of 
patients attending general medical clinics and higher numbers in rheumatology 
clinics. The patients are predominantly female and onset typically occurs in middle 
age before age 50 (Wolfe et al., 1990). ULBP is a common problem in industrialised 
countries with a lifetime prevalence between 58% to 85%. Annual prevalence is 
between 20% to 40% and again more women than men are affected by this pain 
disorder (Werber & Schiltenwolf, 2012).  
 
This study contrasted genotypes at the whole brain level and an additional region of 
interest (ROI) analysis focused on brain regions with known involvement in various 
persistent pain conditions often summarised as the pain neuromatrix (Legrain et al., 
2011). ROIs included the caudate, pallidum and putamen, which form part of the 
basal ganglia (Chudler & Dong, 1995; Downar et al., 2003; Starr et al., 2011). GMD 
increases in the basal ganglia in chronic low back pain patients emerged in 
comparison to healthy controls (Schmidt-Wilcke et al., 2006). Furthermore, the 
amygdala and nucleus accumbens, were selected as areas in which decreased mu-
opioid receptor binding potential has been established to be negatively correlated 
with affective pain ratings in FMS patients (Harris et al., 2007). 
 
Reduced GMD in the hippocampus has been demonstrated in chronic back pain and 
chronic regional pain patients along with other hippocampal abnormalities in rodents 
following spared nerve injury (Mutso et al., 2012). Additionally a hyperactive state of 
the parahippocampal gyrus, amygdala and anterior insula were observed in 
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somatoform pain disorder patients in response to a heat pain stimulus (Gündel et al., 
2008). Additional regions involved in pain processing included thalamus, 
somatosensory cortex I and II (SI & SII), anterior cingulate, posterior cingluate and 
paracingluate. A previous study had demonstrated an inverse relationship between 
GMD in the posterior cingulate cortex, the adjacent precuneus and SI and pain 
sensitivity in participants undergoing a heat pain challenge (Emerson et al., 2014). 
 
Gene characterisation 
 
The 118A>G polymorphism in OPRM1 is located on chromosome 6q24-q25 
and spans over 200 Kb. It comprises at least 9 exons and can encode for 19 different 
splice variants under the control of multiple promoters (Pasternak, 2010; Shabalina et 
al., 2009). In Caucasians the minor G-variant of rs1799971 is found in 11-17% of the 
population (dbSNP Short Genetic Variations database of the American National 
Center for Biotechnology Information; NCBI, Bethesda, MD, USA, Accessed Aug 15, 
2013).  
 
The 118A>G SNP has received much attention due to its functional consequences, 
which affect opiodergic signalling (Lötsch, Skarke, et al., 2002; Wand et al., 2002). It 
causes an amino acid substitution from asparagine to aspartatic acid at position 40 of 
the protein, a putative N-glycosylation site in the extracellular domain. Although the 
gene has been championed as a possible target for concepts in personalised 
medicine in the context of pharmacokinetic and pharmacodynamic effects on opioid 
medications (Hernandez-Avila, Wand, Luo, Gelernter, & Kranzler, 2003; Lötsch, 
Geisslinger, & Tegeder, 2009b; Mura et al., 2013), a meta-analysis of the data so far 
indicates only mild effects (Walter & Lötsch, 2009a). However, some studies point 
towards clinical relevance of the SNP in unmedicated populations. For example, non-
Hispanic white carriers of the 118A-allele exhibit increased thermal and ischemic 
pain sensitivity (Hastie et al., 2012). Also the prevalence of the 118A allele was 
higher in female Turkish FMS patients, than in the general population (Solak et al., 
2014).  
 
The 118G mutation is associated with increased sensitivity to endogenous opioids 
through higher receptor binding affinity for beta-endorphins (Bond et al., 1998a). This 
could leave unmedicated pain patients carrying the wild-type A-allele at a 
disadvantage. In support of this assumption an EEG study of noxious and olfactory 
stimulation of the nasal trigeminal system demonstrated that ERP amplitude N1 is 
greater in 118A carriers in response to the noxious stimuli than in 118G carriers 
(Lötsch et al., 2006). 
 
The aim of this study was to determine the effect of the 118A-allele on GMD in pain-
associated brain regions independent of age and pain duration in combination with 
psychometric assessments of pain. Age and pain duration were controlled for as the 
extent of GMD increases as age and pain duration increase (Apkarian et al., 2004; 
Tisserand et al., 2004) The hypothesis was that the A-allele serves as a risk factor or 
diathesis for pain-related GMD in the presence of chronic pain.  
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Methods 
 
The study was designed in accordance with the guidelines from the Helsinki 
declaration and ethics approval was obtained from the local ethics committee. 
Participants completed informed consent forms prior to all procedures.  
 
Participants 
 
The musculoskeletal pain patients in this study were diagnosed either with 
fibromyalgia syndrome (FMS) or unspecific low back pain (ULBP). Patients were 
recruited from the Mannheim and Heidelberg area, Germany. All participants suffered 
from their pain disorder for at least 12 months. None of the participants were on 
regular medication at the time of testing. T1-weighted structural MRI scans were 
obtained from 22 Caucasian female patients out of which 18 [Mean age=49.94yrs. 
(SD=11.33)] were diagnosed with FMS and four with ULBP (Mean age=46.75yrs. 
(SD=12.92)). There were no significant differences with regard to age (U(18,4)=19.5, 
p<.388) and duration of pain (U(19,3)=13, p<.131) between patient groups (see table 
IV-1). Homozygosity for the A-allele was established in 19 participants, three carried 
the AG genotype and none of the participants were homozygous for the G-allele. 
 
Genotyping 
 
Whole blood was collected in Saarstedt EDTA tubes during the first study visit. 
DNA was extracted from these samples according to standard protocol. Genotyping 
for rs1799971 was first performed on a SNPlex platform (Applied Biosystems 
Warrington, UK), which uses oligonucleotide ligation/polymerase chain reaction and 
capillary electrophoresis to analyse bi-allelic SNP genotypes (Tobler et al., 2005). 
The sample was re-genotyped by means of TaqMan SNP genotyping essays (Life 
Technologies, USA). Hardy-Weinberg-Equilibrium for rs1799971 was confirmed in 
PLINK (Purcell et al., 2007). Call rates for all samples were above .98 and there were 
no discrepancies in genotypes between the samples processed on the different 
platforms.  
 
MRI image acquisition, pre-processing and analysis 
 
T1-weighted images (MPRage) were acquired on a Siemens Magentome MRI 
scanner at a field strength of 3 Tesla. Images were assembled from .ima archive file 
format with dcm2nii (Rorden & Brett, 2000). Pre-processing, segmentation and 
smoothing was performed using VBM8 from the SPM8 toolbox (Mechelli et al., 2005).  
 
A mean image across all participants was created with fslmaths in FSL v5.0 
(www.fmrib.ox.ac.uk/fsl). There were no significant correlations between genotype, 
participant age (r=-.17, p>.46) and pain duration (r=.31, p>.16). Nevertheless, in 
order to avoid potential suppressor effects, a fixed effects model was implemented to 
control for these variables. In addition, age-related decreases in GM were controlled 
for, since the age of participants ranged from 33 to 64 years and also for years of 
ongoing pain, since it has been shown, that GMD become more extensive the longer 
pain persists (Apkarian et al., 2004).  
 
 
Region of Interest Correlations 
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Regions of interest (ROI) for analysis were selected from pain-relevant brain 
areas and included the amygdala, caudate, hippocampus, pallidum, putamen, 
paracingulate, anterior and posterior cingulate, anterior and posterior 
parahippocampus, somatosensory cortex I and II, thalamus and nucleus accumbens. 
Thresholds for ROI masks were set to include only voxels with at least a 25% 
probability of being part of the respective ROI. ROI masks were created in FSLview 
for left and right hemisphere separately for the following bilateral structures: anterior 
and posterior parahippocampus, somatosensory cortex I and II, insula, nucleus 
accumbens, amygdala, caudate, hippocampus, pallidum, putamen, and thalamus. 
Three additional masks were created for the paracingulate, posterior and anterior 
cingulate gyrus. Mean values for each were calculated in FSL using the fslmeants 
function. Correlations were performed in SPSS (IBM SPSS Statistics, version 22). 
 
Comparison of AA vs. AG carriers 
 
The original mean image was thresholded at .15 and a binarised mask was 
created for use in the randomise function in FSL (Bullmore et al., 1999; Nichols & 
Holmes, 2002).  
 
The carriers of the G allele were compared to carriers of the wildtype allele by 
carrying out a non-parametric t-test with up to 5,000 permutations. In this analysis the 
critical threshold was met at 1,540 permutations. The randomise function was 
implemented with the additional options to carry out Threshold-Free Cluster 
Enhancement (TFCE) and variance smoothing with std set to 2mm, which is 
recommended for small sample sizes (Hayasaka & Nichols, 2003). Cluster corrected 
thresholds were set to p<0.05. Peaks, locations and voxel cluster sizes were 
extracted from the Harvard-Oxford and Juelich atlases. 
 
Psychometrics 
 
The participants‘ pain experience was assessed by means of the pain 
experience scale (Schmerzempfindungs-Skala, SES (Geisser, 1996)), a German 
adaptation of the McGill Pain Questionnaire (Melzack, 1975) - a multimodal pain 
assessment scale used to quantify the affective and sensory dimensions of the pain 
experience. 
 
An independent-samples t-test was performed to assess possible differences 
between the FMS and ULBP patient cohorts and between AA and AG carriers with 
regard to age and quality and duration of pain.  
 
 
Results 
 
Psychometrics 
 
There were no significant differences between age, duration and the different 
dimensions of the SES for the FMS and ULBP cohorts (see Table IV-1). In addition, 
there were no significant genotype-dependent differences in the SES scores, age 
and duration between the carriers of the AA- and AG-genotypes (see Table IV-2).  
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 Genotype H Mean rank Value Exact significance (2* 
one-tailed) 
SES sensory pain FMS 18 12.61 16 .638 
 ULBP 4 6.5   
SES affective pain FMS 18 11.81 30.5 .088 
 ULBP 4 10.13   
SES local intrusion FMS 18 12.75 13.5 .053 
 ULBP 4 5.88   
SES rhythmicity FMS 18 12.33 21 .189 
 ULBP 4 7.75   
SES temperature FMS 18 11.83 30 .600 
 ULBP 4 10   
Age FMS 18 12.17 24 .306 
 ULBP 4 8.5   
Pain Duration FMS 18 12.53 17.5 .109 
 ULBP 4 6.88   
Table IV-1: Two sample Mann-Whitney-U-Test for SES scores, pain duration and age by diagnosis 
 
 Genotype H Mean rank Value Exact significance (2* 
one-tailed) 
SES sensory pain AA 19 12.34 18.5 .124 
 AG 3 8.17   
SES affective pain AA 19 12.03 12.5 .337 
 AG 3 6.17   
SES local intrusion AA 19 11.5 28.5 1.000 
 AG 3 11.5   
SES rhythmicity AA 19 11.87 21.5 .491 
 AG 3 9.17   
SES temperature AA 19 12.42 11 .086 
 AG 3 5.67   
Age AA 19 11.97 19.5 .388 
 AG 3 8.5   
Pain Duration AA 19 12.32 13 .131 
 AG 3 6.33   
Table IV-2: Two sample Mann-Whitney-U-Test for SES scores, pain duration and age by genotype 
 
Region of Interest Correlations 
 
For the overall sample including the AA and AG carriers, no significant 
correlations were observed between mean GM densities for any of the extracted 
ROIs with the SES scores for affective and sensory pain (see Table IV-3). However, 
when stratified by genotype, significant negative correlations emerged for the AA 
carriers for the SES sensory score with the posterior cingulate (r=-.46, p=.047), left 
putamen (r=-.51, p=.025) and left pallidum (r=-.47, p=.047). Significant negative 
correlations were also noted for the SES affective score with the posterior cingulate 
(r=-.51, p=.027), paracingulate (r=-.46, p=.049), left pallidum (r=-.49, p=.039) and left 
putamen (r=-.59, p=.008) (see Figure IV-1). For the 118G carriers negative 
correlations between GM density and SES affective pain scores emerged for the 
caudate (r=-1.0, p=.018) and SES sensory scores and GM density of the left 
amygdala (r=-1.0, p=.008) (see Figure IV-2).
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Genotype Total (N=22)    AA (N=19)    AG 
(N=3) 
   
Hemi-
sphere 
   
 left   right   left   right   left   right   
ROI/SES 
score 
SES 
sensory 
SES 
affect 
SES 
sensory 
SES 
affect 
SES 
sensory 
SES affect SES 
sensory 
SES 
affect 
SES 
sensory 
SES 
affect 
SES sensory SES 
affect 
Nucleus 
accumbens 
.156 
.488 
.000 
.999 
.022 
.923 
-.052 
.820 
.087 
.724 
-.119 
.629 
-.047 
.848 
-.165 
.499 
.737 
.472 
-.756 
.454 
.939 
.224 
-.450 
.703 
Amygdala -.021 
.924 
.007 
.974 
.048 
.830 
-.116 
.606 
-.149 
.541 
-.239 
.324 
-.009 
.972 
-.267 
.270 
-1.00* 
.008 
.102 
.935 
-.811 
.398 
-.488 
.675 
Caudate -.036 
.872 
-.077 
.735 
-.153 
.498 
-.162 
.471 
-.122 
.619 
-.220 
.365 
-.252 
.298 
-.335 
.161 
.143 
.909 
-1.00* 
.018 
-.234 
.850 
.993 
.077 
Hippo-
campus 
.011 
.960 
.118 
.600 
-.017 
.939 
.094 
.679 
-.117 
.633 
-.105 
.670 
-.190 
.436 
-.184 
.450 
-.866 
.333 
.596 
.593 
-.584 
.603 
.874 
.324 
Pallidum -.217 
.344 
-.151 
.513 
.001 
.995 
-.023 
.921 
-.474* 
.047 
-.490* 
.039 
-.120 
.626 
-.228 
.348 
-.971 
.154 
.350 
.772 
b b 
Putamen -.317 
.151 
-.302 
.172 
-.169 
.452 
-.213 
.341 
-.513* 
.025 
-.588** 
.008 
-.320 
.181 
-.434 
.063 
.991 
.084 
.017 
.989 
.884 
.310 
-.566 
.617 
Thalamus -.038 
.866 
.132 
.560 
.011 
.960 
.202 
.367 
-.174 
.475 
-.043 
.860 
-.109 
.658 
.052 
.831 
.990 
.091 
.028 
.982 
.929 
.242 
.262 
.831 
Anterior 
Parahippo-
campus 
.131 
.560 
.245 
.272 
-.087 
.699 
-.002 
.994 
.072 
.769 
.143 
.560 
-.190 
.435 
-.169 
.490 
.000 
1.00 
.993 
.073 
.210 
.866 
.947 
.208 
Posterior 
Parahippo-
campus 
.000 
.998 
-.136 
.547 
.008 
.972 
-.198 
.376 
-.068 
.783 
-.306 
.203 
-.017 
.944 
-.336 
.160 
-.871 
.327 
-.388 
.747 
-.973 
.149 
-.118 
.925 
Inslua .008 
.970 
.203 
.366 
.081 
.720 
.264 
.235 
-.123 
.617 
.019 
.939 
-.048 
.846 
.080 
.745 
-.982 
.121 
.300 
.806 
-.812 
.396 
.673 
.530 
Somato-
sensory 
Cortex I 
-.097 
.668 
-.160 
.478 
.049 
.827 
-.023 
.918 
-.107 
.664 
-.200 
.412 
-.018 
.942 
-.137 
.576 
-.933 
.234 
-.249 
.840 
-.178 
.886 
-.957 
.187 
Somato-
sensory 
Cortex II 
.365 
.095 
.033 
.886 
.368 
.092 
.073 
.745 
.397 
.093 
.068 
.782 
.334 
.163 
-.025 
.920 
.639 
.558 
.690 
.515 
-.548 
.630 
-.768 
.443 
Paracingu-
late 
-.225 
.315 
-.341 
.120 
  -.294 
.222 
-.456* 
.049 
    -.265 
.829 
-.927 
.244 
Anterior 
Cingulate 
-.157 
.485 
-.263 
.237 
  -.258 
.286 
-.397 
.093 
    .359 
.766 
-.968 
.161 
Posterior 
Cingulate 
-.244 
.274 
-.194 
.387 
  -.460* 
.047 
-.506* 
.027 
    -.610 
.582 
-.717 
.491 
Table IV-3: Correlation table genotype and ROI (by hemisphere); b = could not be calculated
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Figure IV-1: Negative correlations between SES sensory and affective scores and GM density in AA 
carriers in two structures of the basal ganglia and posterior and paracingulate cortex 
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Figure IV-2: Negative correlations between GM density and SES sensory score in the amygdala and 
affective scores in the left caudate in AG carriers 
 
Comparison of AA vs. AG carriers 
 
The results image from the permutation-based GLM in randomise revealed 
consistently greater GM densities in AA than AG carriers after FWE correction. When 
comparing the patients by genotype alone, significant GM reductions were noted only 
in the right inferior frontal gyrus pars opercularis (local maximum = .959, no. of voxels 
= 84, MNI coordinates(x,y,z) = 37, 15, 25).  
 
 
 
Figure IV-3: Uncorrected for age and duration of pain: GM decreases emerged in 118G carriers 
compared to 118A carriers 
 
After images were controlled for age and pain duration several, significant reductions 
in GM density in 118G carriers in contrast to 118A carriers were noted in the right 
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hippocampus and parahippocampal gyrus, left amygdala and bilaterally in the 
secondary somatosensory cortex (see Table IV-4).  
 
 
 
Figure IV-4: Corrected for age and duration of pain, GM decreases emerged in 118G carriers 
compared to 118A carriers in bilateral posterior insula, left amygdala, posterior cingulate and 
parahippocampus 
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Structure Left Hemisphere Right Hemisphere 
 
 
Local 
max. 
No. of 
voxel
s x y  z 
 
Local 
max. 
No. of 
voxel
s x y  z 
Amygdala 0.974 373 25 -30 -9      
Caudate 0.966 7 -33 -15 -10 0.966 9 33 -25 -9 
Cingulate Gyrus 0.958 359 -6 -52 42 0.958 441 1 -36 43 
Cingulate Gyrus (central) 0.958 87 0 -36 37      
Claustrum 0.969 112 -33 -12 -4 0.966 133 36 -10 4 
Culmen      0.953 4 27 -45 -16 
Declive      0.950 8 25 -58 -16 
Extra-Nuclear 0.974 817 -21 -6 -10 0.974 540 28 -24 -9 
Fusiform Gyrus      0.966 359 27 -48 -12 
Inferior Frontal Gyrus 0.981 1565 -18 27 -22 0.980 1144 45 13 25 
Inferior Occipital Gyrus 0.966 30 -42 -72 -10      
Inferior Parietal Lobule 0.968 1249 -54 -33 42 0.969 434 58 -31 45 
Inferior Temporal Gyrus      0.966 361 55 -13 -25 
Insula 0.969 198 -27 -10 1 0.966 961 48 -19 18 
Lentiform Nucleus 0.971 299 -21 -6 -9 0.966 26 31 -18 -9 
Medial Frontal Gyrus 0.959 54 -6 10 -22      
Middle Frontal Gyrus 0.969 1327 -22 16 58 0.978 737 40 16 30 
Middle Occipital Gyrus 0.971 190 -48 -72 -12      
Middle Temporal Gyrus      0.962 481 58 -1 -19 
Orbital Gyrus 0.980 115 -16 25 -25      
Paracentral Lobule 0.953 12 -6 -49 60      
Parahippocampal Gyrus 0.974 968 -19 -6 -13 0.979 1101 30 -22 -13 
Postcentral Gyrus 0.968 710 -55 -31 40 0.973 1561 58 -24 45 
Posterior Cingulate 0.955 9 -1 -46 24 0.958 240 4 -39 24 
Posterior Cingulate 
(central) 0.958 11 0 -48 24 
     
Precentral Gyrus 0.977 294 -48 18 10 0.971 616 60 -22 43 
Precuneus 0.959 651 -7 -60 46 0.955 44 1 -49 30 
Precuneus (central) 0.956 6 0 -49 30      
Rectal Gyrus 0.962 169 -4 15 -24 0.958 14 4 18 25 
Sub-Gyral 0.969 620 -37 15 28 0.984 906 40 13 25 
Subcallosal Gyrus 0.966 74 -22 3 -13      
Superior Frontal Gyrus 0.969 1249 -21 18 57 0.962 73 36 57 1 
Superior Parietal Lobule 0.952 36 -12 -61 67 0.951 43 34 -51 63 
Superior Temporal 
Gyrus 
     
0.962 113 57 -28 16 
Thalamus 0.958 291 -10 -27 0 0.961 458 16 -24 12 
Transverse Temporal 
Gyrus 0.953 7 -63 -12 13 0.961 43 63 -10 13 
Uncus 0.962 42 -15 -6 -24      
           
 
Table IV-4: MNI coordinates of local maxima comparing OPRM1 118AA > 118AG 
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Discussion 
 
The aim of this study was to determine the effect of the OPRM1 118A-allele on 
GMD in female chronic musculoskeletal pain patients. Overall, we found increased 
grey matter density (GMD) in pain processing regions in the A-allele carriers 
compared to G-allele carriers. This effect became more pronounced when controlling 
for age and duration of pain and could indicate a compensatory response to 
genotype-specific impairment of endorphine-mediated analgesia. Although we found 
no significant correlations between pain reports and GMD when considering the 
complete sample, significant associations were found when computing correlations 
separately for A- and G-allele carriers. Indeed, numerous inverse relationships 
between mean GMD in pain-relevant regions of interest (e.g. putamen, pallidum, 
paracingulate, posterior cingulate) and sensory and affective SES pain scores were 
found in 118A-carriers, and to a lesser extent also for the 118G-carriers. These 
findings will be discussed in detail below. 
 
As stated above, we found negative associations between GMD and pain reports 
when conducting analyses separately for the two genotypes, which provides further 
evidence for rs1799971 genotype-specific effects in different ROIs. These negative 
associations were in line with general findings of an inverse relationship between 
GMD and pain sensitivity (Emerson et al., 2014; May, 2008).  Studies comparing 
patients with healthy controls frequently highlight an inverse relationship between 
GMD and reported pain (May, 2008). Based on GMD reductions, one would expect 
higher pain ratings in the G-carriers. The absence of this difference is suggestive of a 
mild protective effect of the G-allele (Walter & Lötsch, 2009b), and may thus be a 
resilience factor against FMS, not only in Turkish women (Solak et al., 2014).  
 
Associations between SES and mean GMD manifested in subcortical ROIs from the 
basal ganglia and in the amygdala, in which opioid receptor density is high 
(Sprenger, Berthele, Platzer, Boecker, & Tölle, 2005) and where increased opioid-
binding results in down-regulation of affective and sensory response aspects of pain 
(Zubieta et al., 2001b). Hence, genotype-dependent decreases in opioid-binding 
efficacy in A-allele-carriers would lead one to expect adaptive GM increases in these 
structures or similar pain ratings in spite of smaller GMD in G-allele-carriers.  
 
Significant negative correlations for the 118A carriers in the left putamen, left 
pallidum and posterior cingulate with their sensory as well as affective SES scores 
and a significant correlation between mean GM volume of the paracingulate and the 
affective SES scores were in line with previous findings (Emerson et al., 2014; 
Schmidt-Wilcke et al., 2007). Given the prominent role of these areas in motor 
responses (Alexander, 1990), a function which is particularly affected in patients with 
musculoskeletal pain disorders, altered processing in these areas might be involved 
in the perception of (widespread) pain in patients suffering from FMS and ULBP.  
The role of the caudate in chronic pain was investigated in an fMRI study using 
SPECT, which demonstrated lower rCBF in the caudate in FMS patients (Mountz et 
al., 1995) and a BOLD study highlighted signal decreases in comparison to healthy 
controls while performing a Stroop colour word task (Martinsen et al., 2014). In 
addition, there is strong evidence for a special role of the opioid peptide system in 
pain inhibition in the caudate from a study of microinjection of morphine into the head 
of caudate in rats (Li & Tun, 1990). A PET study by Zubieta et al. (Zubieta et al., 
2005) found significant activation of endogenous opioid transmission and mu-opioid 
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receptors in the basal ganglia in response to a sustained pain stimulus and after 
administration of placebo. While the above mentioned study was not analysed by 
genotype, a possible mechanism at work might be that allostatic overload caused by 
chronic musculoskeletal pain (McEwen & Gianaros, 2011) results in reduced down-
regulation of pain in 118A carriers due to decreased endogenous mu-opioid binding 
capacity. Increased SES ratings and the associated decreases in mean GM volume 
are in support of this. However, this study did not assess mu-opioid binding potential. 
 
In spite of the power limitations due to the small number of 118G carriers, the 
negative associations between left amygdala and the SES sensory scores and the 
left caudate and the SES affective scores correspond to previous findings of opioid-
binding studies. Zubieta et al. (Zubieta et al., 2001b), reported a negative correlation 
between mu-opioid binding in the amygdala and the sensory dimension of the McGill 
Pain Inventory. However, they did not perform a genotype specific analysis, which 
would allow conclusions regarding genotype specific mu-opioid binding. The reduced 
GMD in G-carriers in comparison to AA homozygotes, when corrected for age and 
duration of pain, is suggestive of greater pain ratings in G-carriers. However, in spite 
of the smaller average GMD and a negative association between mean amygdala 
GMD and reported sensory pain, the G-allele appears to confer some protection 
against sensory pain as indicated by the difference in SES sensory scores between 
the AA and AG carriers possibly mediated by the G-carriers‘ greater mu-opioid 
binding potential (Bond et al., 1998b). 
 
In summary, finding that the majority of OPRM1-dependent correlations between GM 
reductions and increases in affective and sensory pain ratings were reported within 
structures from the basal ganglia is plausible in light of the fact that the basal ganglia 
possess a high opioid-receptor density (Sprenger et al., 2005). Thus genotype-
mediated differences in sensitivity to endogenous opioids are likely to have effects on 
pain processing and consequent changes in brain plasticity.  
 
The results of the permutation-based GLM at whole brain level, which compared the 
AA and the AG carriers revealed no significant differences in GM density when 
comparing the patients by genotype alone except for the right inferior frontal gyrus 
pars opercularis, which forms part of the secondary somatosensory cortex. It is also 
one of the few regions that elicits a pain sensation, if stimulated electrically (Head & 
Holmes, 1911). When corrected for age and duration of pain, smaller GMD for 118G 
carriers emerged in the bilateral posterior insula, primary somatosensory cortex, 
hippocampus and parahippocampus, posterior cingulate and left amygdala which 
have been described as part of a network of pain-relevant structures (Iannetti & 
Mouraux, 2010).  
 
Since age and pain duration were controlled for in this study, the differences between 
the two groups might not represent relative GMD reductions in G-allele carriers, but 
hypertrophy in the A-allele carriers in order to compensate for genotype-mediated 
reduced effectiveness of endorphine-mediated analgesia.  
 
Overall, the results for the 118A carriers are in line with findings for case-control 
studies, in which reduction of GM volume corresponds to increased pain intensity 
when correlating the SES scores for affect and sensory aspects of pain.  
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Mu-opioid binding potential (MBP) in the nucleus accumbens and thalamus was 
shown to be negatively associated with both the affective and sensory McGill Pain 
Questionnaire scores. Negative correlations were also shown between MBP in the 
amygdala and the sensory pain ratings and in the anterior cingulate with the affective 
dimension of pain (Zubieta et al., 2001b). In another study of differential opioid action 
on sensory and affective pain processing, somatosensory cortex I and II and 
posterior insula were found to be associated. Homozygous 118A carriers revealed 
pain-related activation in the somatosensory cortex I and II, parahippocampus, 
amygdala temporal pole, anterior cingluate and supplementary motor area in 
response to a pain challenge (Oertel, Preibisch, Wallenhorst, Hummel, Geisslinger, 
Lanfermann, & Lötsch, 2008).  
 
The fact that correlations do not occur in all pain-relevant ROIs indicates a brain 
region-specific effect of rs1799971 on opiodergic signalling, which has also been 
demonstrated in SII and thalamus (Oertel, Preibisch, Wallenhorst, Hummel, 
Geisslinger, Lanfermann, & Loetsch, 2008). The study by Oertel et al. applied a 
synthetic opioid, while participants in this study were unmedicated, leaving only 
endorphin-mediated pain regulation. The effect of rs1799971 may thus be 
determined by a combination of factors including disorder, sex (Mogil et al., 2003), 
age, genotype and brain region. Reduced mu-opioid binding has been demonstrated 
in FMS patients (Harris et al., 2007) and symptoms are exacerbated in AA carriers.  
 
While a larger number of 118G carriers would have made for a more robust 
comparison, the results are in line with previous findings. In addition, the permutation-
based GLM was implemented due to known robustness when applied to small 
sample sizes. Apart from the computational aspects the emergence of functionally 
and biologically plausible structures with only three heterozygote patients points 
toward an even stronger effect in homozygotes for the G-allele.  
 
Potential criticism might be directed at the combination of the separate clinical 
diagnoses ULBP and FMS on the assumption that both disorders are rooted in 
maladaptive CNS plasticity. There were no systematic differences between age, 
duration and SES scores between the participants of both diagnoses. Both from a an 
angle of shared mechanism of disorders (Woolf et al., 1998; ―Woolf Central 
Sensitization Pain and Plasticity,‖ n.d.) and that both disorders affect the patients‘ 
musculoskeletal system, a combined analysis appears justifiable.  
 
Previous studies indicated a sex-specific effect of exacerbated pain in female carriers 
of 118G (Olsen et al., 2012), which justifies the exclusive recruitment of female 
participants for this study. The fact that both disorders are more frequent in women 
than men might also be indicative of a sex-effect.  
 
However, a future replication of this study should also include a sufficiently large 
number of male participants to further explore possible sex effects. Additionally, it 
would be also desirable for future studies to include all three possible allele 
combinations and gender, age and genotype matched controls. This would allow for 
a dose response analysis to ascertain whether patients homozygous for the G-allele 
will indeed show the smallest GM densities in comparison to AA carriers. It would 
also allow determination of the effect of genotype in healthy controls in relation to 
sensory and affective pain scores, if a sensory testing battery were included.  
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Overall, this study highlighted a unique genetic contribution of OPRM1 to GMD 
changes in chronic musculoskeletal pain patients. While the direct mechanism of 
action remains elusive, the results highlighted the OPRM1 118A allele as a risk factor 
and biomarker for chronic musculoskeletal pain in female patients. 
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3 GENERAL DISCUSSION 
This chapter provides an evaluation of the results obtained through applying 
genetic and neuroimaging methodologies in two specific painful clinical conditions. It 
will then evaluate how well the methodologies used in this thesis adhered to quality 
criteria for biomarker development specified in the introduction and discuss the 
studies‘ limitations before providing a final summary with future directions. 
 
With regard to the neuroimaging components, the ASL-based rCBF measures 
demonstrated potential as independent endpoints for pain assessment, rather than 
an adjunct to patient self-reported pain. The comparison between rCBF measures 
following surgery and those obtained during the pain-free pre-surgical periods 
demonstrated rCBF increases in an unbiased voxel-wise analysis as well as in a 
priori hypothesised regions inherent in the central processing of pain. Associations of 
the post-surgical rCBF and VAS estimates of self-reported post-surgical pain were 
found in brain regions known to underpin the pain experience, but not in a pain-
unrelated control region, thus adding to the results‘ physiological plausibility.  
 
Stability for rCBF assessments was established within a single session and 
demonstrated robustness with regard to between-session differences in post- 
surgical rCBF following extraction of left, compared to right teeth. Bilateralism is of 
particular relevance within the context of the trigeminal system (Jantsch et al., 2005; 
Weigelt et al., 2010) where evoked painful and non-painful stimulation of the 
trigeminal nerve may elicit bilateral rCBF changes in the thalamus. Crossed and 
uncrossed somatosensory and nociceptive afferents project from the trigeminal 
ganglion to the thalamus and terminate at its ventral medial and lateral posterior 
regions, which contain bilateral representations of the oral cavity (Nieuwenhuys et al., 
2008). Through its interconnections with the hypothalamus (Pogatzki-Zahn et al., 
2007) bilateral changes in post-surgical thalamic rCBF may represent aspects of the 
on-going pain experience, but also changes in arousal (De Leeuw et al., 2005). 
Findings of bilateral rCBF increases in S1 post surgery match findings in bilateral 
receptive fields of primates (Lin et al., 1993). 
 
Further analysis addressed issues regarding the reliability of quantitative cerebral 
perfusion measures in research on ongoing pain. It demonstrated that pain following 
TME could be assessed with good-to-excellent inter- and intra-session reliability 
across both pCASL and VAS modalities within-subject. It also capitalised on the 
advantage of repeated measures designs to limit variability between subjects due to 
experimental error and thus provide good reliability for comparing condition effects 
and thus enable implementation of reliable quantitative perfusion imaging biomarkers 
of ongoing pain to supplement the use of subjective self-report measures. 
 
The importance of careful baseline selection was highlighted, which increased the 
reliability of the ΔCBF parameter (an indicator of change in CBF between pre- and 
post-surgical states) by demonstrating that either a single baseline condition or 
alternatively the mean of more than one baseline produced a higher degree of 
reliability. Hence, this study highlighted that ASL-based studies should be designed 
with several factors in mind to ensure appropriate reliability and to avoid previous 
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issues in detecting reliable drug-induced CBF changes with ASL using the test–retest 
method (Klomp et al., 2012).  
 
An additional achievement of this study was its provision of a framework for future 
use of ASL-based assessments of the cerebrovascular response to pain. Since the 
publication of these results, ASL has successfully revealed altered perfusion patterns 
in other pain populations (e.g. migraineurs without aura and osteoarthritis 
(Hodkinson, Veggeberg, et al., 2015; Sanders et al., 2015)). The ASL technique 
thereby highlighted disease-specific functional deficits in neural pain processing 
pathways (Hodkinson, Veggeberg, et al., 2015), thus adding value above and beyond 
patient self-report (Borsook et al., 2008) and taking us closer to discovering potential 
underlying mechanisms such as adaptive or maladaptive functional plasticity. 
Furthermore, the pCASL rCBF signature demonstrated utility in successful 
differentiation between patients and healthy controls and in assessment of the effects 
of analgesics versus placebo (Hodkinson, Khawaja, et al., 2015a; Hodkinson, 
Veggeberg, et al., 2015; Howard et al., 2012; Sanders et al., 2015). Since no 
experimental augmentation of pain (Owen et al., 2012; Wasan et al., 2011) was 
needed as CBF changes manifested in patients at rest, transfer of ASL-based 
imaging protocols into standard clinical practice similar to those in neurological 
disorders such as dementia and stroke could be used in diagnostics and the 
monitoring of treatment progress.  
 
The following factors in this study proved helpful in achieving reliability: first, 
acquisition of more than one pre- and post-surgical CBF map. Second, a 
counterbalanced within-subject study design and implementation of strict inclusion 
and exclusion criteria to minimise the impact of confounding factors. Reliability tests 
in this study indicated that both functional and psychological interactions occurred 
despite strict adherence to a balanced study protocol and thus demonstrated 
additional volatility factors in the assessment of the pre- and post-surgical states. 
Third, factorial designs have proven more powerful in the analysis of cognitive 
processes (Friston et al., 1996) and should thus be implemented.  
 
Independent of whether the left or right third molar was removed, TME appeared to 
be represented in S1, S2, and insula ipsi- as well as contralateral to the surgery site 
(Howard et al., 2011), which replicated findings from previous investigations 
employing painful (Jantsch et al., 2005) and non-painful (Ettlin et al., 2004) dental 
stimulations. Such low variation across repeated measures facilitates the detection of 
small alterations in CBF. Hence this study demonstrated the suitability of ASL indices 
in the monitoring of disease progression and therapeutic intervention effects, since 
there is no need for contrast agents (Petersen et al., 2006).  
 
Longitudinal reliability of ASL in this study was in line with findings from previous 
studies in healthy volunteers (Chen et al., 2011; S. Gevers et al., 2009a; Gevers et 
al., 2011; Jain et al., 2012; Parkes et al., 2004) and neurological patients (Xu et al., 
2010). There was no relationship between interval length and ICC values, even 
though the study design did not acquire the pre-surgical scans immediately before 
surgery, but on different days. Still further research on reliability of perfusion-based 
measures across the course of longitudinal studies is desirable, even though time-
course stability of the CBF measurements within the ongoing pain state was excellent 
in this study as indicated by higher ICC values between pCASL scans than ICC 
values between sessions. In addition, potential variability in the CBF measurements 
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due to temporal variation was investigated with respect to the duration of scanning for 
each subject. Operator-related variability was deemed to be low and reproducibility 
values to be predominantly physiology dependent as pCASL scans within-session 
did not require repositioning. Hence, potential error from aligning acquisition and 
labelling planes should be minimal. The resulting relative stability of this type of 
perfusion measurement over relatively long-time intervals makes it an attractive 
method to study naturalistic responses to pain, allowing within-subject investigations 
of spontaneous and intervention-dependent fluctuations in pain state. 
 
 With regard to the gene expression component, this study demonstrated the utility of 
gene expression analysis in peripheral whole blood after TME by generating a list of 
target genes in which the top 20 most significantly differentially expressed genes 
demonstrated high potential of being pain and nociception biomarkers, as almost half 
of them had previously been indicated in studies of various pain phenotypes. At the 
same time, the use of a data driven approach utilising pathway and interaction data 
from known functional pathways enabled a better discrimination of genes primarily 
concerned with other biological functions such as digestion, which could be treated 
with less priority in follow up studies on particular candidates.  
 
The particular challenge met by this study was to implement a viable strategy to 
identify candidate genes and molecular pathways with primary relevance in pain and 
nociceptive signalling and processing rather than mere tissue repair and immune 
functions in response to the tissue damage. It demonstrated that the data science 
approach was able to condense the long list of genes to smaller groups with 
significant enrichment of genes from this study in established molecular pathways 
and a custom-designed pathway for inflammatory mediator regulation of TRP 
channels.  
 
 Such studies open a potential avenue to combat one of the greatest criticisms 
directed at analgesic development, that all currently available analgesics are merely 
variations of existing drug classes (e.g. opioids and NSAIDs (Max, 2000; Woolf & 
Max, 2001)). Instead of introducing synthetic agonists and antagonists, which bind to 
pain and nociception-relevant receptors, clarifying the role of genes such as 
membrane metalloendopeptidase (MME) for example, might enable the therapeutic 
modulation of the body‘s own analgesic and anti-nociceptive capacities. Inhibiting 
cleavage of enkephalins, which are often provided by leukocytes in inflamed tissue 
(Schreiter et al., 2012), but are also abundant in peripheral whole blood, might result 
in an analgesic effect.  
 
Some such inhibitory drugs have already been tested, the two main groups being 
dual enkephalinase and fatty acid amide hydrolase (FAAH) inhibitors, in a model of 
inflammatory and neuropathic pain (Roques et al., 2012). Ideally such mechanism-
based treatments would eliminate the irksome aspects of pain, while leaving adaptive 
aspects such as facilitation of tissue repair undisturbed. The multitude of associations 
with a range of different pain phenotypes fosters hope that effects of future 
interventions developed as a result of a biomarker-based approach, are effective 
across different pain pathologies, which might manifest in different phenotypes, but 
share similar mechanisms. Future comparisons of expression profiles from patients in 
pain and upon achieving pain relief might also help in further characterising the 
mechanisms of action inherent in commonly used analgesics.  
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The VBM study featured a combined analysis, thus making it an imaging genetics 
study. The overwhelming majority of studies on GM irrespective of genotype in 
populations suffering from chronic or ongoing pain have highlighted an inverse 
relationship between GM density and pain intensity (Emerson et al., 2014; May, 
2008). Only one report on chronic back pain patients versus healthy controls 
demonstrated increases in GM density in the basal ganglia (Schmidt-Wilcke et al., 
2006), albeit uncorrected for small volumes. Thus the difference in GM density is 
more likely to represent GM hypertrophy in carriers of the wild-type allele. This likely 
represents a compensatory response to the on-going pain, than pain-induced GMD 
in G-carriers, since all participants in this study suffered from musculoskeletal pain. 
Possible mechanisms behind this might be the G-allele‘s facilitative effect on opioid 
binding, which suggests decreased endorphine-mediated analgesia in A-carriers 
(Walter & Lötsch, 2009b). Further support for an ameliorating influence of the G-allele 
are findings that the G-allele is less frequently found in female FMS patients (Solak et 
al., 2014) and has been shown to enhance the ability to maintain positive affect even 
on days with higher pain (Finan, Zautra, Davis, & Lemery-chalfant, 2011). 
 
However, a pattern of inverse relationships between GMD and sensory and affective 
SES scores did emerge mostly for the 118A-carriers in several ROIs with known 
involvement in pain and nociception, but not in an analysis of the overall sample.  
 
Plausible reductions in mean GMD in the 118A-carriers for the left putamen, left 
pallidum and posterior cingulate with their sensory as well as affective SES scores 
and a significant negative correlation of paracingulate mean GMD and the affective 
SES score were in line with previous findings of an inverse relationship between 
GMD and sensory pain ratings in essential neural hubs of the default mode network 
(Buckner, Andrews-Hanna, & Schacter, 2008; Fox et al., 2005) and networks 
regulating somatosensory processing, direction and shifting of attention (Emerson et 
al., 2014; Schmidt-Wilcke et al., 2007). Previous findings of altered activation of the 
posterior cingulate cortex in low back pain (Kobayashi et al., 2009) and in response 
to painful stimulation (Adler et al., 1997; Coghill et al., 1994; Vogt et al., 1996) added 
further plausibility.  
 
Significant negative correlations in ROIs of high opioid receptor density (Sprenger et 
al., 2005) such as the basal ganglia and amygdala pointed toward impaired down-
regulation of pain through opioid-binding (Zubieta et al., 2001b) in the A-carriers and 
affirmed the role of the selected ROIs in motor response (Alexander, 1990), 
nociception (Starr et al., 2011) and integration of somatosensory and motoric 
information (Bingel, Gläscher, Weiller, & Büchel, 2004). The higher prevalence of 
significant negative correlations in A- rather than G-allele-carriers can be viewed as 
further evidence for genotype and brain region-specific effects of rs1799971 (Oertel, 
Preibisch, Wallenhorst, Hummel, Geisslinger, Lanfermann, & Loetsch, 2008). 
However, the number of G-carriers in this sample was limited. 
 
In the light of a mechanism-based approach to the study and classification of pain, 
the absence of significant differences in SES ratings between the two diagnoses 
supported the assumption of a shared underlying mechanism between FMS and 
ULBP. The areas revealed in this study overlapped with pain-related activation in 
response to a pain challenge in a genotype-specific study of differential opioid action 
on sensory and affective pain processing, with a pronounced effect in homozygous 
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118A carriers (Oertel, Preibisch, Wallenhorst, Hummel, Geisslinger, Lanfermann, & 
Lötsch, 2008).  
 
Despite the known effects of this SNP on endogenous opioid binding and opiodergic 
transmission in brain regions of high opioid-receptor density (Sprenger et al., 2005) 
(e.g. basal ganglia (Zubieta et al., 2005)), the exact nature of the underlying 
mechanism remains elusive without concomitant assessment of genotype-specific 
opioid-binding. Reduced mu-opioid binding has previously been demonstrated in 
FMS patients (Harris et al., 2007). Here impaired endogenous mu-opioid binding 
capacity in 118A carriers most likely resulted in reduced down-regulation of pain and 
in turn lead to allostatic overload with exacerbated symptoms, especially in AA 
carriers (McEwen & Gianaros, 2011).  
 
The results also indicated, that the genotype-specific effects can be masked by other 
factors such as age and duration of pain as relative GMDs by genotype alone only 
appeared in the right inferior frontal gyrus pars opercularis. After correction for age 
and duration of pain (Iannetti & Mouraux, 2010) more extensive GMDs for the 118G 
carriers emerged. 
 
This study demonstrated genotype-specific effects on brain plasticity in patients with 
chronic musculoskeletal pain, highlighting an inherent risk of relative hypertrophy in 
pain processing regions of the brain associated with the A-allele of SNP rs1799971 in 
OPRM 1. These effects became more pronounced when controlling for age and 
duration of pain and represent a compensatory response to genotype-specific 
impairment of endorphine-mediated analgesia. While the direct mechanism of action 
remains elusive, results identified the OPRM1 118A allele as a risk factor and 
informative biomarker for chronic musculoskeletal pain in female patients. 
 
 
3.1 Fulfilment of quality criteria in biomarker discovery and limitations 
   
Adherence to commonly used quality criteria was used as a yardstick for the 
critical evaluation of the utility of neuroimaging and genetic technologies in search of 
biomarkers of pain and nociception in this thesis. High reliability, sensitivity, 
specificity, generalizability, comprehensiveness and validity enhance the potential for 
successful identification of novel genetic and neuroimaging biomarkers, clinical and 
surrogate endpoints and will be discussed in the following chapter along with the 
accompanying limitations.  
 
Reliability  
 
The issue of reliability was highlighted in the TME study for both the 
neuroimaging and the gene expression endpoints in baseline selection when 
calculating the differences between pre- and post-surgical gene expression and rCBF 
levels. Both gene expression and rCBF are subject to considerable volatility in 
response to environmental and/or internal factors, which put particular emphasis on 
the choice of a baseline in both endophenotypes.  
 
For the rCBF data to yield good-to-excellent reproducibility the best baseline was 
implemented by either the use of a single baseline condition or the mean of more 
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than one pain-free baseline scan in order to increase the precision of ICC 
estimations. Similarly, the gene expression data included two pain-free baseline 
samples for every post-surgical sample obtained on control MRI scanning days and 
immediately before the surgery, and one baseline follow-up sample.  
 
The amelioration of the effects of fluctuations in rCBF levels could be attributed to 
many factors such as differences in intrinsic physiological factors between the 
individuals, the overall level of brain activity (Wenzel et al., 1996), variations in blood 
T1, neuronal density or number, and arousal (Parkes et al., 2004). A definite 
advantage was the implementation of the pCASL measurements at 3T rather than 
1.5T, which yielded improved spatial and temporal resolution due to the longer T1 
and a higher signal to noise ratio (Chen et al., 2011; Tjandra et al., 2005). 
 
Further confidence in sufficient control for variability between testing days in the ASL 
data stemmed from several sources: First, the pCASL -in comparison to the BOLD 
signal- is known to be less volatile across different time points (Gevers, Majoie, Van 
Den Tweel, Lavini, & Nederveen, 2009b; Gevers et al., 2011). This can be attributed 
to the lower temporal resolution of pCASL as it represents the sum of several 
measurements across a period of several minutes. In addition, pCASL-derived rCBF 
is mapped to parenchyma and thus less sensitive to large draining vein contributions 
since signal loss due to T1 recovery has reduced venous blood labeling by the time 
the blood arrives at the draining veins (Duong et al., 2002). This was complemented 
by the physiological meaningfulness of the measure, while BOLD measures of neural 
activity are a more implicit measure of neural activity (Wong, 2014). Further support 
for the meaningful application of pCASL was drawn from previous studies of 
differential rCBF using ASL in different pain states and disorders (Maleki et al., 2013; 
Owen et al., 2012).  
Within the context of the VBM study, reliability was more difficult to assess. 
Morphometric changes are less dynamic than those observed in neural perfusion and 
gene expression. The method of choice in most VBM studies of pain has been a 
case-control design, which results in a between-subjects comparison (Apkarian & 
Hashmi, 2012; Lutz et al., 2008; Schmidt-Wilcke et al., 2007). Alternatively, repeated 
measure designs allow for a within-subject comparison thus minimising between-
subject error as applied in a study of osteoarthritis patients which compared GMD 
before and after hip joint endoprosthetic surgery (Rodriguez-Raecke, Niemeier, Ihle, 
Ruether, & May, 2013b). Here, patients served as their own controls between pain-
free and painful state. However, pre-morbid structural scans of FMS and ULBP 
patients are rarely available and there is a lack of prospective cohort studies of 
musculoskeletal pain, which include MRI data, due to the late onset of FMS and 
ULBP. One of the reasons for this might be that technological advances impede 
comparisons across different measurement time points. Structural data acquired on 
an older scanner of low(er) field strength (e.g. 1.5T) and structural data acquired a 
contemporary scanner with field strengths of 3T or above would be incompatible for 
joint analysis. In addition, comparability between scans from different manufacturers 
may be limited.      
 
While genotyping DNA has become a highly reliable standardised procedure, 
reliability for the OPRM1 A118G genotype data was ascertained by cross-validating 
genotyping results on two different platforms. The high concordance of results 
indicated high quality thereof.   
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With regard to gene expression studies the issue of reliability was more complex. 
Reliable detection of relatively abundant transcripts has been established for the 
existence and direction of expression changes. However, the magnitude of 
expression changes cannot be assessed accurately by microarrays (Draghici, Khatri, 
Eklund, & Szallasi, 2006). In addition, probe sets vary across microarray platforms 
and the resulting summary values for genes may not correspond with PCR-based 
measures of gene expression. 
 
Sensitivity within the biomarker concept is defined as the ability of a biomarker or a 
change therein to be measured with adequate precision. This requires sufficient 
magnitude of change in order to identify meaningful alterations in important clinical 
endpoints (Lesko & Atkinson, 2001). The pCASL data revealed rCBF increases 
between 5-10% following TME, which can be considered a huge effect, considering 
that the majority of fMRI studies use BOLD imaging, which in studies of cognitive 
effects yield changes in an order of magnitude between 1-5% (Aguirre et al., 1998; 
Glover, 1999).  
 
VAS estimates of pain have been a staple in pain assessment and aided in 
establishing association between painful sensations and significant increases in 
response to TME. However, simple VAS intensity ratings fall short on assessing the 
multi-dimensional character of pain, as they do not allow for further differentiation of 
specific aspects of pain processing (R. Melzack, 1975). In the VBM study additional 
aspects such as sensory and affective ratings of pain from the SES were included 
also based on previous knowledge of a differential influence of opiodergic signalling 
on these aspects (James, 2013; B. G. Oertel, Preibisch, Wallenhorst, Hummel, 
Geisslinger, Lanfermann, & Loetsch, 2008).   
Specificity –the third quality criterion to be discussed within the biomarker concept- 
is defined as the ability of a biomarker or a change in biomarker to distinguish 
patients who are responders to an intervention from those who are non-responders in 
terms of changes in clinical endpoints.  Since none of the study designs included an 
analgesic intervention the criterion of generalizability was emphasized.  
 
Generalizability i.e. the ability of an underlying mechanism to cause a mild as well as 
a severe form of a disorder, highlighted some minor and some broader limitations of 
this thesis. For example, participants in TME study were excluded, if the VAS ratings 
of pain remained below 3 out of 10 after the lidocaine had worn off, thereby excluding 
very mild manifestations of inflammatory pain. Although analysis of non-responders 
bears fascinating prospects, in the context of this thesis, the small number of 
participants would have left such an analysis profoundly underpowered. While 
generalizability is desirable, there is a tendency to focus on the pathological and less 
on the resilient end of the spectrum. Since the resilient individuals are of little interest 
for interventional research and do not represent a burden for healthcare systems, 
studies are designed to often exclude those individuals with mild manifestations of a 
disorder to enable better detection of statistical effects in small pilot studies due to 
the cost of this type of research.   
 
With regard to the VBM study an additional reference population of age, genotype 
and gender matched healthy controls would have been preferable. This thesis 
examined the differences in GMD between OPRM1 118A- and 118G-carriers 
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suffering from FMS and ULBP, but did not include healthy control participants. Hence 
the general effects of this genotype on GMD warrant further examination.  
Overall an analysis for a dose-response relationship for both homozygous and the 
heterozygous groups would have made a much stronger point with regard to the 
hypothesis of this study. Furthermore, replication of the age-dependent effects on 
GMD demonstrated by Ceko et al. (Ceko et al., 2013) in association with genotype 
would have been of interest as well, since GMD differences between OPRM 1 118A- 
and 118G-carriers became more pronounced after controlling for age and duration of 
pain.  
 
The criterion of comprehensiveness, is defined as providing as many diagnoses as 
necessary within a categorical system of pathology to sufficiently classify manifest 
disorders. It touches upon the most divisive point between phenomenological and 
mechanism based classifications of pain. Even though a disorder might present with 
very heterogeneous phenomenology (with ULBP and FMS being diagnosed as 
separate disorders in current clinical practice (WHO, 2010)), the same classification 
as a maladaptive CNS plasticity syndrome may apply due to a shared underlying 
mechanism (Yunus, 2008). In a mechanism-based classification of pain, both 
disorders are counted among the central sensitivity syndromes i.e. nervous system 
injury pain brought on by maladaptive CNS processing (Woolf, 2004). Support for a 
shared mechanism was found in the VBM study in that both FMS and ULBP patients 
demonstrated exacerbated sensory and affective pain levels and relative GMD 
reductions mediated by the presence of the A-allele of rs1977791.  
 
A similar line of reasoning applies with regard to gender. Previous studies 
demonstrated a gender specific effect of exacerbated pain in female carriers of 118G 
(Olsen et al., 2012), which justifies the exclusive recruitment of female participants for 
this study. The fact that both disorders are more frequent in women than men might 
also be indicative of a sex-effect. The exclusive use of female participants was well 
justified by the higher frequency rates of FMS and ULBP (Werber & Schiltenwolf, 
2012; Wolfe et al., 2010) in women and while the exclusive use of men in the TME 
study allowed for control of hormonal variations at the price of limiting extrapolation of 
the results to female TME patients. Although men were recruited for the VBM study, 
the number of male data sets was too small to allow for gender-specific analysis. This 
is apparent gender bias is a general concern in medical research. Pharmacological 
studies and clinical trials are predominantly conducted in men (Gluud, 2006; Herz, 
1997). Female participants are mostly post-menopausal women due to the 
aforementioned hormonal variation, but also to exclude potential teratogenic effects 
in women of child-bearing age (Ramasubbu, Gurm, & Litaker, 2001; Ruiz & 
Verbrugge, 1997). With regard to pain this is particularly unsatisfying since the 
majority of pain conditions affect more women than men and there is evidence that 
pain affects women differently as well (Fillingim, 2000; Greenspan et al., 2007). This 
thesis included both male and female participants. However, they split into an all 
male sample in the TME study and an all female sample for the VBM study.  
 
In addition, both studies were also subjected to an inherent age bias, which was 
rooted in the typical prevalence and age of onset of the clinical phenotypes. The 
potential risk here is that results are subject to limitations when extrapolating to the 
respective opposite sex for both studies or to older or younger age cohorts. Studies 
of ASL have demonstrated a decline in overall rCBF levels in older patients (Parkes 
et al., 2004), which is attributed to the well-established age-related decline in grey 
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matter (Ge et al., 2002). For the TME study, extrapolation to other types of surgery-
induced pain or older populations with worse overall health status, comorbidities or 
on concomitant medication due to age-related conditions might be impeded as well.  
 
While age-related grey matter decrease has been controlled for in the VBM study, the 
small sample size and limitation to female subjects has slightly greater implications 
for the VBM study, where the small number of participants resulted in a lack of 
gender, age and genotype matched controls.  
In spite of the small sample size, the criteria for Hardy-Weinberg equilibrium were 
met. Hence, reasonable confidence could be placed in a lack of systematic 
differences in genotype distribution. Although the minor allele is less common than 
the wild-type allele, the fact that there are hardly any GG carriers in most studies of 
this genotype and in particular in FMS patients, is also making an implicit statement 
with regard to the protective properties of the G-allele and is in line with previous 
findings (Solak et al., 2014). 
 
Validity in biomarker research is defined as the degree of achieving the objective of 
a study and pertains to the ability with which a diagnostic measure can answer a 
medical question (Büttner, 1997). Clinical relevance is thus an important cornerstone 
of biomarker evaluation and has strong bearing on the (ecological) validity of a 
biomarker.  
 
The most commonly used approach in increasing validity is employing a gold 
standard model of a disorder. While many of the mechanisms underlying pain and 
nociception are yet unknown to date, the TME model currently represents a gold 
standard model for inflammatory pain. It has been used in combination with genetic, 
QST and other phenotypes in addition to its applications in determining the efficacy 
of analgesics (Flores & Mogil, 2001; Hargreaves, Schmidt, Mueller, & Dionne, 1987; 
Juhl et al., 2008; Wang et al., 2007). The TME model also allows a direct comparison 
between a pain-free and a painful state in patients without confounding co-
morbidities as is the case in most chronic pain disorders, where there is often little 
reliable information regarding the pre-morbid state. 
 
The VBM study in patients with chronic musculoskeletal pain suffering from FMS and 
ULBP represented a model of stimulus-independent pain, since no external event to 
precipitate its onset was identifiable. Hence there is no intervention such as a surgery 
to precipitate the pain. Here a gold standard would be to perform a prospective study 
to identify factors, which lead to participants developing the pathology later in life, 
which is impeded by the aforementioned difficulties of high drop out rates for 
longitudinal cohort studies and MRI platform incompatibilities.   
 
In further support of validity, both studies were performed in humans and in actual 
clinical cohorts. Hence, both studies adhered to recommendations for studying 
common genes that contribute to human pain. Hence, minimising the risk of failure 
often associated with animal model-derived genetic targets in the treatment of human 
disorders (e.g. tachykinin NK1 receptor antagonists (Hill, 2000)) and to increase the 
chance of a return of the results from bench to bedside (Mitchell B Max, 2008).  
 
An advantage of working with human participants was that it enabled the assessment 
of cognitive components of the pain experience such as sensory and affective ratings 
of pain, which are essential components of the human pain experience, but difficult to 
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operationalize in animals (Max & Stewart, 2008b). Another aspect pertained to the 
ecological validity of the study designs. The TME model offered a pain stimulus with 
a higher threat value than many experimental pain stimuli, with the threat component 
being an essential part of the pain definition (Mersky & Bogduk, 1994).  
 
While nociception and pain are universal in humans, pharmacogenomics have 
demonstrated different efficacies of the same medications in different ethnicities 
based on genetic variation (Argoff, 2010; Roses, 2000; Wang, Zhang, He, & Fang, 
2006) . The same might apply in the case of rs1799971 with regard the prevalence of 
FMS and ULBP due to the different distributions of the minor allele frequency across 
ethnicities. Low prevalence for FMS has been reported in Chinese populations (Zeng 
et al., 2008), where in some cases the A- and not the G-allele can be the minor allele. 
There are general differences with regard to the frequency of the G-allele, which is 
present in 5-10 % of Africans, 10-20% Caucasians and 40-60% Asians. Whether the 
findings in this study replicate in other populations remains to be proven and requires 
further research in FMS patients of different genetic backgrounds. 
  
Participants in the VBM and TME study were screened for depression prior to 
inclusion and none of the participants had clinically relevant scores. With regard to 
the VBM study, future inclusion of depressed pain patients might reveal additional 
effects on affective pain scores. OPRM1 has demonstrated effects on pain-related 
affect and consistency of GMD differences when controlling for affective disorders 
(Finan et al., 2011; Hsu et al., 2009).  
 
Particular attention was drawn to the spatial non-uniformity of reliability in the CBF 
measurements. ASL measures have demonstrated spontaneous CBF fluctuations in 
resting state (Petersen et al., 2010) and in response to brain activation at different 
levels in previous studies (Wenzel et al., 1996). While ICC is clearly dependent on 
the heterogeneity of the sample and fluctuations in physiology induced by the pain 
state, the seeming independence of distribution of high ICC values and high values 
of t may be rooted in differences in the spatial distribution of the CBF response to 
pain. Another explanation of these findings might be differences in intrinsic 
physiological factors between the individuals, attributable to physiological variability 
without being a limitation of the pCASL methodology. 
 
Yet another explanation for individual differences in the perfusion estimate may 
depend upon variations in blood T1, neuronal density, and arousal (Parkes et al., 
2004). Here acquisition of CBF data at higher field strengths provided the advantage 
of longer T1 and enhanced signal to noise ratio in addition to improved spatial and 
temporal resolution.  
 
3.2 General thesis conclusion 
 
This final section will evaluate potential of the application of genetic analysis 
and neuroimaging tools in the quest for new insights into the mechanisms underlying 
pain and nociception.  
 
The bottom-up approach (Mogil & McCarson, 2000) used in the TME study 
demonstrated the utility of gene expression data from peripheral whole blood in 
combination with a data science approach in highlighting differentially expressed 
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genes with raised potential of being relevant in pain and nociception. In the future this 
approach will become more refined as new pathways will be added to reference 
databases and more information will become available on transcripts, genes and their 
interactions, which are poorly characterised to date.  
 
At the same time a combination of genetic and neuroimaging techniques was utilised 
in a top-down approach, where the effects of a common genetic variant from the 
gene encoding mu-oipoid receptor 1 on grey matter density was assessed at the 
whole brain level, and the relationship between mean GMD and psychometric ratings 
of sensory and affective pain in important nodes of neural pain processing networks 
were assessed. The results revealed greater GMD in the carriers of the wild-type 
allele in comparison to carriers of the minor allele. At the same time there were 
significant negative genotype-dependent associations between GMD and sensory 
and affective pain ratings pointing towards relative hypertrophy in the wild-type allele 
carriers. However, the exact mechanism by which this maladaptive process is 
initiated and sustained warrants further investigation.  
 
By adapting an augmented multi-level approach to a mechanism-based classification 
of pain disorders in lieu of the traditional phenomenological approach, it was possible 
to implement viable strategies involving well-characterised, controlled, clinically 
relevant biomarkers in pain and nociception that are robust, yet relatively easy to 
acquire. 
 
It enabled the investigation of three clinical pain conditions (i.e. FMS, ULBP and TME 
induced post-surgical pain) at the symptoms level by using the classical 
phenomenological descriptors such as intensity, location and duration in conjunction 
with additional physiological measures i.e. gene expression and rCBF levels, GM 
volume and genotype closer to the biological underpinnings of the disorders under 
investigation. These were used as additional (endo-)phenotypes to refine 
identification of possible biomarkers in search of mechanisms and biological 
diatheses, which govern pain and nociception in the abovementioned clinical pain 
states and to maximise the chances of generating suitable targets for further 
investigation with regard to developing therapeutic and diagnostic procedures.  
 
Neuroimaging and genetic biomarkers demonstrated utility in both a stimulus 
dependent prolonged pain experience as implemented in the TME study, as well as 
stimulus-independent musculoskeletal pain conditions. The idea of disease-specific 
‗neurosignatures‘ beyond a single universally active pain matrix (Iannetti & Mouraux, 
2010; Iannetti, Salomons, Moayedi, Mouraux, & Davis, 2013; Tracey & Johns, 2010a) 
can be tested and implemented in the context of activation and perfusion measures, 
but also with regard to structural changes depicted as variations in grey matter 
density. Hence, selecting a set of a priori ROIs based on previous knowledge of a 
specific pain condition instead of a universally applied approach to all persistent pain 
states appears preferable. Since ROIs with known high OPRM1 density emerged 
from the analysis in this study, these might lend themselves as preferred targets for 
future investigation.  
 
While the decline in GMD in various pain populations in comparison to healthy 
controls is well established (Emerson et al., 2014; May, 2008; Robinson et al., 2011), 
the study of OPRM1 genotype-dependent differences in GMD highlighted the need to 
investigate adaptation and coping responses to on-going pain and the potentially 
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modulating effects of factors such as age and gender in addition to genotype. If 
conditions such as FMS and ULBP are characterised by an initial increase in GMD in 
younger patients (Ceko et al., 2013) and if these increases are more pronounced 
depending on genotype this might facilitate the development of screening methods 
for detection of risk as well as resilience factors, but also the development of new 
treatments targeting a reversal of these maladaptive neural processes. Repeated 
MRI-based assessments of patients and volumetric analyses might then be used in 
monitoring diseases progression or treatment success respectively. 
 
Similarly, the pCASL methodology (Borsook et al., 2008) lends itself to investigation 
of central effects of pain medications and their effects in pain-free participants 
(Wagner et al., 2001). It also enables future exploration of the effectiveness and 
putative mechanisms of action for novel analgesics and novel indications for existing 
compounds as well as differential efficacy across pharmacological classes and doses 
in preclinical studies and should facilitate translational research, thus becoming a 
valuable addition to simple behavioural endpoints which have predominated to date 
(Mogil, 2009). Additional applications might include the assessment of pain in 
individuals with reduced capacity for self-report such as children (Eccleston et al., 
2012) or patients with consciousness disorders (Owen & Coleman, 2008).  
 
Another possible application would be research into resilience factors, which promote 
protection against maladaptive pain states such as ULBP and FMS or excessive 
suffering post surgery. While pharmacological research focuses on non-responders 
to treatment interventions, little is known regarding non-responders to painful 
procedures such as surgery. Such patients may go undetected in clinical practice 
either because the have been administered analgesics pre-emptively or because 
they go undetected as they do not initiate further contact with the medical system, 
unlike those with further complaints. The exception are cases, where the inability to 
experience any pain at all becomes a life threatening condition, as is the case with 
hereditary sensory and autonomic neuropathies caused by rare ion channel 
mutations (Cox et al., 2006; Einarsdottir et al., 2004; Lafreniere et al., 2004; Minde et 
al., 2004; Oertel & Lötsch, 2008).  
 
With regard to genetics, future studies on pain-relevant genotypes would apply the 
quantitative trait loci approach to disorders by focusing on the end of the distribution 
with increased resilience, i.e. those patients who fail to experience relevant pain post 
surgery. Two participants examined in the context of this thesis failed to develop 
clinically relevant levels of pain post surgery. While these numbers were too small to 
perform separate analyses, further use of the TME model as implemented in this 
thesis, will potentially generate more data sets of this kind. In addition, an extension 
of the model to other types of surgery beyond TME might achieve similar results. 
Incorporation of follow up appointments might also generate data with the ability to 
predict which patients move on to develop chronic pain conditions post surgery as 
well as identify particularly resilient patients. 
 
Differences in gene expression patterns between those who did and those who did 
not develop clinically significant levels of pain would be of future interest. Further 
validation of parallel and joint application of genetic and neuroimaging techniques 
could be derived from their application in the context of analgesic trials. Analysis of 
patterns of co-variation in gene expression, subjective pain ratings by means of VAS 
and questionnaire measures and as rCBF levels within TME model might generate 
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strong leads towards potential additional mechanisms and treatments. This in turn 
might enable progress beyond the serendipitous discoveries of effective analgesic 
compounds with later discovery of the actual mechanism – as was the case with 
NSAIDs such as acetyl salicylic acid (Sneader, 1997) for example. A rational top-
down approach to the development of pharmacological and other types of 
interventions (e.g. bio-feedback) would become possible with increasing knowledge 
of the actual mechanisms of pain and nociception.  
 
Ultimately, the findings generated by the combination of neuroimaging and genetic 
methodologies may generate analgesics and therapies, where the same medication 
proves to be effective in disorders, which present with heterogeneous clinical 
features, but which share an underlying mechanism. At the same time it may facilitate 
the discovery of very specific mechanisms and the development of drugs targeted 
towards them. This may result in more individualised medications and prescription 
practices, with some drugs being gender-specifically prescribed, taking into account 
sexual dimorphisms in pain (Craft, Mogil, & Maria Aloisi, 2004; Joseph & Levine, 
2003). 
 
Until we are able to inspect the contents of the boxes within the bigger box, the use 
of biomarkers represents the most valuable tool in researching pain and the 
development of possible interventions. In particular the pCASL-derived markers met 
the majority of criteria for a meaningful biomarker. Within a classification of 
biomarkers gene expression levels and pCASL results represent type I biomarkers. 
This type determines the biological effect of a therapeutic intervention with regard to 
the mechanism of action, even though the exact nature of the mechanism‘s 
association with clinical outcomes may still be unknown. 
 
Establishing peripheral whole blood as an easily accessible tissue to use as a proxy 
for pain-related molecular changes is a first step towards facilitating the use of this 
technology within pain research akin to the use of the commonly used blood counts 
and chemistry analyses in many clinical settings. In the future proliferation of genetic 
and neuroimaging techniques and further advances in the development of 
bioinformatic tools such as genome browsers and databases of molecular pathways 
(Hillman-Jackson et al., 2007; Rhead et al., 2009) will help to better discriminate 
between pain and nociception-related and pathways and those concerned with pain-
unrelated functions. This will also increase general knowledge of genes, the proteins 
they encode and their specific functions and interactions.  
 
Even though a biomarker by definition represents a reduction in complexity, their 
implementation with strong adherence to biomarker quality criteria in actual clinical 
pain conditions has definite advantages over the purely phenomenological approach 
in search of novel components and circuit in pain and nociceptive regulation. The 
combination of tools to generate genetic and neuroimaging biomarkers for parallel 
and joint analyses explicitly investigating phenotypes in pain and nociception thus 
represents an important step towards uncovering the mechanisms underlying pain 
and nociception. Knowing the contents of the Wittgensteinian box that contains the 
pain experience will help us to think outside the box when revising new treatments 
and interventions. 
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5 APPENDIX 
5.1.1 Supplementary table II-1: Correlation table repeated measures interval and 
within-subject ICC 
 
 
 
Supplementary figure II-1: No significant correlations were observed between the repeated 
measures interval and within-subject ICC. Abbreviations: amygdala (AMY), hippocampus 
(HIPP), brainstem (BS), thalamus (THAL), anterior insula (antINS), posterior insula (posINS), 
somatosensory cortex (primary, S1 and secondary, S2), posterior cingulate cortex (PCC), 
anterior cingulate cortex (ACC). 
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5.1.2 Supplementary table III-1: Differentially expressed genes post surgery 
 
Probe Set ID 
Gene 
Symbol 
Ls mean 
Pain Ctrl 
Ls mean 
Pain Pain 
Difference 
(Pain)-(Ctrl) 
t-Statistic 
Difference 
(Pain)-(Ctrl) 
p-Value 
Difference 
(Pain)-(Ctrl) 
Adjusted p-
Value for 
Difference 
(Pain)-(Ctrl) 
64397_at ZNF106 7,685 7,976 0,291 7,132 8,84085E-11 2,14948E-06 
660_at BMX 3,784 4,220 0,436 6,800 4,67664E-10 5,68515E-06 
23569_at PADI4 4,707 5,220 0,513 6,142 1,15201E-08 7,00218E-05 
63971_at KIF13A 5,151 5,600 0,449 6,161 1,05244E-08 7,00218E-05 
10123_at ARL4C 7,638 7,277 -0,361 -5,879 3,98964E-08 0,000138572 
353189_at SLCO4C1 6,342 6,835 0,492 5,909 3,47132E-08 0,000138572 
80183_at KIAA0226L 5,874 6,531 0,658 5,880 3,96096E-08 0,000138572 
535_at ATP6V0A1 6,876 7,326 0,449 5,848 4,60853E-08 0,000139627 
84255_at SLC37A3 6,166 6,936 0,769 5,823 5,16861E-08 0,000139627 
22853_at LMTK2 4,909 5,218 0,309 5,791 6,00367E-08 0,000145967 
2204_at FCAR 5,000 5,547 0,547 5,750 7,24522E-08 0,000160139 
4311_at MME 8,373 9,071 0,698 5,726 8,11398E-08 0,000164396 
1362_at CPD 8,340 8,792 0,452 5,646 1,16727E-07 0,00016694 
2005_at ELK4 7,024 6,734 -0,291 -5,656 1,11493E-07 0,00016694 
3930_at LBR 9,114 9,455 0,341 5,686 9,73636E-08 0,00016694 
5058_at PAK1 8,813 9,083 0,271 5,651 1,14058E-07 0,00016694 
57161_at PELI2 5,882 6,216 0,333 5,693 9,43899E-08 0,00016694 
57633_at LRRN1 4,019 4,237 0,218 5,619 1,32213E-07 0,000169184 
64101_at LRRC4 5,090 5,555 0,465 5,630 1,25711E-07 0,000169184 
5663_at PSEN1 8,161 8,361 0,200 5,576 1,6033E-07 0,000194906 
53346_at TM6SF1 6,412 6,838 0,425 5,557 1,75242E-07 0,000202888 
55526_at DHTKD1 5,176 5,451 0,276 5,504 2,22634E-07 0,000246041 
79660_at PPP1R3B 5,048 5,480 0,432 5,474 2,54658E-07 0,000269196 
101927873_at LINC01508 3,560 3,658 0,098 5,449 2,84242E-07 0,000287949 
50486_at G0S2 4,991 5,404 0,414 5,437 3,00907E-07 0,000289322 
57136_at APMAP 7,294 7,713 0,419 5,431 3,09397E-07 0,000289322 
4318_at MMP9 5,351 5,883 0,532 5,397 3,58833E-07 0,000323122 
407008_at MIR223 8,321 8,935 0,613 5,370 4,04816E-07 0,000341871 
6176_at RPLP1 8,789 8,228 -0,560 -5,369 4,07776E-07 0,000341871 
23604_at DAPK2 5,043 5,263 0,220 5,349 4,45691E-07 0,000361203 
83658_at DYNLRB1 8,170 7,911 -0,260 -5,329 4,8615E-07 0,000381283 
159013_at CXorf38 5,356 5,696 0,340 5,294 5,68496E-07 0,000407574 
51314_at NME8 3,751 3,989 0,238 5,293 5,69964E-07 0,000407574 
728558_at 
ENTPD1-
AS1 4,164 4,415 0,251 5,295 5,63823E-07 0,000407574 
4358_at MPV17 6,588 6,343 -0,245 -5,271 6,26999E-07 0,000435549 
6655_at SOS2 7,995 8,393 0,398 5,255 6,73647E-07 0,000454955 
285521_at COX18 5,826 5,599 -0,227 -5,225 7,69813E-07 0,00050585 
23157_at SEPT6 6,900 6,577 -0,323 -5,167 9,89876E-07 0,000633339 
10057_at ABCC5 4,587 4,809 0,222 5,136 1,13471E-06 0,000683084 
285848_at PNPLA1 4,470 4,659 0,189 5,132 1,15191E-06 0,000683084 
6386_at SDCBP 10,268 10,563 0,295 5,142 1,10601E-06 0,000683084 
5836_at PYGL 8,870 9,408 0,538 5,103 1,30816E-06 0,000757269 
8655_at DYNLL1 6,675 6,347 -0,327 -5,079 1,44892E-06 0,000819247 
5218_at CDK14 5,264 5,835 0,571 5,051 1,63191E-06 0,000856119 
6222_at RPS18 10,771 10,261 -0,510 -5,060 1,57245E-06 0,000856119 
64757_at MARC1 4,745 5,136 0,391 5,048 1,65498E-06 0,000856119 
9975_at NR1D2 5,822 5,533 -0,289 -5,052 1,63011E-06 0,000856119 
2353_at FOS 4,712 4,961 0,249 5,029 1,80017E-06 0,000893214 
94097_at SFXN5 4,600 4,747 0,148 5,031 1,78445E-06 0,000893214 
154141_at MBOAT1 6,354 6,638 0,284 4,992 2,10523E-06 0,001003618 
55752_at SEPT11 6,023 5,754 -0,269 -4,992 2,10215E-06 0,001003618 
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84641_at MFSD14B 6,624 7,098 0,474 4,984 2,17907E-06 0,001018842 
729296_at LOC729296 4,114 4,299 0,185 4,973 2,28077E-06 0,001046272 
192670_at AGO4 7,732 8,099 0,366 4,958 2,43172E-06 0,00109486 
3087_at HHEX 6,237 6,493 0,256 4,938 2,6492E-06 0,001171091 
3560_at IL2RB 4,993 4,766 -0,227 -4,932 2,71988E-06 0,001180864 
83716_at CRISPLD2 5,253 5,766 0,513 4,922 2,83834E-06 0,001210676 
84674_at CARD6 4,718 5,022 0,304 4,899 3,12011E-06 0,001307918 
105375667_at 
LOC105375
667 3,685 3,839 0,154 4,880 3,38268E-06 0,001326501 
120425_at JAML 10,620 10,883 0,264 4,890 3,24111E-06 0,001326501 
3704_at ITPA 5,048 4,890 -0,157 -4,881 3,36287E-06 0,001326501 
9885_at OSBPL2 6,966 7,264 0,299 4,886 3,30491E-06 0,001326501 
57488_at ESYT2 7,360 7,164 -0,196 -4,872 3,49995E-06 0,001350705 
128646_at SIRPD 5,381 5,798 0,417 4,862 3,65751E-06 0,001389456 
222389_at BEND7 3,700 3,845 0,145 4,843 3,95552E-06 0,001414273 
338339_at CLEC4D 5,471 6,218 0,748 4,849 3,86089E-06 0,001414273 
6141_at RPL18 10,211 9,909 -0,302 -4,844 3,93529E-06 0,001414273 
7039_at TGFA 4,720 4,936 0,216 4,849 3,84952E-06 0,001414273 
170575_at GIMAP1 8,220 7,909 -0,311 -4,839 4,02802E-06 0,001419323 
10296_at MAEA 4,846 5,035 0,189 4,832 4,13571E-06 0,001436451 
2950_at GSTP1 8,377 8,100 -0,277 -4,822 4,32159E-06 0,00147987 
388011_at LINC01550 6,394 5,972 -0,422 -4,812 4,50087E-06 0,001519855 
54956_at PARP16 4,481 4,657 0,176 4,807 4,59951E-06 0,001531888 
2713_at GK3P 6,998 7,666 0,669 4,800 4,72396E-06 0,001552076 
1089_at CEACAM4 5,462 5,792 0,330 4,791 4,90731E-06 0,001562724 
22990_at PCNX1 7,835 8,182 0,347 4,777 5,20629E-06 0,001562724 
26053_at AUTS2 4,316 4,197 -0,119 -4,787 4,9849E-06 0,001562724 
51596_at CUTA 7,022 6,776 -0,247 -4,778 5,19078E-06 0,001562724 
6132_at RPL8 8,704 8,340 -0,364 -4,777 5,20628E-06 0,001562724 
6281_at S100A10 9,871 9,625 -0,246 -4,781 5,12094E-06 0,001562724 
731424_at MIR3945HG 4,771 5,108 0,337 4,790 4,92688E-06 0,001562724 
55692_at LUC7L 6,258 6,043 -0,215 -4,771 5,33931E-06 0,001583105 
23534_at TNPO3 5,773 6,064 0,291 4,758 5,63457E-06 0,001650521 
8500_at PPFIA1 5,685 5,943 0,258 4,739 6,10409E-06 0,001766771 
101927433_at LINC01255 3,493 3,567 0,074 4,717 6,66954E-06 0,001842687 
8993_at PGLYRP1 4,404 4,715 0,311 4,722 6,53988E-06 0,001842687 
9214_at FCMR 7,870 7,599 -0,271 -4,718 6,66134E-06 0,001842687 
978_at CDA 5,962 6,455 0,492 4,724 6,49759E-06 0,001842687 
3034_at HAL 5,401 5,872 0,471 4,710 6,86344E-06 0,001874953 
152007_at GLIPR2 7,568 7,795 0,227 4,707 6,94792E-06 0,001876942 
6792_at CDKL5 5,055 5,398 0,342 4,699 7,17755E-06 0,001917669 
3187_at HNRNPH1 9,092 8,795 -0,297 -4,679 7,79488E-06 0,002059966 
23074_at UHRF1BP1L 6,684 7,079 0,395 4,667 8,21299E-06 0,002074221 
3588_at IL10RB 5,770 6,135 0,365 4,668 8,179E-06 0,002074221 
366_at AQP9 10,061 10,482 0,421 4,673 7,98892E-06 0,002074221 
64745_at METTL17 5,342 5,147 -0,195 -4,665 8,27538E-06 0,002074221 
84188_at FAR1 7,577 7,814 0,237 4,666 8,23276E-06 0,002074221 
16_at AARS 5,185 5,018 -0,167 -4,622 9,8571E-06 0,002396556 
400863_at NA 5,350 5,091 -0,258 -4,622 9,84159E-06 0,002396556 
6223_at RPS19 8,285 7,975 -0,310 -4,625 9,75087E-06 0,002396556 
120892_at LRRK2 9,331 9,715 0,384 4,611 1,02893E-05 0,002476859 
6932_at TCF7 5,185 5,032 -0,152 -4,604 1,06182E-05 0,002530983 
6209_at RPS15 8,680 8,330 -0,350 -4,592 1,11227E-05 0,002625503 
8972_at MGAM 7,980 8,677 0,697 4,589 1,1292E-05 0,002639838 
154881_at KCTD7 4,760 4,604 -0,156 -4,576 1,18595E-05 0,002686079 
28504_at IGHD2-8 3,305 3,392 0,087 4,575 1,19317E-05 0,002686079 
57189_at KIAA1147 5,313 5,119 -0,194 -4,577 1,18493E-05 0,002686079 
6203_at RPS9 5,315 5,049 -0,266 -4,581 1,16501E-05 0,002686079 
100233209_at 
PCED1B-
AS1 5,005 4,747 -0,258 -4,570 1,21879E-05 0,00269512 
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10472_at ZBTB18 5,950 6,238 0,288 4,567 1,23369E-05 0,00269512 
353345_at GPR141 5,179 5,593 0,414 4,563 1,2547E-05 0,00269512 
4482_at MSRA 4,647 4,824 0,177 4,564 1,2471E-05 0,00269512 
54902_at TTC19 6,692 6,507 -0,186 -4,560 1,26669E-05 0,00269512 
58528_at RRAGD 5,303 5,726 0,422 4,561 1,2641E-05 0,00269512 
94241_at TP53INP1 7,894 8,226 0,333 4,559 1,27479E-05 0,00269512 
131118_at DNAJC19 5,994 5,713 -0,281 -4,550 1,3191E-05 0,002697095 
25797_at QPCT 7,361 7,834 0,472 4,554 1,2972E-05 0,002697095 
26648_at OR7E24 3,820 3,999 0,179 4,551 1,31698E-05 0,002697095 
81565_at NDEL1 7,788 8,050 0,262 4,550 1,32009E-05 0,002697095 
6434_at TRA2B 7,316 7,062 -0,253 -4,537 1,38899E-05 0,0028142 
254428_at SLC41A1 4,709 4,603 -0,107 -4,531 1,4231E-05 0,002859481 
23463_at ICMT 5,000 4,858 -0,142 -4,528 1,44084E-05 0,002867269 
27101_at CACYBP 6,103 5,875 -0,228 -4,525 1,46079E-05 0,002867269 
57542_at KLHL42 4,737 4,602 -0,136 -4,523 1,47414E-05 0,002867269 
9926_at LPGAT1 7,014 7,297 0,283 4,524 1,46632E-05 0,002867269 
6158_at RPL28 4,791 4,555 -0,235 -4,507 1,56824E-05 0,003022315 
8826_at IQGAP1 9,694 9,900 0,206 4,505 1,57872E-05 0,003022315 
11180_at WDR6 4,708 4,601 -0,107 -4,497 1,63032E-05 0,003033602 
5496_at PPM1G 5,924 5,767 -0,157 -4,497 1,63452E-05 0,003033602 
5936_at RBM4 5,613 5,407 -0,205 -4,499 1,62343E-05 0,003033602 
81671_at VMP1 10,571 10,802 0,231 4,498 1,62989E-05 0,003033602 
5813_at PURA 7,392 7,185 -0,207 -4,493 1,66104E-05 0,003059466 
842_at CASP9 4,372 4,504 0,133 4,490 1,67934E-05 0,003069904 
1431_at CS 7,314 7,078 -0,236 -4,485 1,715E-05 0,003111694 
4841_at NONO 6,217 5,979 -0,239 -4,479 1,75641E-05 0,003163225 
9761_at MLEC 5,857 5,651 -0,205 -4,474 1,78764E-05 0,003195793 
516_at ATP5G1 6,355 6,099 -0,256 -4,454 1,9374E-05 0,003388784 
5336_at PLCG2 6,125 6,378 0,252 4,455 1,93084E-05 0,003388784 
55784_at MCTP2 7,074 7,498 0,424 4,456 1,92554E-05 0,003388784 
6809_at STX3 6,820 7,205 0,385 4,449 1,97748E-05 0,003434173 
55276_at PGM2 7,447 7,831 0,383 4,439 2,06213E-05 0,003555788 
22978_at NT5C2 7,428 7,796 0,367 4,432 2,12037E-05 0,003630465 
51635_at DHRS7 8,360 8,575 0,215 4,427 2,15488E-05 0,003663742 
4723_at NDUFV1 6,168 5,926 -0,243 -4,412 2,28972E-05 0,003865971 
6604_at SMARCD3 4,807 4,996 0,189 4,408 2,32524E-05 0,003898868 
127829_at ARL8A 5,306 5,641 0,335 4,403 2,37149E-05 0,003949173 
100506144_at ZMYM6NB 7,749 7,514 -0,235 -4,396 2,44453E-05 0,004015807 
10147_at SUGP2 5,005 4,897 -0,108 -4,396 2,43885E-05 0,004015807 
121512_at FGD4 5,110 5,407 0,296 4,391 2,49261E-05 0,004058016 
1432_at MAPK14 6,575 6,934 0,359 4,390 2,50361E-05 0,004058016 
23210_at JMJD6 5,012 5,183 0,171 4,380 2,59674E-05 0,004142935 
283687_at ST20-AS1 4,698 4,926 0,228 4,380 2,60436E-05 0,004142935 
4783_at NFIL3 7,977 8,353 0,376 4,379 2,61192E-05 0,004142935 
51_at ACOX1 7,294 7,671 0,377 4,378 2,62416E-05 0,004142935 
55301_at OLAH 3,420 3,466 0,046 4,367 2,74073E-05 0,004299049 
5329_at PLAUR 6,661 7,025 0,364 4,362 2,78541E-05 0,004341129 
55718_at POLR3E 5,292 5,169 -0,123 -4,360 2,81169E-05 0,004354178 
23435_at TARDBP 7,873 7,672 -0,201 -4,355 2,87288E-05 0,004420778 
5256_at PHKA2 5,187 5,330 0,143 4,346 2,97158E-05 0,004543901 
207063_at DHRSX 4,225 4,640 0,415 4,326 3,21139E-05 0,004790098 
3695_at ITGB7 4,915 4,779 -0,136 -4,326 3,20815E-05 0,004790098 
5971_at RELB 4,505 4,631 0,125 4,327 3,19952E-05 0,004790098 
683_at BST1 6,501 6,848 0,347 4,330 3,15782E-05 0,004790098 
953_at ENTPD1 7,520 7,790 0,270 4,320 3,29557E-05 0,004885687 
662_at BNIP1 3,972 3,880 -0,092 -4,314 3,36671E-05 0,004960896 
10492_at SYNCRIP 6,102 5,873 -0,228 -4,300 3,55755E-05 0,005187176 
116369_at SLC26A8 4,202 4,488 0,286 4,292 3,67255E-05 0,005187176 
2091_at FBL 9,470 9,138 -0,332 -4,295 3,62473E-05 0,005187176 
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2153_at F5 5,383 5,952 0,569 4,298 3,58956E-05 0,005187176 
5997_at RGS2 9,938 10,352 0,414 4,295 3,62819E-05 0,005187176 
6693_at SPN 4,876 4,752 -0,124 -4,298 3,58926E-05 0,005187176 
7099_at TLR4 9,173 9,575 0,403 4,290 3,69095E-05 0,005187176 
9778_at KIAA0232 5,305 5,621 0,316 4,291 3,69014E-05 0,005187176 
51335_at NGRN 5,814 5,621 -0,193 -4,286 3,75055E-05 0,005240644 
1820_at ARID3A 4,509 4,617 0,108 4,276 3,90332E-05 0,005422935 
148145_at LINC00906 3,971 4,213 0,241 4,263 4,11069E-05 0,005539336 
5160_at PDHA1 6,673 6,403 -0,270 -4,262 4,1238E-05 0,005539336 
55754_at TMEM30A 4,725 5,057 0,332 4,264 4,09307E-05 0,005539336 
6304_at SATB1 7,288 7,075 -0,213 -4,267 4,04029E-05 0,005539336 
8086_at AAAS 5,985 5,735 -0,250 -4,263 4,10398E-05 0,005539336 
9880_at ZBTB39 4,713 4,564 -0,148 -4,264 4,09835E-05 0,005539336 
8445_at DYRK2 6,945 6,711 -0,234 -4,253 4,26991E-05 0,005704078 
254065_at BRWD3 6,508 6,709 0,202 4,235 4,56931E-05 0,005999379 
26253_at CLEC4E 6,911 7,467 0,556 4,234 4,58966E-05 0,005999379 
5209_at PFKFB3 4,988 5,366 0,378 4,237 4,54896E-05 0,005999379 
79817_at MOB3B 4,694 4,555 -0,139 -4,235 4,57063E-05 0,005999379 
201931_at TMEM192 4,844 4,662 -0,182 -4,232 4,63622E-05 0,006014638 
84078_at KBTBD7 4,734 5,106 0,372 4,231 4,65081E-05 0,006014638 
118932_at ANKRD22 3,930 4,413 0,484 4,223 4,79082E-05 0,006086504 
27236_at ARFIP1 6,655 7,030 0,375 4,224 4,77907E-05 0,006086504 
5580_at PRKCD 7,896 8,228 0,332 4,222 4,80652E-05 0,006086504 
84263_at HSDL2 5,950 6,306 0,356 4,222 4,80529E-05 0,006086504 
7409_at VAV1 5,738 5,971 0,233 4,213 4,97085E-05 0,006201102 
8563_at THOC5 5,696 5,919 0,223 4,215 4,93747E-05 0,006201102 
9448_at MAP4K4 7,600 7,851 0,251 4,213 4,97353E-05 0,006201102 
317_at APAF1 7,193 7,480 0,287 4,201 5,21171E-05 0,006464917 
8291_at DYSF 5,048 5,418 0,370 4,197 5,28656E-05 0,006524469 
55529_at TMEM55A 7,803 8,184 0,381 4,182 5,61432E-05 0,006885715 
606293_at KLKP1 3,578 3,675 0,098 4,181 5,6359E-05 0,006885715 
102724819_at 
LOC102724
819 3,380 3,488 0,108 4,171 5,8483E-05 0,00710949 
5004_at ORM1 4,007 4,604 0,597 4,169 5,90022E-05 0,007112455 
6950_at TCP1 8,459 8,222 -0,237 -4,168 5,90925E-05 0,007112455 
54893_at MTMR10 6,995 7,266 0,272 4,164 6,00293E-05 0,007189622 
9394_at HS6ST1 10,456 10,139 -0,317 -4,162 6,04238E-05 0,007201388 
4644_at MYO5A 6,206 6,456 0,251 4,159 6,1271E-05 0,007266741 
27131_at SNX5 5,404 5,227 -0,177 -4,157 6,1773E-05 0,00729071 
762_at CA4 4,297 4,424 0,128 4,154 6,24061E-05 0,007329854 
100287632_at 
LOC100287
632 4,118 4,270 0,152 4,152 6,286E-05 0,007347673 
79026_at AHNAK 8,430 8,176 -0,255 -4,148 6,38471E-05 0,007391975 
9874_at TLK1 7,805 7,630 -0,175 -4,149 6,35935E-05 0,007391975 
63939_at FAM217B 4,288 4,567 0,279 4,139 6,61641E-05 0,007623928 
2114_at ETS2 5,588 5,857 0,269 4,131 6,81423E-05 0,007740176 
340061_at TMEM173 5,089 4,954 -0,135 -4,131 6,80277E-05 0,007740176 
55652_at SLC48A1 4,507 4,406 -0,102 -4,130 6,84464E-05 0,007740176 
6400_at SEL1L 7,370 7,533 0,163 4,131 6,81892E-05 0,007740176 
100130460_at CAND1.11 3,712 3,867 0,155 4,123 7,02426E-05 0,007833979 
105373442_at 
LOC105373
442 5,075 5,427 0,352 4,123 7,01535E-05 0,007833979 
200185_at KRTCAP2 5,188 4,930 -0,258 -4,123 7,01986E-05 0,007833979 
328_at APEX1 7,522 7,203 -0,319 -4,117 7,19348E-05 0,007936371 
5432_at POLR2C 4,397 4,501 0,104 4,116 7,21399E-05 0,007936371 
79892_at MCMBP 6,845 7,049 0,204 4,116 7,21109E-05 0,007936371 
101927149_at LINC01471 4,125 4,260 0,135 4,103 7,58248E-05 0,00822417 
2180_at ACSL1 8,910 9,543 0,633 4,102 7,59226E-05 0,00822417 
57198_at ATP8B2 5,245 5,121 -0,124 -4,101 7,64233E-05 0,00822417 
6431_at SRSF6 7,543 7,301 -0,242 -4,099 7,67855E-05 0,00822417 
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84803_at GPAT3 5,697 6,074 0,376 4,099 7,67438E-05 0,00822417 
8825_at LIN7A 5,976 6,522 0,546 4,102 7,61315E-05 0,00822417 
101927018_at 
LOC101927
018 6,076 6,590 0,514 4,094 7,83306E-05 0,008280229 
55239_at OGFOD1 6,063 5,840 -0,223 -4,095 7,81937E-05 0,008280229 
7185_at TRAF1 4,363 4,273 -0,090 -4,094 7,8311E-05 0,008280229 
57186_at RALGAPA2 5,429 5,697 0,268 4,092 7,87953E-05 0,008293289 
100151683_at RNU4ATAC 3,943 4,222 0,279 4,090 7,95708E-05 0,008338811 
10129_at FRY 6,871 7,187 0,316 4,083 8,17849E-05 0,008534059 
89857_at KLHL6 6,040 5,814 -0,226 -4,076 8,36856E-05 0,008695073 
266747_at RGL4 4,595 4,758 0,163 4,071 8,54361E-05 0,008819607 
91662_at NLRP12 4,922 5,283 0,361 4,070 8,56096E-05 0,008819607 
414778_at HCG17 3,548 3,497 -0,051 -4,069 8,62103E-05 0,008835246 
55152_at DALRD3 5,275 5,107 -0,168 -4,068 8,64882E-05 0,008835246 
11238_at CA5B 6,142 5,817 -0,325 -4,063 8,79569E-05 0,008947687 
400955_at LINC01122 3,512 3,554 0,041 4,061 8,86304E-05 0,008964891 
53838_at C11orf24 5,027 4,889 -0,138 -4,061 8,88635E-05 0,008964891 
54861_at SNRK 7,022 7,188 0,165 4,057 9,0145E-05 0,009052716 
85028_at SNHG12 6,982 6,656 -0,326 -4,056 9,04788E-05 0,009052716 
100129827_at MRVI1-AS1 4,941 5,263 0,323 4,054 9,10731E-05 0,009074839 
728290_at LOC728290 3,337 3,419 0,082 4,050 9,23265E-05 0,009127225 
79689_at STEAP4 7,914 8,422 0,508 4,049 9,26966E-05 0,009127225 
9378_at NRXN1 3,702 3,746 0,043 4,049 9,27251E-05 0,009127225 
30061_at SLC40A1 6,704 7,042 0,338 4,047 9,33583E-05 0,009152504 
4215_at MAP3K3 5,251 5,484 0,233 4,043 9,50633E-05 0,009282225 
5608_at MAP2K6 4,536 4,791 0,255 4,039 9,64318E-05 0,009378184 
26003_at GORASP2 7,142 6,957 -0,185 -4,036 9,74004E-05 0,009434644 
10606_at PAICS 4,163 4,024 -0,138 -4,028 0,000100326 0,009617757 
3772_at KCNJ15 8,827 9,405 0,578 4,029 9,993E-05 0,009617757 
8537_at BCAS1 4,183 4,264 0,081 4,028 0,000100478 0,009617757 
23287_at AGTPBP1 8,282 8,540 0,258 4,022 0,000102784 0,009767434 
29997_at GLTSCR2 7,385 7,146 -0,239 -4,021 0,000103187 0,009767434 
64211_at LHX5 3,985 3,897 -0,088 -4,020 0,000103246 0,009767434 
6515_at SLC2A3 9,999 10,437 0,438 4,019 0,000103761 0,009778092 
10613_at ERLIN1 6,479 6,756 0,277 4,013 0,000106175 0,00985987 
112398_at EGLN2 6,412 6,089 -0,323 -4,013 0,000105982 0,00985987 
344807_at CD200R1L 3,393 3,444 0,051 4,015 0,000105507 0,00985987 
55272_at IMP3 8,891 8,652 -0,239 -4,013 0,000106251 0,00985987 
6732_at SRPK1 6,269 6,682 0,413 4,011 0,000106869 0,009879524 
166_at AES 5,203 5,011 -0,192 -4,007 0,000108586 0,010000239 
55454_at 
CSGALNAC
T2 6,025 6,277 0,252 4,002 0,000110375 0,01012658 
53827_at FXYD5 7,644 7,385 -0,259 -3,997 0,000112425 0,01027594 
93432_at MGAM2 4,072 4,311 0,240 3,996 0,00011302 0,010291561 
10765_at KDM5B 5,793 6,033 0,240 3,994 0,000113837 0,01032728 
9043_at SPAG9 7,378 7,608 0,231 3,991 0,000114962 0,010390626 
3326_at HSP90AB1 7,582 7,284 -0,298 -3,990 0,000115534 0,010403582 
51719_at CAB39 6,739 6,971 0,232 3,989 0,000116115 0,01041737 
54069_at MIS18A 4,958 4,792 -0,165 -3,987 0,000117072 0,010438359 
81539_at SLC38A1 8,803 8,516 -0,287 -3,986 0,000117208 0,010438359 
146691_at TOM1L2 4,443 4,551 0,108 3,985 0,00011769 0,01044306 
23046_at KIF21B 4,719 4,842 0,123 3,984 0,000118343 0,010456066 
83862_at TMEM120A 4,665 4,830 0,165 3,983 0,000118697 0,010456066 
10205_at MPZL2 5,355 5,646 0,291 3,980 0,000120062 0,01053819 
2113_at ETS1 7,619 7,324 -0,295 -3,977 0,000121319 0,010610179 
8556_at CDC14A 6,427 6,208 -0,219 -3,972 0,000123531 0,010764944 
10404_at CPQ 7,063 7,370 0,307 3,969 0,000124954 0,010811383 
91050_at CCDC149 4,068 4,163 0,095 3,969 0,00012489 0,010811383 
2182_at ACSL4 6,272 6,588 0,316 3,966 0,000126202 0,010855801 
83890_at SPATA9 3,665 3,602 -0,063 -3,966 0,00012636 0,010855801 
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1845_at DUSP3 4,938 5,075 0,137 3,962 0,000128289 0,010953187 
4670_at HNRNPM 7,715 7,500 -0,215 -3,962 0,000128395 0,010953187 
27347_at STK39 5,942 5,713 -0,229 -3,960 0,00012896 0,01096293 
125144_at 
LRRC75A-
AS1 5,074 4,920 -0,154 -3,958 0,000130081 0,010981418 
57700_at FAM160B1 6,777 7,028 0,252 3,958 0,00012998 0,010981418 
337975_at KRTAP20-1 4,255 4,045 -0,210 -3,955 0,000131369 0,011051829 
101928143_at 
LOC101928
143 6,665 7,222 0,557 3,947 0,000135692 0,011328517 
8493_at PPM1D 5,961 6,144 0,183 3,946 0,000136056 0,011328517 
90025_at UBE3D 4,235 4,140 -0,095 -3,947 0,000135709 0,011328517 
105373606_at 
LOC105373
606 5,389 5,917 0,528 3,943 0,000137659 0,011422882 
5893_at RAD52 5,117 5,005 -0,112 -3,941 0,000138622 0,01146364 
55615_at PRR5 5,019 4,892 -0,127 -3,939 0,00013964 0,011508714 
101928551_at 
LOC101928
551 3,362 3,439 0,077 3,936 0,000140868 0,01153175 
284757_at MIR646HG 3,895 4,032 0,137 3,937 0,000140812 0,01153175 
10941_at UGT2A1 3,520 3,614 0,095 3,934 0,000142071 0,011591189 
1378_at CR1 6,936 7,452 0,516 3,931 0,000143598 0,011676593 
121642_at ALKBH2 4,494 4,372 -0,122 -3,929 0,000144754 0,011696877 
26118_at WSB1 9,319 9,528 0,209 3,929 0,00014481 0,011696877 
9402_at GRAP2 5,756 5,521 -0,234 -3,927 0,000145785 0,011736641 
3340_at NDST1 4,799 4,961 0,162 3,924 0,000147711 0,011815122 
8073_at PTP4A2 8,141 7,984 -0,157 -3,923 0,000147732 0,011815122 
167555_at FAM151B 4,079 4,298 0,219 3,914 0,000152803 0,012072244 
26234_at FBXL5 8,858 9,099 0,241 3,916 0,000151718 0,012072244 
373156_at GSTK1 6,762 6,547 -0,216 -3,913 0,000153413 0,012072244 
5859_at QARS 6,149 6,009 -0,139 -3,913 0,000153429 0,012072244 
65265_at C8orf33 4,789 4,681 -0,108 -3,915 0,000152495 0,012072244 
3156_at HMGCR 6,401 6,728 0,326 3,912 0,000154353 0,012105737 
2926_at GRSF1 6,130 5,982 -0,148 -3,910 0,000155386 0,012147613 
101927950_at 
LOC101927
950 4,995 4,805 -0,190 -3,905 0,000157909 0,012282179 
390195_at OR5AN1 3,659 3,762 0,103 3,905 0,000158118 0,012282179 
23186_at RCOR1 7,063 7,265 0,202 3,901 0,000160186 0,012403174 
51167_at CYB5R4 7,335 7,632 0,297 3,895 0,000163964 0,012655394 
54682_at MANSC1 5,621 6,209 0,588 3,894 0,000164511 0,012657463 
51490_at C9orf114 4,656 4,576 -0,080 -3,891 0,000166553 0,012774171 
101927124_at 
LOC101927
124 3,620 3,541 -0,079 -3,885 0,000170052 0,013001481 
7016_at TESK1 6,134 5,878 -0,256 -3,884 0,000170605 0,013002855 
92170_at MTG1 5,021 4,899 -0,122 -3,882 0,000172151 0,013079675 
8893_at EIF2B5 4,428 4,313 -0,115 -3,881 0,000172825 0,013089992 
26031_at OSBPL3 5,425 5,233 -0,192 -3,876 0,000175446 0,013242442 
56005_at MYDGF 5,712 5,510 -0,202 -3,876 0,000175927 0,013242442 
122011_at CSNK1A1L 5,555 5,923 0,367 3,874 0,000177195 0,013296716 
645638_at WFDC21P 4,203 4,066 -0,137 -3,870 0,000179422 0,013381242 
972_at CD74 8,943 8,646 -0,297 -3,870 0,000179419 0,013381242 
60437_at CDH26 3,931 4,002 0,071 3,869 0,000180395 0,013390047 
646424_at SPINK8 3,497 3,597 0,099 3,868 0,000180641 0,013390047 
4267_at CD99 7,284 7,060 -0,223 -3,867 0,000181332 0,013400368 
104326191_at LINC01336 5,919 5,601 -0,318 -3,865 0,000182547 0,013412337 
8634_at RTCA 7,171 6,999 -0,172 -3,865 0,000182597 0,013412337 
6283_at S100A12 9,888 10,409 0,521 3,859 0,000186686 0,013671371 
29081_at METTL5 5,776 5,554 -0,222 -3,858 0,000187511 0,013690527 
837_at CASP4 8,924 9,201 0,277 3,854 0,000190471 0,013823682 
9096_at TBX18 3,519 3,558 0,039 3,854 0,000190066 0,013823682 
871_at SERPINH1 4,369 4,287 -0,082 -3,852 0,000191927 0,01384663 
9815_at GIT2 8,474 8,607 0,133 3,852 0,00019143 0,01384663 
596_at BCL2 6,572 6,322 -0,250 -3,839 0,000200585 0,014428454 
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7077_at TIMP2 7,972 8,220 0,248 3,837 0,000202042 0,014490399 
10783_at NEK6 4,492 4,634 0,142 3,836 0,000203136 0,014495999 
222487_at ADGRG3 5,833 6,400 0,568 3,835 0,000203681 0,014495999 
7311_at UBA52 6,644 6,431 -0,213 -3,835 0,000203909 0,014495999 
100302135_at MIR320C1 6,234 6,647 0,413 3,825 0,000211107 0,014877204 
518_at ATP5G3 5,555 5,356 -0,199 -3,827 0,000210179 0,014877204 
80777_at CYB5B 7,818 7,564 -0,253 -3,826 0,000210827 0,014877204 
79758_at DHRS12 4,635 4,786 0,150 3,823 0,000212795 0,014924058 
81833_at SPACA1 3,437 3,412 -0,026 -3,822 0,000213613 0,014924058 
8799_at PEX11B 6,313 6,152 -0,162 -3,822 0,000213306 0,014924058 
916_at CD3E 8,382 7,998 -0,384 -3,819 0,000215596 0,015019474 
53917_at RAB24 6,268 6,480 0,212 3,816 0,000218349 0,015167796 
4217_at MAP3K5 6,188 6,470 0,282 3,810 0,0002229 0,015395948 
9801_at MRPL19 5,250 5,083 -0,167 -3,811 0,000222467 0,015395948 
7136_at TNNI2 4,978 5,149 0,171 3,808 0,000225014 0,015497919 
25996_at REXO2 5,567 5,348 -0,219 -3,806 0,000226553 0,015559841 
64771_at C6orf106 6,159 5,980 -0,179 -3,803 0,000228859 0,015668682 
83759_at RBM4B 6,549 6,315 -0,234 -3,802 0,000229427 0,015668682 
2821_at GPI 5,571 5,408 -0,162 -3,797 0,000233353 0,015847773 
9870_at AREL1 7,383 7,670 0,286 3,798 0,000232956 0,015847773 
123720_at WHAMM 5,329 5,156 -0,173 -3,792 0,000238064 0,016091765 
4809_at SNU13 6,455 6,259 -0,196 -3,791 0,000238931 0,016091765 
55297_at CCDC91 5,651 5,392 -0,259 -3,791 0,000238553 0,016091765 
283635_at FAM177A1 3,930 4,038 0,109 3,788 0,000241678 0,01614264 
79918_at SETD6 5,029 4,910 -0,119 -3,788 0,000241648 0,01614264 
9520_at NPEPPS 8,243 8,449 0,206 3,788 0,000241062 0,01614264 
10794_at ZNF460 7,443 7,268 -0,175 -3,785 0,000243868 0,016199895 
3099_at HK2 5,213 5,459 0,246 3,785 0,00024372 0,016199895 
23001_at WDFY3 7,292 7,731 0,439 3,775 0,00025298 0,0167594 
88455_at ANKRD13A 7,842 8,003 0,161 3,774 0,000253947 0,016777784 
10572_at SIVA1 5,021 4,905 -0,116 -3,773 0,000254932 0,016783751 
116092_at DNTTIP1 5,515 5,688 0,174 3,772 0,000255418 0,016783751 
50650_at ARHGEF3 5,909 5,719 -0,190 -3,768 0,00025918 0,016985026 
5611_at DNAJC3 7,101 7,455 0,354 3,766 0,000260743 0,016995809 
729633_at MRS2P2 3,851 4,055 0,205 3,767 0,000260452 0,016995809 
11123_at RCAN3 7,530 7,263 -0,267 -3,764 0,000262892 0,017090111 
1937_at EEF1G 7,318 7,071 -0,247 -3,761 0,000266235 0,017261242 
1438_at CSF2RA 4,423 4,627 0,204 3,758 0,000268814 0,017334255 
399665_at FAM102A 6,578 6,300 -0,279 -3,758 0,000268971 0,017334255 
6799_at SULT1A2 4,149 4,260 0,111 3,757 0,0002695 0,017334255 
406954_at MIR181A2 4,708 5,184 0,476 3,752 0,000274646 0,01761866 
100873933_at DPYD-AS2 4,300 4,555 0,255 3,748 0,000278184 0,017751927 
23250_at ATP11A 5,004 5,272 0,268 3,749 0,000277864 0,017751927 
123879_at DCUN1D3 4,367 4,555 0,188 3,743 0,00028313 0,018020273 
55723_at ASF1B 4,258 4,395 0,137 3,741 0,000285073 0,018096543 
440944_at 
THUMPD3-
AS1 6,480 6,218 -0,262 -3,738 0,000288707 0,018279494 
1785_at DNM2 6,291 6,493 0,201 3,737 0,000289909 0,018307933 
100130231_at LINC00861 10,034 9,653 -0,381 -3,735 0,000291339 0,018350595 
8994_at LIMD1 4,912 4,806 -0,106 -3,734 0,000292438 0,01837219 
101929664_at 
HORMAD2-
AS1 3,861 4,006 0,144 3,730 0,000297047 0,018518226 
1955_at MEGF9 9,111 9,407 0,297 3,731 0,000295634 0,018518226 
389072_at PLEKHM3 4,675 4,841 0,167 3,730 0,000296682 0,018518226 
80762_at NDFIP1 7,750 7,559 -0,191 -3,728 0,00029879 0,018579253 
2355_at FOSL2 5,117 5,271 0,154 3,725 0,000302305 0,018749832 
101928161_at 
LOC101928
161 3,737 3,638 -0,099 -3,722 0,000305058 0,018872438 
10043_at TOM1 4,778 4,935 0,157 3,720 0,000307002 0,018944507 
51176_at LEF1 8,241 7,909 -0,332 -3,719 0,000308148 0,018967073 
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104384744_at TET2-AS1 4,493 4,739 0,246 3,716 0,000311732 0,019139267 
143384_at CACUL1 7,345 7,533 0,188 3,714 0,000314534 0,019262659 
6016_at RIT1 7,068 7,330 0,262 3,712 0,000316678 0,019345225 
407034_at MIR30E 5,240 5,694 0,454 3,710 0,000318725 0,019421428 
100885782_at MYO16-AS1 4,133 4,548 0,414 3,709 0,000320049 0,019453408 
5583_at PRKCH 8,322 7,971 -0,351 -3,708 0,000320947 0,019459294 
7852_at CXCR4 9,566 9,736 0,170 3,706 0,000322844 0,019525627 
23387_at SIK3 5,758 5,962 0,204 3,705 0,000324125 0,019554457 
1051_at CEBPB 4,259 4,382 0,122 3,700 0,000329737 0,019843813 
114885_at OSBPL11 6,773 7,009 0,236 3,699 0,000331705 0,019912974 
5037_at PEBP1 7,573 7,279 -0,294 -3,696 0,000334212 0,020014045 
353514_at LILRA5 4,254 4,494 0,240 3,693 0,000337814 0,020180055 
868_at CBLB 6,917 6,636 -0,281 -3,689 0,000343129 0,020447285 
151475_at LOC151475 3,711 3,798 0,086 3,685 0,00034835 0,020707674 
1610_at DAO 3,890 3,981 0,092 3,683 0,000350781 0,020801319 
101928523_at 
LOC101928
523 3,355 3,432 0,077 3,681 0,000352538 0,020826038 
5226_at PGD 8,873 9,171 0,298 3,681 0,000352911 0,020826038 
93190_at C1orf158 3,696 3,771 0,075 3,678 0,000356442 0,02098348 
1155_at TBCB 5,393 5,202 -0,191 -3,677 0,000357979 0,021005258 
2314_at FLII 4,857 4,991 0,133 3,675 0,000360051 0,021005258 
29914_at UBIAD1 5,497 5,344 -0,153 -3,676 0,000359142 0,021005258 
9219_at MTA2 6,229 6,058 -0,171 -3,675 0,000360268 0,021005258 
7342_at UBP1 6,605 6,455 -0,150 -3,672 0,000363627 0,021104099 
9875_at URB1 4,513 4,438 -0,075 -3,672 0,000363699 0,021104099 
26297_at SERGEF 5,488 5,319 -0,169 -3,669 0,000367723 0,021236204 
388695_at LYSMD1 4,386 4,575 0,189 3,669 0,000367374 0,021236204 
3892_at KRT86 4,388 4,249 -0,139 -3,668 0,000368983 0,021258465 
347517_at RAB41 3,776 3,707 -0,069 -3,666 0,000371336 0,021343452 
8225_at GTPBP6 4,633 4,547 -0,086 -3,665 0,000372822 0,021378333 
102503427_at 
LOC102503
427 3,412 3,460 0,048 3,664 0,000374034 0,021397367 
6402_at SELL 10,076 10,315 0,239 3,655 0,000386306 0,022047572 
6777_at STAT5B 6,572 6,865 0,292 3,654 0,000388137 0,022100185 
5052_at PRDX1 6,984 6,754 -0,229 -3,649 0,00039406 0,022334272 
55011_at PIH1D1 5,193 5,034 -0,159 -3,649 0,000394086 0,022334272 
80212_at CCDC92 4,499 4,399 -0,099 -3,647 0,000397505 0,022475645 
80004_at ESRP2 4,347 4,292 -0,055 -3,645 0,0003997 0,022547359 
10682_at EBP 5,905 5,666 -0,238 -3,643 0,000403143 0,02268892 
3936_at LCP1 10,983 11,148 0,165 3,641 0,00040597 0,02271949 
646627_at LYPD8 4,459 4,550 0,091 3,641 0,000405849 0,02271949 
6756_at SSX1 3,504 3,577 0,073 3,640 0,000407424 0,02271949 
677840_at SNORA71D 3,788 4,045 0,257 3,640 0,000406872 0,02271949 
137835_at TMEM71 8,189 8,465 0,276 3,639 0,0004091 0,022760743 
100128770_at 
LOC100128
770 3,940 4,037 0,096 3,637 0,000411988 0,022869121 
339448_at C1orf174 5,054 4,915 -0,139 -3,636 0,000413123 0,022879849 
57504_at MTA3 4,111 4,037 -0,074 -3,632 0,000418445 0,023069535 
84628_at NTNG2 4,371 4,448 0,077 3,633 0,000417766 0,023069535 
2014_at EMP3 7,887 7,582 -0,305 -3,629 0,00042318 0,023225228 
26469_at PTPN18 5,755 5,605 -0,150 -3,629 0,000422964 0,023225228 
11060_at WWP2 5,544 5,749 0,205 3,625 0,00042859 0,023416417 
161253_at REM2 4,350 4,498 0,148 3,626 0,000428006 0,023416417 
116842_at LEAP2 5,743 5,552 -0,192 -3,623 0,000431998 0,023546986 
29065_at ASAP1-IT1 5,337 5,729 0,392 3,622 0,000432917 0,023546986 
375341_at C3orf62 6,082 6,400 0,318 3,622 0,000434232 0,023565805 
80216_at ALPK1 6,728 7,068 0,339 3,620 0,000436458 0,023633872 
10673_at TNFSF13B 6,696 7,114 0,418 3,618 0,000439524 0,02366084 
3192_at HNRNPU 7,949 7,782 -0,167 -3,619 0,000438546 0,02366084 
374907_at B3GNT8 4,583 4,683 0,100 3,618 0,000439876 0,02366084 
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55907_at CMAS 5,784 5,616 -0,167 -3,616 0,000442081 0,023726965 
498_at ATP5A1 7,635 7,422 -0,214 -3,615 0,000444446 0,023801368 
10972_at TMED10 7,009 6,829 -0,180 -3,613 0,000446698 0,023869394 
51571_at FAM49B 7,966 8,115 0,149 3,612 0,000448262 0,023900444 
8809_at IL18R1 4,298 4,606 0,308 3,611 0,000450278 0,023955372 
55129_at ANO10 4,705 4,927 0,222 3,609 0,000454059 0,024103774 
5435_at POLR2F 7,168 6,942 -0,225 -3,607 0,000457039 0,02415648 
79887_at PLBD1 8,424 8,731 0,308 3,607 0,000456994 0,02415648 
3182_at HNRNPAB 8,284 8,063 -0,221 -3,604 0,000462267 0,02435213 
8897_at MTMR3 6,921 7,182 0,261 3,603 0,000462744 0,02435213 
3554_at IL1R1 4,286 4,592 0,306 3,602 0,000464964 0,024402391 
360_at AQP3 5,123 4,981 -0,142 -3,601 0,000465706 0,024402391 
101930746_at LINC00945 3,624 3,558 -0,066 -3,598 0,000471469 0,024555472 
2000_at ELF4 4,873 5,025 0,152 3,598 0,000471657 0,024555472 
4001_at LMNB1 5,453 5,742 0,289 3,598 0,000471118 0,024555472 
23220_at DTX4 4,627 4,731 0,104 3,597 0,000473091 0,024577485 
84968_at PNMA6A 4,273 4,548 0,275 3,593 0,00048023 0,024895184 
10154_at PLXNC1 8,247 8,531 0,284 3,591 0,000481915 0,024929377 
286046_at XKR6 4,149 4,088 -0,061 -3,591 0,000483012 0,024933064 
84138_at SLC7A6OS 6,812 6,628 -0,184 -3,589 0,000486027 0,025035524 
1606_at DGKA 6,640 6,429 -0,211 -3,586 0,000490722 0,025223963 
8553_at BHLHE40 5,266 5,119 -0,147 -3,585 0,000492677 0,025271013 
538_at ATP7A 6,498 6,682 0,184 3,583 0,00049686 0,025431932 
1650_at DDOST 6,385 6,221 -0,164 -3,581 0,000499596 0,025518222 
23627_at PRND 4,456 4,324 -0,132 -3,580 0,000501435 0,025558453 
81554_at WBSCR16 4,773 4,675 -0,098 -3,578 0,000504609 0,025612868 
83853_at ROPN1L 4,841 5,078 0,237 3,578 0,000504555 0,025612868 
101928604_at 
ZBTB46-
AS1 4,180 4,322 0,142 3,575 0,000510962 0,025881288 
9404_at LPXN 5,780 5,599 -0,181 -3,574 0,000512521 0,025906273 
23168_at RTF1 5,078 5,260 0,182 3,572 0,000514939 0,025920724 
6416_at MAP2K4 5,889 6,128 0,239 3,572 0,000514881 0,025920724 
84440_at RAB11FIP4 4,940 5,048 0,108 3,569 0,000520455 0,026144253 
10451_at VAV3 6,416 6,664 0,248 3,566 0,000526004 0,02627587 
339883_at C3orf35 4,165 4,067 -0,098 -3,567 0,000524761 0,02627587 
6484_at ST3GAL4 4,183 4,270 0,087 3,566 0,000526317 0,02627587 
10169_at SERF2 6,086 5,917 -0,168 -3,564 0,000530375 0,026424172 
7091_at TLE4 7,015 7,254 0,238 3,561 0,000536016 0,026650608 
58478_at ENOPH1 5,510 5,366 -0,144 -3,560 0,000537294 0,026659667 
10578_at GNLY 6,733 6,362 -0,371 -3,557 0,000542109 0,026828361 
399_at RHOH 5,456 5,231 -0,225 -3,557 0,000542901 0,026828361 
894_at CCND2 5,151 4,983 -0,168 -3,554 0,000548197 0,027035138 
6888_at TALDO1 10,276 10,491 0,215 3,552 0,000551907 0,027162989 
6774_at STAT3 8,519 8,813 0,294 3,550 0,000556384 0,027244256 
7259_at TSPYL1 6,952 6,765 -0,187 -3,549 0,000558041 0,027244256 
7587_at ZNF37A 4,309 4,189 -0,120 -3,549 0,000557984 0,027244256 
80301_at PLEKHO2 6,027 6,262 0,235 3,550 0,000555233 0,027244256 
202020_at TAPT1-AS1 5,051 4,935 -0,116 -3,548 0,000559702 0,027270597 
10008_at KCNE3 4,700 4,891 0,191 3,546 0,000563629 0,027407027 
101928517_at 
LOC101928
517 3,673 3,747 0,074 3,540 0,000576116 0,027700124 
26037_at SIPA1L1 6,306 6,608 0,302 3,539 0,000577242 0,027700124 
2876_at GPX1 5,220 4,973 -0,247 -3,541 0,000572955 0,027700124 
5191_at PEX7 4,745 4,626 -0,120 -3,542 0,000571797 0,027700124 
6280_at S100A9 8,712 9,123 0,411 3,539 0,000577632 0,027700124 
643036_at SLED1 5,166 5,631 0,465 3,540 0,000575632 0,027700124 
6555_at SLC10A2 4,126 4,032 -0,094 -3,539 0,000576283 0,027700124 
84898_at PLXDC2 7,531 7,838 0,307 3,538 0,000579423 0,027731307 
23593_at HEBP2 7,418 7,626 0,207 3,533 0,000589046 0,028081343 
8773_at SNAP23 8,060 8,315 0,256 3,533 0,000588999 0,028081343 
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60685_at ZFAND3 5,573 5,747 0,174 3,532 0,000590339 0,028087912 
100874150_at LINC00379 3,868 3,730 -0,138 -3,531 0,000593304 0,028173817 
23357_at ANGEL1 4,863 4,756 -0,107 -3,529 0,00059656 0,02823318 
6748_at SSR4 6,133 5,920 -0,213 -3,529 0,000596876 0,02823318 
6248_at RSC1A1 8,732 8,460 -0,272 -3,529 0,000598125 0,02823731 
55739_at NAXD 4,533 4,461 -0,073 -3,527 0,000601273 0,028276135 
84226_at C2orf16 3,700 3,771 0,071 3,527 0,000600563 0,028276135 
79772_at MCTP1 6,451 6,664 0,213 3,526 0,000604326 0,028364842 
2176_at FANCC 3,688 3,652 -0,036 -3,521 0,000612781 0,028656355 
57217_at TTC7A 4,662 4,584 -0,078 -3,521 0,000612895 0,028656355 
9537_at TP53I11 4,507 4,620 0,114 3,520 0,00061487 0,02869356 
100505933_at ADD3-AS1 3,871 3,970 0,099 3,518 0,000620904 0,028711085 
11259_at FILIP1L 4,568 4,417 -0,151 -3,518 0,000619124 0,028711085 
23076_at RRP1B 4,747 4,642 -0,106 -3,518 0,00062071 0,028711085 
4660_at PPP1R12B 5,482 5,755 0,273 3,520 0,000616682 0,028711085 
55370_at PPP4R1L 4,731 5,027 0,296 3,517 0,00062115 0,028711085 
5818_at NECTIN1 4,368 4,455 0,087 3,516 0,000624067 0,02879115 
123606_at NIPA1 5,444 5,251 -0,193 -3,512 0,00063371 0,029037235 
23043_at TNIK 5,915 5,647 -0,269 -3,512 0,000632129 0,029037235 
28375_at IGHVII-20-1 3,553 3,694 0,141 3,511 0,000634178 0,029037235 
79961_at DENND2D 6,654 6,471 -0,184 -3,512 0,000632219 0,029037235 
105369535_at 
LOC105369
535 4,386 4,692 0,306 3,511 0,000635986 0,029065256 
7150_at TOP1 6,781 6,971 0,190 3,510 0,000638096 0,029106994 
26133_at TRPC4AP 6,218 6,397 0,179 3,509 0,00063937 0,029110491 
50484_at RRM2B 5,262 5,473 0,211 3,506 0,000645095 0,029265244 
8148_at TAF15 9,184 8,929 -0,255 -3,506 0,000645176 0,029265244 
51363_at CHST15 5,730 6,001 0,271 3,505 0,000648228 0,029348903 
100132341_at CLUHP3 4,187 4,123 -0,063 -3,504 0,00065114 0,029371346 
293_at SLC25A6 9,072 8,847 -0,224 -3,504 0,000650459 0,029371346 
9797_at TATDN2 4,969 4,851 -0,118 -3,502 0,000653637 0,029429388 
3309_at HSPA5 6,862 6,680 -0,182 -3,502 0,000655559 0,029461366 
5873_at RAB27A 6,663 6,829 0,166 3,501 0,000657476 0,029492998 
18_at ABAT 4,965 5,140 0,175 3,498 0,000663087 0,029635352 
6742_at SSBP1 6,310 6,029 -0,281 -3,498 0,000662918 0,029635352 
374899_at ZNF829 4,038 3,928 -0,110 -3,496 0,000668443 0,029819939 
114883_at OSBPL9 5,783 5,956 0,173 3,494 0,000672235 0,029824927 
3091_at HIF1A 7,188 7,440 0,252 3,495 0,000671399 0,029824927 
901_at CCNG2 8,463 8,633 0,170 3,495 0,000671361 0,029824927 
10130_at PDIA6 6,005 5,776 -0,229 -3,491 0,000678923 0,029849265 
101928386_at 
LOC101928
386 3,728 3,867 0,139 3,492 0,000676511 0,029849265 
112574_at SNX18 5,604 5,791 0,188 3,492 0,000676262 0,029849265 
54432_at YIPF1 5,344 5,586 0,242 3,493 0,000674583 0,029849265 
7873_at MANF 6,996 6,750 -0,246 -3,492 0,000677912 0,029849265 
54847_at SIDT1 6,060 5,808 -0,252 -3,489 0,000683157 0,02998124 
4691_at NCL 8,653 8,273 -0,380 -3,488 0,00068715 0,030047988 
994_at CDC25B 5,396 5,270 -0,127 -3,488 0,000685959 0,030047988 
114804_at RNF157 4,974 4,851 -0,122 -3,487 0,00068957 0,030099687 
2802_at GOLGA3 4,424 4,369 -0,054 -3,483 0,000697464 0,030389683 
10146_at G3BP1 7,877 7,663 -0,214 -3,481 0,000702255 0,03050597 
10335_at MRVI1 4,624 4,747 0,123 3,481 0,000703897 0,03050597 
84945_at ABHD13 5,148 5,352 0,204 3,481 0,000703417 0,03050597 
914_at CD2 7,965 7,561 -0,403 -3,479 0,000706763 0,030575665 
689_at BTF3 7,177 6,946 -0,231 -3,478 0,00070998 0,03066027 
340578_at DCAF12L2 4,115 3,978 -0,137 -3,476 0,000713907 0,030716905 
751071_at METTL12 5,067 4,886 -0,181 -3,475 0,000716345 0,030716905 
84928_at TMEM209 5,755 5,560 -0,195 -3,476 0,000715203 0,030716905 
97_at ACYP1 4,243 4,120 -0,123 -3,476 0,000715309 0,030716905 
1912_at PHC2 5,136 5,299 0,163 3,475 0,000717807 0,030725422 
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55841_at WWC3 5,054 5,217 0,163 3,472 0,000723856 0,030929897 
55332_at DRAM1 4,424 4,642 0,217 3,470 0,000728808 0,031050089 
57689_at LRRC4C 3,615 3,571 -0,045 -3,470 0,000729223 0,031050089 
3703_at STT3A 8,069 7,862 -0,207 -3,469 0,000732809 0,031081263 
81553_at FAM49A 7,846 8,066 0,219 3,468 0,00073379 0,031081263 
8396_at PIP4K2B 5,914 5,767 -0,147 -3,469 0,000731856 0,031081263 
50862_at RNF141 7,517 7,836 0,319 3,465 0,000741885 0,031262037 
6626_at SNRPA 4,494 4,392 -0,102 -3,465 0,000740754 0,031262037 
96459_at FNIP1 7,605 7,840 0,235 3,465 0,000741916 0,031262037 
8668_at EIF3I 7,964 7,706 -0,257 -3,464 0,000744762 0,031327676 
116729_at PPP1R27 3,785 3,843 0,058 3,463 0,000748244 0,031419803 
550113_at LOC550113 3,535 3,593 0,059 3,462 0,000750554 0,031462431 
10553_at HTATIP2 6,119 6,326 0,207 3,461 0,000752724 0,031499098 
284067_at C17orf105 3,473 3,519 0,046 3,459 0,00075821 0,03156567 
7048_at TGFBR2 8,093 8,266 0,172 3,459 0,00075764 0,03156567 
9423_at NTN1 4,775 4,646 -0,129 -3,459 0,000756706 0,03156567 
401093_at MBNL1-AS1 5,563 5,387 -0,176 -3,458 0,000760205 0,031594645 
23095_at KIF1B 5,364 5,651 0,287 3,453 0,000772643 0,03197024 
29802_at VPREB3 4,549 4,398 -0,151 -3,453 0,00077338 0,03197024 
51466_at EVL 5,535 5,391 -0,144 -3,452 0,000774502 0,03197024 
54778_at RNF111 5,771 5,955 0,184 3,453 0,000773627 0,03197024 
54539_at NDUFB11 7,482 7,221 -0,261 -3,451 0,000777234 0,032028626 
54807_at ZNF586 6,395 6,562 0,168 3,450 0,000779549 0,032069682 
2870_at GRK6 4,766 4,872 0,106 3,449 0,00078321 0,032165844 
101927048_at 
LOC101927
048 3,536 3,478 -0,059 -3,444 0,000796965 0,032501721 
127833_at SYT2 4,396 4,502 0,106 3,443 0,000798072 0,032501721 
27141_at CIDEB 5,816 6,045 0,229 3,444 0,000797474 0,032501721 
286467_at FIRRE 3,698 3,639 -0,059 -3,445 0,00079466 0,032501721 
6421_at SFPQ 8,762 8,558 -0,204 -3,445 0,00079324 0,032501721 
56139_at PCDHA10 3,670 3,617 -0,054 -3,442 0,0008006 0,032550142 
101929212_at SMIM2-AS1 3,596 3,653 0,057 3,441 0,000805475 0,032693699 
51052_at PRLH 5,251 5,036 -0,216 -3,440 0,000808284 0,032753015 
140258_at KRTAP13-1 3,627 3,548 -0,079 -3,438 0,000811853 0,032842896 
255488_at RNF144B 7,268 7,536 0,268 3,437 0,000815009 0,032915801 
1396_at CRIP1 7,510 7,234 -0,276 -3,436 0,000818239 0,032936831 
390940_at PINLYP 3,984 4,092 0,108 3,436 0,000817153 0,032936831 
22849_at CPEB3 4,106 4,220 0,114 3,433 0,000827435 0,033058445 
25978_at CHMP2B 5,870 6,134 0,264 3,432 0,000828107 0,033058445 
51105_at PHF20L1 6,967 7,192 0,226 3,433 0,000825799 0,033058445 
5892_at RAD51D 4,987 4,869 -0,118 -3,432 0,000827715 0,033058445 
6472_at SHMT2 5,350 5,210 -0,140 -3,432 0,000829418 0,033058445 
690_at BTF3P11 3,441 3,506 0,064 3,433 0,000826189 0,033058445 
27018_at BEX3 4,815 4,679 -0,136 -3,431 0,000831203 0,033075342 
51433_at ANAPC5 6,043 5,915 -0,128 -3,430 0,000834565 0,033079229 
54536_at EXOC6 5,690 6,007 0,317 3,430 0,000835382 0,033079229 
79781_at IQCA1 3,610 3,577 -0,033 -3,430 0,000833323 0,033079229 
100507316_at MINCR 4,451 4,321 -0,130 -3,424 0,000852564 0,033548073 
102724612_at 
LOC102724
612 3,490 3,551 0,061 3,425 0,000849679 0,033548073 
1353_at COX11 4,441 4,345 -0,096 -3,424 0,000852358 0,033548073 
9462_at RASAL2 3,865 3,824 -0,041 -3,424 0,000852742 0,033548073 
79863_at RBFA 4,487 4,408 -0,079 -3,423 0,000854786 0,033574152 
727993_at LOC727993 4,025 4,135 0,109 3,420 0,000864246 0,033890985 
821_at CANX 9,363 9,218 -0,145 -3,419 0,000867022 0,033945101 
220004_at PPP1R32 4,539 4,641 0,102 3,418 0,000868707 0,033956387 
101927084_at LINC01359 3,613 3,700 0,087 3,417 0,000872778 0,034060743 
101928894_at 
LOC101928
894 4,178 4,305 0,126 3,415 0,00087684 0,034164436 
3454_at IFNAR1 7,034 7,334 0,300 3,413 0,000883074 0,034235695 
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4773_at NFATC2 5,907 5,690 -0,218 -3,413 0,000884301 0,034235695 
526_at ATP6V1B2 9,912 10,058 0,146 3,413 0,000883731 0,034235695 
606495_at CYB5RL 4,355 4,272 -0,083 -3,413 0,000882993 0,034235695 
9818_at NUP58 6,419 6,622 0,203 3,411 0,000888778 0,034354294 
100130155_at 
MIR124-
2HG 3,476 3,521 0,045 3,409 0,000894888 0,03453557 
84253_at GARNL3 3,775 3,733 -0,042 -3,408 0,000898373 0,034560335 
84658_at ADGRE3 8,614 8,994 0,380 3,408 0,000897341 0,034560335 
100507266_at STX18-AS1 4,339 4,216 -0,124 -3,405 0,000907124 0,034841884 
100506134_at 
TTC21B-
AS1 3,759 3,897 0,139 3,404 0,000910462 0,034914908 
5437_at POLR2H 6,018 5,816 -0,203 -3,402 0,000915712 0,035060958 
101928773_at LINC01449 3,421 3,462 0,041 3,402 0,000917621 0,035078821 
57458_at TMCC3 5,676 5,959 0,284 3,401 0,000920238 0,035123626 
9908_at G3BP2 6,413 6,280 -0,133 -3,400 0,000921963 0,035134295 
7084_at TK2 4,535 4,658 0,123 3,399 0,000925017 0,035195517 
55175_at KLHL11 5,652 5,433 -0,219 -3,398 0,000927399 0,035231013 
90673_at PPP1R3E 4,887 4,770 -0,118 -3,398 0,000929135 0,035241914 
81704_at DOCK8 8,247 8,459 0,213 3,397 0,000932874 0,035328622 
23468_at CBX5 6,963 6,733 -0,230 -3,396 0,000936082 0,035394962 
204801_at NLRP11 3,565 3,535 -0,029 -3,394 0,000941063 0,035418068 
5023_at P2RX1 4,871 5,033 0,162 3,394 0,000940557 0,035418068 
84148_at KAT8 4,888 4,999 0,110 3,394 0,000941034 0,035418068 
255725_at OR52B2 3,990 4,164 0,174 3,393 0,000945007 0,035511527 
220929_at ZNF438 4,854 5,158 0,304 3,391 0,000949027 0,03555269 
7507_at XPA 5,950 5,748 -0,202 -3,391 0,000948938 0,03555269 
84859_at LRCH3 6,465 6,316 -0,149 -3,390 0,000952817 0,035639765 
1521_at CTSW 6,815 6,449 -0,366 -3,388 0,00095889 0,035811825 
26502_at NARF 6,052 6,232 0,179 3,387 0,000964105 0,035951345 
284756_at C20orf197 4,406 4,510 0,105 3,385 0,000971024 0,03609863 
57096_at RPGRIP1 3,774 3,847 0,073 3,385 0,000969957 0,03609863 
10204_at NUTF2 5,009 4,906 -0,103 -3,383 0,000976111 0,036182945 
9025_at RNF8 4,647 4,492 -0,155 -3,383 0,000977228 0,036182945 
9677_at PPIP5K1 4,432 4,330 -0,102 -3,382 0,000977757 0,036182945 
347918_at EP400NL 4,162 4,082 -0,080 -3,381 0,000982433 0,036300742 
10330_at CNPY2 5,286 5,126 -0,160 -3,378 0,000991083 0,036564785 
147991_at DPY19L3 4,478 4,767 0,289 3,370 0,001017747 0,037491652 
26959_at HBP1 7,992 8,180 0,188 3,369 0,001021048 0,037556335 
10921_at RNPS1 4,529 4,435 -0,094 -3,368 0,001025448 0,037614371 
158158_at RASEF 3,639 3,605 -0,034 -3,368 0,00102572 0,037614371 
55350_at VNN3 6,024 6,447 0,423 3,366 0,001032759 0,03775859 
8218_at CLTCL1 4,002 4,066 0,065 3,366 0,001031661 0,03775859 
6619_at SNAPC3 6,767 6,566 -0,201 -3,365 0,001034329 0,03775922 
100130872_at 
LOC100130
872 5,040 4,856 -0,184 -3,363 0,001042936 0,037808222 
116362_at RBP7 6,736 7,202 0,467 3,365 0,001037435 0,037808222 
127124_at ATP6V1G3 3,418 3,460 0,042 3,364 0,001040376 0,037808222 
3384_at ICAM2 4,885 4,789 -0,096 -3,363 0,001043447 0,037808222 
57658_at CALCOCO1 4,975 5,115 0,140 3,364 0,001040539 0,037808222 
10612_at TRIM3 4,397 4,343 -0,054 -3,359 0,001055785 0,038111105 
284391_at ZNF844 3,890 4,044 0,154 3,359 0,001054874 0,038111105 
7053_at TGM3 4,203 4,320 0,117 3,359 0,001056508 0,038111105 
5165_at PDK3 6,339 6,597 0,258 3,356 0,001066062 0,038398759 
283385_at MORN3 4,190 4,277 0,086 3,355 0,001069972 0,038482584 
140803_at TRPM6 5,151 5,584 0,433 3,353 0,001078379 0,038556798 
1588_at CYP19A1 3,509 3,541 0,032 3,353 0,001076305 0,038556798 
5236_at PGM1 4,312 4,448 0,136 3,353 0,001077653 0,038556798 
83442_at SH3BGRL3 8,213 7,968 -0,245 -3,354 0,001075326 0,038556798 
64645_at MFSD14A 6,796 7,030 0,234 3,352 0,001081689 0,038618374 
5613_at PRKX 6,097 5,966 -0,131 -3,351 0,001083881 0,038639896 
Appendix 
 
145 
101928232_at LINC01280 4,013 4,202 0,189 3,350 0,001087704 0,03866279 
285335_at SLC9C1 3,350 3,368 0,018 3,350 0,001087411 0,03866279 
80012_at PHC3 8,022 7,861 -0,161 -3,348 0,001093915 0,03882678 
51530_at ZC3HC1 4,522 4,432 -0,090 -3,347 0,001098256 0,038867388 
51567_at TDP2 7,945 8,222 0,277 3,348 0,001096835 0,038867388 
3632_at INPP5A 4,383 4,516 0,134 3,346 0,00110133 0,03889967 
9654_at TTLL4 4,945 5,118 0,173 3,346 0,001102368 0,03889967 
100506470_at 
LOC100506
470 4,114 3,959 -0,155 -3,345 0,001106609 0,038992729 
26578_at OSTF1 8,775 8,944 0,169 3,344 0,001110164 0,039061391 
26152_at ZNF337 4,917 4,817 -0,100 -3,342 0,001118255 0,039232511 
28970_at C11orf54 5,784 6,058 0,274 3,342 0,001117785 0,039232511 
10981_at RAB32 6,232 6,428 0,196 3,340 0,001123408 0,039299889 
401494_at HACD4 6,644 6,916 0,272 3,340 0,001122952 0,039299889 
10898_at CPSF4 4,578 4,488 -0,090 -3,338 0,001133017 0,039579093 
246175_at CNOT6L 8,259 8,081 -0,178 -3,336 0,001139195 0,039737796 
102800310_at HAGLROS 3,823 3,987 0,164 3,335 0,001143616 0,039834876 
57696_at DDX55 4,624 4,495 -0,129 -3,334 0,001146431 0,039875779 
51727_at CMPK1 5,935 5,778 -0,156 -3,330 0,001161407 0,040338977 
64756_at ATPAF1 5,132 4,995 -0,137 -3,326 0,001176094 0,040790836 
677823_at SNORA80E 5,649 5,975 0,326 3,325 0,001179803 0,040861166 
241_at ALOX5AP 9,133 9,428 0,296 3,323 0,001188181 0,041064602 
79885_at HDAC11 4,272 4,192 -0,080 -3,323 0,001189054 0,041064602 
80339_at PNPLA3 4,066 3,999 -0,068 -3,322 0,00119289 0,041138618 
135935_at NOBOX 4,060 4,120 0,060 3,320 0,001200436 0,041340211 
10586_at MAB21L2 4,788 4,627 -0,160 -3,319 0,001206595 0,041430784 
1687_at DFNA5 4,062 4,013 -0,049 -3,317 0,001211586 0,041430784 
283951_at C16orf91 5,230 5,060 -0,170 -3,318 0,001210326 0,041430784 
54462_at CCSER2 5,439 5,220 -0,219 -3,318 0,001209977 0,041430784 
64332_at NFKBIZ 6,791 7,025 0,234 3,317 0,0012112 0,041430784 
29916_at SNX11 5,383 5,566 0,183 3,316 0,001216903 0,041495869 
51099_at ABHD5 9,233 9,481 0,249 3,316 0,001216144 0,041495869 
9051_at PSTPIP1 5,330 5,494 0,164 3,315 0,001218719 0,041499613 
51398_at WDR83OS 7,312 7,111 -0,202 -3,314 0,001223325 0,04154007 
80896_at NPL 5,804 6,091 0,287 3,315 0,001222119 0,04154007 
3920_at LAMP2 8,510 8,785 0,275 3,314 0,001225481 0,041555254 
254128_at NIFK-AS1 5,167 5,036 -0,132 -3,312 0,001230799 0,041619509 
3482_at IGF2R 8,016 8,406 0,390 3,313 0,001229404 0,041619509 
240_at ALOX5 6,155 6,461 0,306 3,311 0,001235254 0,041712126 
51614_at ERGIC3 8,379 8,115 -0,264 -3,309 0,001243017 0,04191605 
200315_at APOBEC3A 7,677 8,108 0,431 3,307 0,001253148 0,04214077 
6907_at TBL1X 5,266 5,493 0,227 3,307 0,0012523 0,04214077 
7014_at TERF2 5,426 5,308 -0,118 -3,305 0,001262188 0,042386144 
100131980_at ZNF705G 3,612 3,722 0,111 3,303 0,001267562 0,042390962 
10140_at TOB1 7,368 7,202 -0,166 -3,304 0,001267084 0,042390962 
10912_at GADD45G 4,103 4,020 -0,082 -3,304 0,001264736 0,042390962 
105376875_at 
LOC105376
875 4,051 4,282 0,231 3,300 0,001280785 0,042460178 
27284_at SULT1B1 7,238 7,717 0,479 3,301 0,001276592 0,042460178 
3952_at LEP 3,990 4,085 0,095 3,302 0,001274807 0,042460178 
3983_at ABLIM1 5,408 5,225 -0,184 -3,300 0,001281856 0,042460178 
81688_at C6orf62 8,559 8,440 -0,118 -3,301 0,001276637 0,042460178 
81846_at SBF2 5,727 5,987 0,260 3,300 0,001280238 0,042460178 
8562_at DENR 6,169 5,963 -0,207 -3,302 0,001273973 0,042460178 
101927196_at 
LOC101927
196 3,484 3,554 0,070 3,292 0,001314695 0,043311912 
4051_at CYP4F3 6,730 7,138 0,408 3,293 0,001309822 0,043311912 
64753_at CCDC136 4,033 3,979 -0,054 -3,292 0,001313557 0,043311912 
7351_at UCP2 8,317 8,058 -0,259 -3,293 0,001312317 0,043311912 
130013_at ACMSD 3,604 3,643 0,039 3,291 0,001318263 0,043312078 
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25873_at RPL36 5,663 5,472 -0,191 -3,292 0,001316761 0,043312078 
340156_at MYLK4 4,427 4,344 -0,083 -3,290 0,00132269 0,043398857 
100500829_at MIR3943 4,078 3,899 -0,180 -3,289 0,001329121 0,043444763 
154386_at LINC01600 3,768 3,861 0,093 3,289 0,001328192 0,043444763 
2649_at NR6A1 4,175 4,257 0,082 3,289 0,001329449 0,043444763 
1486_at CTBS 7,789 8,028 0,239 3,288 0,001334189 0,043541126 
94107_at TMEM203 5,887 5,676 -0,210 -3,286 0,001339969 0,043671134 
5272_at SERPINB9 6,043 5,797 -0,246 -3,285 0,001345492 0,043792417 
9686_at VGLL4 4,826 4,740 -0,086 -3,283 0,001355492 0,044058936 
6138_at RPL15 7,652 7,460 -0,192 -3,282 0,001357835 0,044076145 
2534_at FYN 8,228 7,988 -0,239 -3,281 0,001361478 0,04413549 
9839_at ZEB2 6,607 6,485 -0,123 -3,281 0,001365108 0,044194242 
22856_at CHSY1 5,434 5,607 0,173 3,280 0,001368643 0,044249765 
115426_at UHRF2 6,031 5,828 -0,203 -3,279 0,001372864 0,044313976 
116534_at MRGPRE 4,651 4,870 0,219 3,276 0,00138402 0,044313976 
2135_at EXTL2 3,728 3,645 -0,083 -3,276 0,001383959 0,044313976 
23360_at FNBP4 6,042 5,834 -0,209 -3,278 0,00137528 0,044313976 
3205_at HOXA9 4,782 4,640 -0,142 -3,278 0,001378013 0,044313976 
4818_at NKG7 9,747 9,256 -0,491 -3,276 0,001385969 0,044313976 
503538_at A1BG-AS1 3,986 3,895 -0,091 -3,276 0,001387033 0,044313976 
80067_at DCAF17 4,894 4,758 -0,136 -3,277 0,001380334 0,044313976 
81577_at GFOD2 4,025 4,102 0,077 3,277 0,001381335 0,044313976 
11235_at PDCD10 7,386 7,186 -0,201 -3,275 0,001392242 0,044363807 
1129_at CHRM2 3,583 3,626 0,043 3,275 0,001391079 0,044363807 
105375110_at 
LOC105375
110 4,139 4,332 0,193 3,274 0,001395562 0,04441138 
101409254_at LINC00681 3,574 3,686 0,112 3,273 0,001399977 0,044493637 
101927821_at LINC01425 3,531 3,605 0,073 3,272 0,001405715 0,044559515 
6224_at RPS20 7,075 6,744 -0,331 -3,272 0,001405242 0,044559515 
10938_at EHD1 4,617 4,697 0,079 3,270 0,001411668 0,04468994 
602_at BCL3 5,090 5,296 0,206 3,270 0,001414633 0,044725596 
9296_at ATP6V1F 8,183 7,915 -0,267 -3,269 0,001419184 0,044811181 
5036_at PA2G4 9,073 8,853 -0,220 -3,268 0,001421196 0,044816528 
10432_at RBM14 5,027 4,893 -0,134 -3,267 0,001425375 0,04489008 
388759_at C1orf229 4,251 4,389 0,138 3,265 0,001433941 0,045101441 
23062_at GGA2 5,622 5,503 -0,119 -3,264 0,001442419 0,045309483 
7203_at CCT3 6,015 5,849 -0,166 -3,263 0,001445103 0,045335226 
2237_at FEN1 6,204 5,972 -0,232 -3,260 0,001457011 0,045635132 
353323_at KRTAP12-2 5,034 4,800 -0,235 -3,260 0,001458417 0,045635132 
4600_at MX2 7,189 7,475 0,286 3,259 0,001464083 0,045753539 
645682_at POU5F1P4 5,138 5,357 0,218 3,258 0,001468566 0,04583472 
10327_at AKR1A1 5,472 5,340 -0,132 -3,255 0,001483515 0,046117667 
126231_at ZNF573 3,980 3,870 -0,110 -3,255 0,001484551 0,046117667 
79829_at NAA40 4,440 4,343 -0,097 -3,255 0,001481404 0,046117667 
9187_at SLC24A1 4,361 4,299 -0,062 -3,255 0,001485219 0,046117667 
101926950_at LINC01570 4,406 4,271 -0,135 -3,253 0,001490761 0,046160423 
389123_at IQCF2 3,381 3,430 0,050 3,253 0,001492292 0,046160423 
4134_at MAP4 4,930 4,846 -0,084 -3,253 0,001491822 0,046160423 
23530_at NNT 5,907 5,763 -0,143 -3,252 0,001496814 0,046241462 
91694_at LONRF1 4,279 4,394 0,115 3,251 0,001500765 0,046304702 
139067_at SPANXN3 3,554 3,655 0,101 3,250 0,001505812 0,04640152 
25791_at NGEF 4,123 4,207 0,084 3,248 0,001515499 0,046582653 
6583_at SLC22A4 4,820 5,050 0,230 3,248 0,001515522 0,046582653 
51504_at TRMT112 7,069 6,921 -0,148 -3,245 0,001529637 0,046957165 
28892_at IGKV1D-42 3,668 3,566 -0,102 -3,244 0,001534535 0,046962093 
4726_at NDUFS6 8,028 7,813 -0,214 -3,244 0,001535593 0,046962093 
57567_at ZNF319 4,217 4,353 0,135 3,244 0,001535435 0,046962093 
10541_at ANP32B 9,275 9,028 -0,247 -3,243 0,001542828 0,047124105 
3738_at KCNA3 6,537 6,298 -0,239 -3,239 0,00155912 0,047561958 
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3329_at HSPD1 6,100 5,901 -0,198 -3,238 0,00156648 0,047690232 
731789_at 
LINC00202-
2 3,858 3,918 0,060 3,238 0,001567248 0,047690232 
400027_at LINC00938 5,498 5,303 -0,195 -3,236 0,001578146 0,047961838 
102723590_at BMP7-AS1 4,058 4,184 0,125 3,234 0,001589022 0,04816276 
124935_at SLC43A2 4,849 5,008 0,158 3,233 0,00159286 0,04816276 
4552_at MTRR 6,417 6,210 -0,207 -3,232 0,00159858 0,04816276 
64432_at MRPS25 5,348 5,234 -0,115 -3,233 0,001592529 0,04816276 
6503_at SLA 7,950 8,171 0,221 3,233 0,001590492 0,04816276 
84229_at DRC7 3,894 3,938 0,044 3,232 0,001598177 0,04816276 
90693_at CCDC126 4,846 5,133 0,287 3,232 0,001598624 0,04816276 
83544_at DNAL1 3,577 3,534 -0,043 -3,230 0,001607021 0,048355809 
254225_at RNF169 6,909 7,074 0,165 3,229 0,001610801 0,048409652 
133619_at PRRC1 6,333 6,185 -0,148 -3,226 0,001627002 0,048536573 
23358_at USP24 7,052 6,870 -0,182 -3,228 0,00161952 0,048536573 
5686_at PSMA5 6,709 6,481 -0,228 -3,228 0,00161778 0,048536573 
65220_at NADK 5,463 5,649 0,185 3,226 0,00162695 0,048536573 
79027_at ZNF655 6,769 6,649 -0,120 -3,227 0,001625009 0,048536573 
8867_at SYNJ1 5,675 5,875 0,200 3,227 0,001625038 0,048536573 
4942_at OAT 4,374 4,580 0,206 3,225 0,001631704 0,048617175 
22901_at ARSG 5,246 5,428 0,181 3,225 0,001635543 0,048671932 
101927411_at 
LOC101927
411 4,164 4,257 0,093 3,222 0,001648225 0,048818136 
105376353_at 
LOC105376
353 4,620 4,945 0,325 3,223 0,001643471 0,048818136 
25938_at HEATR5A 4,822 4,987 0,165 3,223 0,001645181 0,048818136 
5693_at PSMB5 4,304 4,200 -0,104 -3,222 0,001649704 0,048818136 
7386_at UQCRFS1 4,694 4,941 0,247 3,222 0,001651012 0,048818136 
9046_at DOK2 5,067 4,917 -0,150 -3,221 0,001652504 0,048818136 
148581_at UBE2U 3,440 3,465 0,025 3,219 0,001665704 0,049128177 
23195_at MDN1 4,654 4,541 -0,114 -3,219 0,00166704 0,049128177 
83640_at FAM103A1 3,646 3,880 0,234 3,218 0,001669517 0,049141599 
3142_at HLX 5,189 5,316 0,127 3,217 0,001676153 0,049277267 
100289473_at 
LOC100289
473 3,936 4,025 0,089 3,214 0,001690841 0,049469826 
10550_at ARL6IP5 8,255 8,075 -0,180 -3,214 0,001690739 0,049469826 
54433_at GAR1 4,759 4,623 -0,136 -3,214 0,001689988 0,049469826 
93624_at TADA2B 4,984 5,140 0,156 3,214 0,001690434 0,049469826 
10808_at HSPH1 5,539 5,273 -0,266 -3,213 0,001694555 0,0495189 
10333_at TLR6 6,995 7,345 0,350 3,213 0,001699337 0,049599005 
11247_at NXPH4 4,366 4,286 -0,080 -3,212 0,001704708 0,049666481 
9031_at BAZ1B 6,267 6,100 -0,167 -3,211 0,001705734 0,049666481 
100996573_at 
LOC100996
573 4,194 4,424 0,230 3,210 0,001711278 0,049708832 
64854_at USP46 3,993 3,927 -0,066 -3,211 0,00171034 0,049708832 
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5.1.3 Supplementary Table III-2a: ES and rank scores for genes in the osteoclast 
differentiation pathway 
 
PROBE 
GENE  
SYMBOL GENE TITLE 
RANK IN 
GENE LIST RANK METRIC SCORE RUNNING ES 
3554 IL1R1 interleukin 1 receptor type 1 65 0.171 0.03331613 
5608 MAP2K6 
mitogen-activated protein kinase 
kinase 6 138 0.141 0.059910223 
353514 LILRA5 
leukocyte immunoglobulin like 
receptor A5 147 0.136 0.088175714 
1432 MAPK14 
mitogen-activated protein kinase 
14 166 0.131 0.1149766 
79168 LILRA6 
leukocyte immunoglobulin like 
receptor A6 176 0.130 0.14188443 
11027 LILRA2 
leukocyte immunoglobulin like 
receptor A2 189 0.128 0.1681944 
2353 FOS 
FBJ murine osteosarcoma viral 
oncogene homolog 196 0.126 0.1944211 
9846 GAB2 
GRB2 associated binding protein 
2 300 0.109 0.21313561 
4689 NCF4 neutrophil cytosolic factor 4 303 0.109 0.23599717 
3454 IFNAR1 
interferon alpha and beta 
receptor subunit 1 348 0.104 0.2560934 
5336 PLCG2 phospholipase C gamma 2 378 0.101 0.276099 
3460 IFNGR2 
interferon gamma receptor 2 
(interferon gamma transducer 1) 620 0.084 0.28368548 
7040 TGFB1 transforming growth factor beta 1 628 0.083 0.3008908 
1147 CHUK 
conserved helix-loop-helix 
ubiquitous kinase 633 0.083 0.31816998 
3553 IL1B interleukin 1 beta 831 0.074 0.32554778 
2355 FOSL2 FOS like antigen 2 875 0.072 0.33900252 
5595 MAPK3 
mitogen-activated protein kinase 
3 938 0.070 0.35114598 
5971 RELB 
v-rel avian reticuloendotheliosis 
viral oncogene homolog B 998 0.068 0.3629658 
11025 LILRB3 
leukocyte immunoglobulin like 
receptor B3 1007 0.068 0.37683624 
10326 SIRPB1 signal regulatory protein beta 1 1083 0.065 0.38731176 
2213 FCGR2B Fc fragment of IgG receptor IIb 1260 0.059 0.39250892 
3726 JUNB jun B proto-oncogene 1424 0.056 0.39744228 
11024 LILRA1 
leukocyte immunoglobulin like 
receptor A1 1428 0.055 0.40898195 
3455 IFNAR2 
interferon alpha and beta 
receptor subunit 2 1451 0.055 0.4196273 
7048 TGFBR2 
transforming growth factor beta 
receptor II 1622 0.051 0.42340788 
4688 NCF2 neutrophil cytosolic factor 2 1718 0.050 0.42992634 
5879 RAC1 
ras-related C3 botulinum toxin 
substrate 1 (rho family. small 
GTP binding protein Rac1) 1847 0.048 0.4346525 
10288 LILRB2 
leukocyte immunoglobulin like 
receptor B2 1864 0.048 0.44397527 
9021 SOCS3 
suppressor of cytokine signaling 
3 1868 0.047 0.45382264 
126014 OSCAR 
osteoclast associated. 
immunoglobulin-like receptor 1875 0.047 0.46352413 
6688 SPI1 Spi-1 proto-oncogene 1892 0.047 0.472775 
5603 MAPK13 
mitogen-activated protein kinase 
13 2005 0.046 0.47772962 
4791 NFKB2 
nuclear factor of kappa light 
polypeptide gene enhancer in B- 2331 0.041 0.4729852 
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cells 2 
5594 MAPK1 
mitogen-activated protein kinase 
1 2386 0.041 0.47931698 
5530 PPP3CA 
protein phosphatase 3 catalytic 
subunit alpha 2388 0.041 0.48783866 
140885 SIRPA signal regulatory protein alpha 2443 0.040 0.4940357 
207 AKT1 
v-akt murine thymoma viral 
oncogene homolog 1 2494 0.040 0.50027627 
2885 GRB2 
growth factor receptor bound 
protein 2 2495 0.040 0.50858384 
5290 PIK3CA 
phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic 
subunit alpha 2875 0.036 0.5003934 
5294 PIK3CG 
phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic 
subunit gamma 2905 0.035 0.5066097 
3459 IFNGR1 interferon gamma receptor 1 2912 0,035 0.5137642 
5291 PIK3CB 
phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic 
subunit beta 3347 0.031 0.5023933 
695 BTK Bruton tyrosine kinase 3363 0.031 0.50832057 
6850 SYK spleen tyrosine kinase 3543 0.030 0.5072015 
23533 PIK3R5 
phosphoinositide-3-kinase 
regulatory subunit 5 3572 0.030 0.5122718 
4792 NFKBIA NFKB inhibitor alpha 3611 0.029 0.51688164 
23118 TAB2 
TGF-beta activated kinase 
1/MAP3K7 binding protein 2 3759 0.028 0.5167917 
11006 LILRB4 
leukocyte immunoglobulin like 
receptor B4 4079 0.026 0.50916827 
3552 IL1A interleukin 1 alpha 4735 0.023 0.48688638 
5293 PIK3CD 
phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic 
subunit delta 4877 0.022 0.48569188 
1436 CSF1R 
colony stimulating factor 1 
receptor 4895 0.022 0.48961207 
1435 CSF1 colony stimulating factor 1 5131 0.021 0.48429412 
2212 FCGR2A Fc fragment of IgG receptor IIa 5183 0.021 0.48653117 
2354 FOSB 
FBJ murine osteosarcoma viral 
oncogene homolog B 5227 0.020 0.489058 
1513 CTSK cathepsin K 5313 0.020 0.4897568 
23547 LILRA4 
leukocyte immunoglobulin like 
receptor A4 5338 0.020 0.49295676 
6773 STAT2 
signal transducer and activator of 
transcription 2 5357 0.020 0.4963886 
8600 TNFSF11 
tumor necrosis factor superfamily 
member 11 5429 0.020 0.49756795 
7124 TNF tumor necrosis factor 5491 0.019 0.49910983 
8517 IKBKG 
inhibitor of kappa light 
polypeptide gene enhancer in B-
cells. kinase gamma 5925 0.018 0.4848992 
7132 TNFRSF1A 
tumor necrosis factor receptor 
superfamily member 1A 6076 0.017 0.48227096 
10859 LILRB1 
leukocyte immunoglobulin like 
receptor B1 6626 0.015 0.46270847 
5602 MAPK10 
mitogen-activated protein kinase 
10 6914 0.014 0.45378423 
9020 MAP3K14 
mitogen-activated protein kinase 
kinase kinase 14 7306 0.013 0.44028223 
5468 PPARG 
peroxisome proliferator activated 
receptor gamma 7382 0.012 0.4397952 
7297 TYK2 tyrosine kinase 2 7497 0.012 0.4376258 
5296 PIK3R2 
phosphoinositide-3-kinase 
regulatory subunit 2 8233 0.010 0.4093378 
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7046 TGFBR1 
transforming growth factor beta 
receptor I 8247 0.010 0.41089284 
54 ACP5 
acid phosphatase 5, tartrate 
resistant 8331 0.010 0.40949705 
5604 MAP2K1 
mitogen-activated protein kinase 
kinase 1 8566 0.009 0.4017148 
1536 CYBB 
cytochrome b-245, beta 
polypeptide 8994 0.008 0.38569617 
3716 JAK1 Janus kinase 1 9242 0.007 0.37696484 
27035 NOX1 NADPH oxidase 1 9245 0.007 0.37836218 
6772 STAT1 
signal transducer and activator of 
transcription 1 9809 0.006 0.35626137 
7189 TRAF6 TNF receptor associated factor 6 10091 0.005 0.34565714 
10990 LILRB5 
leukocyte immunoglobulin like 
receptor B5 10289 0.004 0.33840805 
10454 TAB1 
TGF-beta activated kinase 
1/MAP3K7 binding protein 1 10722 0.003 0.32122055 
4286 MITF 
microphthalmia-associated 
transcription factor 10752 0.003 0.3206776 
3937 LCP2 lymphocyte cytosolic protein 2 11148 0.002 0.30478245 
5609 MAP2K7 
mitogen-activated protein kinase 
kinase 7 11217 0.002 0.30236506 
5970 RELA 
v-rel avian reticuloendotheliosis 
viral oncogene homolog A 11324 0.002 0.29832092 
50508 NOX3 NADPH oxidase 3 11453 0.001 0.29330757 
799 CALCR calcitonin receptor 11690 676501775160.431 0.28369245 
7305 TYROBP 
TYRO protein tyrosine kinase 
binding protein 11734 580195977818.220 0.28203657 
5534 PPP3R1 
protein phosphatase 3 regulatory 
subunit B, alpha 12668 -0.002 0.24382015 
7186 TRAF2 TNF receptor associated factor 2 12718 -0.002 0.24217357 
5601 MAPK9 
mitogen-activated protein kinase 
9 12958 -0.002 0.23281395 
1535 CYBA 
cytochrome b-245, alpha 
polypeptide 13154 -0.003 0.22538179 
5599 MAPK8 
mitogen-activated protein kinase 
8 13156 -0.003 0.22597149 
5532 PPP3CB 
protein phosphatase 3 catalytic 
subunit beta 13268 -0.003 0.22207832 
4772 NFATC1 
nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-
dependent 1 13278 -0.003 0.22240824 
3551 IKBKB 
inhibitor of kappa light 
polypeptide gene enhancer in B-
cells, kinase beta 13462 -0.004 0.21565863 
8792 TNFRSF11A 
tumor necrosis factor receptor 
superfamily member 11a 13917 -0.005 0.19794624 
10379 IRF9 interferon regulatory factor 9 14897 -0.008 0.15908806 
3725 JUN jun proto-oncogene 15414 -0.009 0.13970372 
2214 FCGR3A Fc fragment of IgG receptor IIIa 15528 -0.010 0.13704884 
5535 PPP3R2 
protein phosphatase 3 regulatory 
subunit B, beta 15735 -0.010 0.13069208 
4790 NFKB1 
nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1 16234 -0.012 0.11257468 
208 AKT2 
v-akt murine thymoma viral 
oncogene homolog 2 16396 -0.012 0.10849883 
1540 CYLD CYLD lysine 63 deubiquitinase 16402 -0.012 0.11088098 
6300 MAPK12 
mitogen-activated protein kinase 
12 16696 -0.013 0.101556025 
1385 CREB1 
cAMP responsive element 
binding protein 1 16888 -0.014 0.09659159 
7042 TGFB2 transforming growth factor beta 2 17253 -0.015 0.08476528 
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4982 TNFRSF11B 
tumor necrosis factor receptor 
superfamily member 11b 18244 -0.019 0.047831133 
5600 MAPK11 
mitogen-activated protein kinase 
11 18296 -0.019 0.049762312 
8061 FOSL1 FOS like antigen 1 18329 -0.019 0.05251048 
54209 TREM2 
triggering receptor expressed on 
myeloid cells 2 18434 -0.020 0.05238389 
8878 SQSTM1 sequestosome 1 18660 -0.021 0.047468197 
3690 ITGB3 integrin subunit beta 3 18670 -0.021 0.05149536 
3456 IFNB1 interferon, beta 1, fibroblast 18854 -0.022 0.04850237 
8651 SOCS1 
suppressor of cytokine signaling 
1 18962 -0.022 0.04874891 
2274 FHL2 four and a half LIM domains 2 19338 -0.024 0.038252965 
29760 BLNK B-cell linker 20260 -0.029 0.006221308 
8503 PIK3R3 
phosphoinositide-3-kinase 
regulatory subunit 3 20858 -0.033 -0.011581848 
6885 MAP3K7 
mitogen-activated protein kinase 
kinase kinase 7 21388 -0.037 -0.025740072 
5533 PPP3CC 
protein phosphatase 3 catalytic 
subunit gamma 21783 -0.040 -0.03358892 
7006 TEC tec protein tyrosine kinase 22629 -0.050 -0.05809652 
3458 IFNG interferon, gamma 22656 -0.050 -0.04864443 
814 CAMK4 
calcium/calmodulin-dependent 
protein kinase IV 22717 -0.051 -0.040421534 
3727 JUND jun D proto-oncogene 22846 -0.053 -0.034606956 
55423 SIRPG signal regulatory protein gamma 23277 -0.060 -0.039750647 
5295 PIK3R1 
phosphoinositide-3-kinase 
regulatory subunit 1 23370 -0.063 -0.030401625 
3932 LCK 
LCK proto-oncogene, Src family 
tyrosine kinase 23498 -0.066 -0.02180087 
2534 FYN 
FYN proto-oncogene, Src family 
tyrosine kinase 23689 -0.072 -0.014592583 
4773 NFATC2 
nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-
dependent 2 24078 -0.091 -0.011586786 
10000 AKT3 
v-akt murine thymoma viral 
oncogene homolog 3 24179 -0.101 0.005498807 
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5.1.4 Supplementary Table III-2b: Es and rank scores for genes in the MAP kinase 
signaling pathway 
 
PROBE GENE  
SYMBOL 
GENE TITLE RANK IN 
GENE LIST 
RANK METRIC SCORE RUNNING ES 
3554 IL1R1 interleukin 1 receptor type 1 65 0,171 0.020782057 
5608 MAP2K6 mitogen-activated protein kinase 
kinase 6 
138 0.141 0.0370774 
7850 IL1R2 interleukin 1 receptor type 2 143 0.138 0.055797216 
1432 MAPK14 mitogen-activated protein kinase 
14 
166 0.131 0.07284942 
2353 FOS FBJ murine osteosarcoma viral 
oncogene homolog 
196 0.126 0.08891255 
6655 SOS2 SOS Ras/Rho guanine 
nucleotide exchange factor 2 
218 0.121 0.104645476 
4215 MAP3K3 mitogen-activated protein kinase 
kinase kinase 3 
286 0.111 0.11709238 
4217 MAP3K5 mitogen-activated protein kinase 
kinase kinase 5 
294 0.110 0.13186273 
1843 DUSP1 dual specificity phosphatase 1 359 0.103 0.1433498 
6416 MAP2K4 mitogen-activated protein kinase 
kinase 4 
418 0.099 0.15444621 
9693 RAPGEF2 Rap guanine nucleotide 
exchange factor 2 
505 0.091 0.16338848 
10746 MAP3K2 mitogen-activated protein kinase 
kinase kinase 2 
570 0.086 0.17257577 
7040 TGFB1 transforming growth factor beta 
1 
628 0.083 0.18161775 
1147 CHUK conserved helix-loop-helix 
ubiquitous kinase 
633 0.083 0.19282994 
9448 MAP4K4 mitogen-activated protein kinase 
kinase kinase kinase 4 
653 0.082 0.20326643 
9252 RPS6KA5 ribosomal protein S6 kinase A5 659 0.082 0.21423402 
785 CACNB4 calcium voltage-gated channel 
auxiliary subunit beta 4 
662 0.081 0.22530486 
115727 RASGRP4 RAS guanyl releasing protein 4 751 0.077 0.23226441 
5058 PAK1 p21 protein (Cdc42/Rac)-
activated kinase 1 
801 0.075 0.24050967 
3553 IL1B interleukin 1 beta 831 0.074 0.24942917 
5595 MAPK3 mitogen-activated protein kinase 
3 
938 0.070 0.25461605 
5971 RELB v-rel avian reticuloendotheliosis 
viral oncogene homolog B 
998 0.068 0.26146445 
1845 DUSP3 dual specificity phosphatase 3 1047 0.066 0.26854336 
5894 RAF1 Raf-1 proto-oncogene. 
serine/threonine kinase 
1185 0.062 0.27131084 
9261 MAPKAPK2 mitogen-activated protein 
kinase-activated protein kinase 
2 
1187 0.062 0.27971923 
3310 HSPA6 heat shock protein family A 
(Hsp70) member 6 
1257 0.059 0.28500193 
4763 NF1 neurofibromin 1 1590 0.052 0.27833423 
7048 TGFBR2 transforming growth factor beta 
receptor II 
1622 0.051 0.28409615 
8569 MKNK1 MAP kinase interacting 
serine/threonine kinase 1 
1744 0.049 0.28582168 
5879 RAC1 ras-related C3 botulinum toxin 
substrate 1 (rho family, small 
GTP binding protein Rac1) 
1847 0.048 0.28811663 
8822 FGF17 fibroblast growth factor 17 2001 0.046 0.2880137 
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51776 ZAK sterile alpha motif and leucine 
zipper containing kinase AZK 
2003 0.046 0.29422808 
5603 MAPK13 mitogen-activated protein kinase 
13 
2005 0.046 0.30043858 
2872 MKNK2 MAP kinase interacting 
serine/threonine kinase 2 
2024 0.045 0.30591595 
1649 DDIT3 DNA damage inducible 
transcript 3 
2093 0.044 0.30917093 
8649 LAMTOR3 late endosomal/lysosomal 
adaptor, MAPK and MTOR 
activator 3 
2151 0.044 0.3127749 
5606 MAP2K3 mitogen-activated protein kinase 
kinase 3 
2165 0.043 0.31818688 
4791 NFKB2 nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 2 
2331 0.041 0.31699857 
4616 GADD45B growth arrest and DNA damage 
inducible beta 
2381 0.041 0.32055372 
5594 MAPK1 mitogen-activated protein kinase 
1 
2386 0.041 0.3259737 
5530 PPP3CA protein phosphatase 3 catalytic 
subunit alpha 
2388 0.041 0.33151746 
3305 HSPA1L heat shock protein family A 
(Hsp70) member 1 like 
2440 0.040 0.33489907 
207 AKT1 v-akt murine thymoma viral 
oncogene homolog 1 
2494 0.040 0.338115 
2885 GRB2 growth factor receptor bound 
protein 2 
2495 0.040 0.34353375 
7867 MAPKAPK3 mitogen-activated protein 
kinase-activated protein kinase 
3 
2524 0.039 0.3477451 
5495 PPM1B protein phosphatase, 
Mg2+/Mn2+ dependent 1B 
2635 0.038 0.34840533 
1398 CRK v-crk avian sarcoma virus CT10 
oncogene homolog 
2855 0.036 0.3442015 
5321 PLA2G4A phospholipase A2 group IVA 2924 0.035 0.34619147 
6788 STK3 serine/threonine kinase 3 3129 0.033 0.34227455 
777 CACNA1E calcium voltage-gated channel 
subunit alpha1 E 
3257 0.032 0.34138742 
1326 MAP3K8 mitogen-activated protein kinase 
kinase kinase 8 
3336 0.031 0.3424407 
8491 MAP4K3 mitogen-activated protein kinase 
kinase kinase kinase 3 
3688 0.029 0.33181953 
23118 TAB2 TGF-beta activated kinase 
1/MAP3K7 binding protein 2 
3759 0.028 0.33281556 
998 CDC42 cell division cycle 42 3976 0.027 0.3275475 
100506
012 
PPP5D1 PPP5 tetratricopeptide repeat 
domain containing 1 
4494 0.024 0.30936128 
3552 IL1A interleukin 1 alpha 4735 0.023 0.30251586 
4909 NTF4 neurotrophin 4 4793 0.023 0.30323958 
5494 PPM1A protein phosphatase, 
Mg2+/Mn2+ dependent 1A 
4811 0.022 0.30561456 
5922 RASA2 RAS p21 protein activator 2 4950 0.022 0.30286506 
57551 TAOK1 TAO kinase 1 5188 0.021 0.29584628 
776 CACNA1D calcium voltage-gated channel 
subunit alpha1 D 
5260 0.020 0.29568303 
6195 RPS6KA1 ribosomal protein S6 kinase A1 5269 0.020 0.2981331 
5566 PRKACA protein kinase cAMP-activated 
catalytic subunit alpha 
5305 0.020 0.29943135 
1647 GADD45A growth arrest and DNA damage 
inducible alpha 
5394 0.020 0.29847705 
4914 NTRK1 neurotrophic tyrosine kinase, 
receptor, type 1 
5417 0.020 0.30025205 
51347 TAOK3 TAO kinase 3 5455 0.019 0.30138317 
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7124 TNF tumor necrosis factor 5491 0.019 0.3025791 
5062 PAK2 p21 protein (Cdc42/Rac)-
activated kinase 2 
5807 0.018 0.2919633 
8517 IKBKG inhibitor of kappa light 
polypeptide gene enhancer in B-
cells, kinase gamma 
5925 0.018 0.28950813 
5871 MAP4K2 mitogen-activated protein kinase 
kinase kinase kinase 2 
6029 0.017 0.28758138 
9064 MAP3K6 mitogen-activated protein kinase 
kinase kinase 6 
6064 0.017 0.28850526 
7132 TNFRSF1A tumor necrosis factor receptor 
superfamily member 1A 
6076 0.017 0.29037887 
6789 STK4 serine/threonine kinase 4 6110 0.017 0.29131868 
2261 FGFR3 fibroblast growth factor receptor 
3 
6142 0.017 0.29232207 
23162 MAPK8IP3 mitogen-activated protein kinase 
8 interacting protein 3 
6216 0.016 0.2915352 
1852 DUSP9 dual specificity phosphatase 9 6222 0.016 0.29357326 
773 CACNA1A calcium voltage-gated channel 
subunit alpha1 A 
6323 0.016 0.2916168 
2318 FLNC filamin C 6459 0.015 0.28812844 
6197 RPS6KA3 ribosomal protein S6 kinase A3 6613 0.015 0.2838213 
4137 MAPT microtubule associated protein 
tau 
6864 0.014 0.2753741 
5602 MAPK10 mitogen-activated protein kinase 
10 
6914 0.014 0.2752562 
3304 HSPA1B heat shock protein family A 
(Hsp70) member 1B 
6916 0.014 0.27713326 
22808 MRAS muscle RAS oncogene homolog 6955 0.014 0.2774519 
4214 MAP3K1 mitogen-activated protein kinase 
kinase kinase 1, E3 ubiquitin 
protein ligase 
6999 0.014 0.2775414 
2250 FGF5 fibroblast growth factor 5 7016 0.014 0.2787467 
23542 MAPK8IP2 mitogen-activated protein kinase 
8 interacting protein 2 
7106 0.013 0.27686986 
5923 RASGRF1 Ras protein specific guanine 
nucleotide releasing factor 1 
7245 0.013 0.27289912 
5536 PPP5C protein phosphatase 5 catalytic 
subunit 
7261 0.013 0.27403453 
9020 MAP3K14 mitogen-activated protein kinase 
kinase kinase 14 
7306 0.013 0.27394313 
786 CACNG1 calcium voltage-gated channel 
auxiliary subunit gamma 1 
7332 0.013 0.27462947 
123745 PLA2G4E phospholipase A2 group IVE 7375 0.012 0.2745915 
779 CACNA1S calcium voltage-gated channel 
subunit alpha1 S 
7444 0.012 0.27344596 
51295 ECSIT ECSIT signalling integrator 7501 0.012 0.27277595 
2264 FGFR4 fibroblast growth factor receptor 
4 
7521 0.012 0.27363333 
255189 PLA2G4F phospholipase A2 group IVF 7725 0.011 0.26675865 
7043 TGFB3 transforming growth factor beta 
3 
7767 0.011 0.2666023 
3845 KRAS Kirsten rat sarcoma viral 
oncogene homolog 
7881 0.011 0.26341197 
3303 HSPA1A heat shock protein family A 
(Hsp70) member 1A 
7924 0.011 0.26315668 
6722 SRF serum response factor 8002 0.011 0.26141968 
5579 PRKCB protein kinase C beta 8045 0.011 0.26111805 
27091 CACNG5 calcium voltage-gated channel 
auxiliary subunit gamma 5 
8222 0.010 0.25517792 
7046 TGFBR1 transforming growth factor beta 
receptor I 
8247 0.010 0.25554523 
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1850 DUSP8 dual specificity phosphatase 8 8272 0.010 0.25589928 
781 CACNA2D1 calcium voltage-gated channel 
auxiliary subunit alpha2delta 1 
8450 0.009 0.24981655 
5604 MAP2K1 mitogen-activated protein kinase 
kinase 1 
8566 0.009 0.24627095 
5582 PRKCG protein kinase C gamma 8656 0.009 0.24377425 
5598 MAPK7 mitogen-activated protein kinase 
7 
8937 0.008 0.23322345 
3164 NR4A1 nuclear receptor subfamily 4 
group A member 1 
9087 0.007 0.22805755 
355 FAS Fas cell surface death receptor 9102 0.007 0.22849573 
5159 PDGFRB platelet derived growth factor 
receptor beta 
9167 0.007 0.22683215 
5155 PDGFB platelet derived growth factor 
subunit B 
9402 0.007 0.21801947 
6196 RPS6KA2 ribosomal protein S6 kinase A2 9453 0.006 0.21683216 
10369 CACNG2 calcium voltage-gated channel 
auxiliary subunit gamma 2 
9578 0.006 0.21252409 
1950 EGF epidermal growth factor 9891 0.005 0.20028965 
5906 RAP1A RAP1A, member of RAS 
oncogene family 
9912 0.005 0.20018657 
5778 PTPN7 protein tyrosine phosphatase, 
non-receptor type 7 
9954 0.005 0.19919538 
7189 TRAF6 TNF receptor associated factor 
6 
10091 0.005 0.19420373 
4296 MAP3K11 mitogen-activated protein kinase 
kinase kinase 11 
10155 0.005 0.1922232 
7786 MAP3K12 mitogen-activated protein kinase 
kinase kinase 12 
10230 0.004 0.18975316 
5801 PTPRR protein tyrosine phosphatase, 
receptor type R 
10265 0.004 0.18893495 
25780 RASGRP3 RAS guanyl releasing protein 3 10428 0.004 0.18274246 
1956 EGFR epidermal growth factor receptor 10477 0.004 0.18126664 
2259 FGF14 fibroblast growth factor 14 10495 0.004 0.18107389 
2249 FGF4 fibroblast growth factor 4 10589 0.004 0.17768899 
2255 FGF10 fibroblast growth factor 10 10657 0.003 0.17536317 
59284 CACNG7 calcium voltage-gated channel 
auxiliary subunit gamma 7 
10666 0.003 0.17548849 
8823 FGF16 fibroblast growth factor 16 10685 0.003 0.17519331 
8605 PLA2G4C phospholipase A2 group IVC 10702 0.003 0.17497443 
10454 TAB1 TGF-beta activated kinase 
1/MAP3K7 binding protein 1 
10722 0.003 0.17462389 
673 BRAF B-Raf proto-oncogene, 
serine/threonine kinase 
10732 0.003 0.17468572 
9344 TAOK2 TAO kinase 2 10905 0.003 0.16790885 
778 CACNA1F calcium voltage-gated channel 
subunit alpha1 F 
11063 0.002 0.16169725 
27330 RPS6KA6 ribosomal protein S6 kinase A6 11077 0.002 0.16146623 
409 ARRB2 arrestin, beta 2 11155 0.002 0.15854761 
5609 MAP2K7 mitogen-activated protein kinase 
kinase 7 
11217 0.002 0.15626918 
4342 MOS v-mos Moloney murine sarcoma 
viral oncogene homolog 
11244 0.002 0.15543768 
8986 RPS6KA4 ribosomal protein S6 kinase A4 11249 0.002 0.15551914 
1846 DUSP4 dual specificity phosphatase 4 11319 0.002 0.15287302 
5970 RELA v-rel avian reticuloendotheliosis 
viral oncogene homolog A 
11324 0.002 0.15292749 
10368 CACNG3 calcium voltage-gated channel 
auxiliary subunit gamma 3 
11336 0.002 0.15268724 
5568 PRKACG protein kinase cAMP-activated 
catalytic subunit gamma 
11476 0.001 0.14708045 
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8074 FGF23 fibroblast growth factor 23 11491 0.001 0.14666532 
1386 ATF2 activating transcription factor 2 11560 0.001 0.14397849 
8912 CACNA1H calcium voltage-gated channel 
subunit alpha1 H 
11822 359000000000.000 0.13317935 
1844 DUSP2 dual specificity phosphatase 2 11865 268000000000.000 0.13147035 
2252 FGF7 fibroblast growth factor 7 12005 -293000000000.000 0.1256969 
2122 MECOM MDS1 and EVI1 complex locus 12351 -895000000000.000 0.11147986 
8911 CACNA1I calcium voltage-gated channel 
subunit alpha1 I 
12371 -950000000000.000 0.110820375 
84867 PTPN5 protein tyrosine phosphatase, 
non-receptor type 5 
12426 -0.001 0.10872375 
5534 PPP3R1 protein phosphatase 3 
regulatory subunit B, alpha 
12668 -0.002 0.09894022 
2256 FGF11 fibroblast growth factor 11 12712 -0.002 0.09739785 
7186 TRAF2 TNF receptor associated factor 
2 
12718 -0.002 0.097437434 
627 BDNF brain-derived neurotrophic factor 12831 -0.002 0.09307656 
774 CACNA1B calcium voltage-gated channel 
subunit alpha1 B 
12953 -0.002 0.08838522 
5601 MAPK9 mitogen-activated protein kinase 
9 
12958 -0.002 0.08855926 
5156 PDGFRA platelet derived growth factor 
receptor alpha 
12970 -0.003 0.088446036 
408 ARRB1 arrestin, beta 1 13040 -0.003 0.085947625 
5599 MAPK8 mitogen-activated protein kinase 
8 
13156 -0.003 0.08157931 
8817 FGF18 fibroblast growth factor 18 13158 -0.003 0.0819501 
5532 PPP3CB protein phosphatase 3 catalytic 
subunit beta 
13268 -0.003 0.07787359 
4772 NFATC1 nuclear factor of activated T-
cells, cytoplasmic. calcineurin-
dependent 1 
13278 -0.003 0.0779574 
4208 MEF2C myocyte enhancer factor 2C 13444 -0.004 0.07162491 
3551 IKBKB inhibitor of kappa light 
polypeptide gene enhancer in B-
cells, kinase beta 
13462 -0.004 0.07145085 
5881 RAC3 ras-related C3 botulinum toxin 
substrate 3 (rho family, small 
GTP binding protein Rac3) 
13610 -0.004 0.06592801 
784 CACNB3 calcium voltage-gated channel 
auxiliary subunit beta 3 
13910 -0.005 0.054186627 
836 CASP3 caspase 3 13927 -0.005 0.054217048 
2263 FGFR2 fibroblast growth factor receptor 
2 
13965 -0.005 0.053389404 
4915 NTRK2 neurotrophic tyrosine kinase, 
receptor, type 2 
14153 -0.006 0.046392094 
9965 FGF19 fibroblast growth factor 19 14163 -0.006 0.046795897 
3306 HSPA2 heat shock protein family A 
(Hsp70) member 2 
14436 -0.006 0.036369722 
9254 CACNA2D2 calcium voltage-gated channel 
auxiliary subunit alpha2delta 2 
14605 -0.007 0.030336963 
2253 FGF8 fibroblast growth factor 8 14787 -0.007 0.02382762 
2257 FGF12 fibroblast growth factor 12 14946 -0.008 0.018339701 
2317 FLNB filamin B 14952 -0.008 0.019213421 
2246 FGF1 fibroblast growth factor 1 15035 -0.008 0.016920274 
2251 FGF6 fibroblast growth factor 6 15046 -0.008 0.017624982 
5605 MAP2K2 mitogen-activated protein kinase 
kinase 2 
15068 -0.008 0.017882572 
3725 JUN jun proto-oncogene 15414 -0.009 0.0048143677 
7157 TP53 tumor protein p53 15485 -0.009 0.0032063094 
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8913 CACNA1G calcium voltage-gated channel 
subunit alpha1 G 
15498 -0.010 0.004012888 
27006 FGF22 fibroblast growth factor 22 15562 -0.010 0.0027241355 
5535 PPP3R2 protein phosphatase 3 
regulatory subunit B, beta 
15735 -0.010 -0.003015929 
2258 FGF13 fibroblast growth factor 13 15853 -0.011 -
0.0064195893 
9175 MAP3K13 mitogen-activated protein kinase 
kinase kinase 13 
15930 -0.011 -0.008082654 
59283 CACNG8 calcium voltage-gated channel 
auxiliary subunit gamma 8 
15935 -0.011 -
0.0067516705 
3925 STMN1 stathmin 1 15986 -0.011 -
0.0073111122 
283748 PLA2G4D phospholipase A2 group IVD 16072 -0.011 -0.009293311 
4893 NRAS neuroblastoma RAS viral (v-ras) 
oncogene homolog 
16097 -0.011 -0.008728041 
929 CD14 CD14 molecule 16137 -0.011 -0.008775188 
4790 NFKB1 nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1 
16234 -0.012 -0.011152871 
208 AKT2 v-akt murine thymoma viral 
oncogene homolog 2 
16396 -0.012 -0.016161518 
6300 MAPK12 mitogen-activated protein kinase 
12 
16696 -0.013 -0.026770143 
55799 CACNA2D3 calcium voltage-gated channel 
auxiliary subunit alpha2delta 3 
16828 -0.014 -0.0303306 
5154 PDGFA platelet derived growth factor 
subunit A 
17163 -0.015 -0.04216443 
7042 TGFB2 transforming growth factor beta 
2 
17253 -0.015 -0.043761365 
775 CACNA1C calcium voltage-gated channel 
subunit alpha1 C 
17345 -0.016 -0.045399915 
2260 FGFR1 fibroblast growth factor receptor 
1 
17433 -0.016 -0.046826407 
783 CACNB2 calcium voltage-gated channel 
auxiliary subunit beta 2 
17523 -0.016 -0.048285425 
356 FASLG Fas ligand 17675 -0.017 -0.052241728 
1847 DUSP5 dual specificity phosphatase 5 17817 -0.017 -0.05571387 
5921 RASA1 RAS p21 protein activator 1 17902 -0.018 -0.056783155 
2248 FGF3 fibroblast growth factor 3 17997 -0.018 -0.058220573 
5880 RAC2 ras-related C3 botulinum toxin 
substrate 2 (rho family, small 
GTP binding protein Rac2) 
18039 -0.018 -0.057432074 
3265 HRAS Harvey rat sarcoma viral 
oncogene homolog 
18212 -0.019 -0.06198983 
5600 MAPK11 mitogen-activated protein kinase 
11 
18296 -0.019 -0.06280471 
93589 CACNA2D4 calcium voltage-gated channel 
auxiliary subunit alpha2delta 4 
18463 -0.020 -0.066966355 
2002 ELK1 ELK1, ETS transcription factor 18612 -0.021 -0.07028573 
26291 FGF21 fibroblast growth factor 21 18656 -0.021 -0.06921322 
782 CACNB1 calcium voltage-gated channel 
auxiliary subunit beta 1 
19411 -0.024 -0.09723639 
27092 CACNG4 calcium voltage-gated channel 
auxiliary subunit gamma 4 
19460 -0.024 -0.09588268 
11221 DUSP10 dual specificity phosphatase 10 19490 -0.025 -0.09372384 
4149 MAX MYC associated factor X 19730 -0.026 -0.1001044 
2768 GNA12 G protein subunit alpha 12 19786 -0.026 -0.09879063 
2316 FLNA filamin A 19849 -0.027 -0.097732104 
80824 DUSP16 dual specificity phosphatase 16 19874 -0.027 -0.09507861 
4908 NTF3 neurotrophin 3 20061 -0.028 -0.099036135 
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6654 SOS1 SOS Ras/Rac guanine 
nucleotide exchange factor 1 
20067 -0.028 -0.0954683 
2247 FGF2 fibroblast growth factor 2 20865 -0.033 -0.12410476 
55970 GNG12 G protein subunit gamma 12 20973 -0.033 -0.12396019 
9479 MAPK8IP1 mitogen-activated protein kinase 
8 interacting protein 1 
21026 -0.034 -0.121482514 
1616 DAXX death-domain associated protein 21057 -0.034 -0.11806048 
8550 MAPKAPK5 mitogen-activated protein 
kinase-activated protein kinase 
5 
21337 -0.036 -0.12468304 
6885 MAP3K7 mitogen-activated protein kinase 
kinase kinase 7 
21388 -0.037 -0.12173034 
1848 DUSP6 dual specificity phosphatase 6 21523 -0.038 -0.12211614 
4775 NFATC3 nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent 3 
21541 -0.038 -0.11762262 
5533 PPP3CC protein phosphatase 3 catalytic 
subunit gamma 
21783 -0.040 -0.12213398 
51701 NLK nemo-like kinase 21823 -0.041 -0.11820009 
4803 NGF nerve growth factor 21850 -0.041 -0.11369464 
5908 RAP1B RAP1B, member of RAS 
oncogene family 
21950 -0.042 -0.11211199 
2254 FGF9 fibroblast growth factor 9 21957 -0.042 -0.10665579 
1399 CRKL v-crk avian sarcoma virus CT10 
oncogene homolog-like 
22015 -0.042 -0.103234515 
11184 MAP4K1 mitogen-activated protein kinase 
kinase kinase kinase 1 
22226 -0.044 -0.1058782 
26281 FGF20 fibroblast growth factor 20 22234 -0.045 -0.100065276 
1849 DUSP7 dual specificity phosphatase 7 22435 -0.047 -0.10194425 
10912 GADD45G growth arrest and DNA damage 
inducible gamma 
22725 -0.051 -0.10696277 
5613 PRKX protein kinase, X-linked 22746 -0.051 -0.100766316 
10235 RASGRP2 RAS guanyl releasing protein 2 22764 -0.052 -0.094406635 
5607 MAP2K5 mitogen-activated protein kinase 
kinase 5 
22776 -0.052 -0.08776823 
468 ATF4 activating transcription factor 4 22810 -0.052 -0.08197386 
3727 JUND jun D proto-oncogene 22846 -0.053 -0.076184146 
4216 MAP3K4 mitogen-activated protein kinase 
kinase kinase 4 
22904 -0.054 -0.07119045 
5578 PRKCA protein kinase C alpha 23050 -0.056 -0.06953261 
3312 HSPA8 heat shock protein family A 
(Hsp70) member 8 
23066 -0.056 -0.062442154 
4609 MYC v-myc avian myelocytomatosis 
viral oncogene homolog 
23176 -0.058 -0.059011027 
994 CDC25B cell division cycle 25B 23215 -0.059 -0.052543826 
22800 RRAS2 related RAS viral (r-ras) 
oncogene homolog 2 
23250 -0.059 -0.04581202 
6237 RRAS related RAS viral (r-ras) 
oncogene homolog 
23415 -0.064 -0.043904167 
3315 HSPB1 heat shock protein family B 
(small) member 1 
23488 -0.066 -0.03790336 
5567 PRKACB protein kinase cAMP-activated 
catalytic subunit beta 
23795 -0.076 -0.040178865 
5924 RASGRF2 Ras protein specific guanine 
nucleotide releasing factor 2 
23835 -0.078 -0.03115253 
10125 RASGRP1 RAS guanyl releasing protein 1 23842 -0.078 -0.020726288 
59285 CACNG6 calcium voltage-gated channel 
auxiliary subunit gamma 6 
24026 -0.087 -0.016403418 
10000 AKT3 v-akt murine thymoma viral 
oncogene homolog 3 
24179 -0.101 -0.008880179 
2005 ELK4 ELK4, ETS transcription factor 24204 -0.105 0.0044891406 
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5.1.5 Supplementary Table III-2c: ES and rank scores for genes in the chemokine 
signaling pathway 
PROBE GENE  
SYMBOL 
GENE TITLE RANK IN 
GENE LIST 
RANK METRIC SCORE RUNNING ES 
6655 SOS2 SOS Ras/Rho guanine 
nucleotide exchange factor 2 
218 0.121 0.011438798 
6777 STAT5B signal transducer and activator 
of transcription 5B 
314 0.107 0.025648568 
3717 JAK2 Janus kinase 2 326 0.106 0.04311809 
5580 PRKCD protein kinase C delta 367 0.102 0.058749933 
7409 VAV1 vav guanine nucleotide 
exchange factor 1 
411 0.099 0.07365365 
10451 VAV3 vav guanine nucleotide 
exchange factor 3 
444 0.096 0.08849276 
3055 HCK HCK proto-oncogene, Src family 
tyrosine kinase 
512 0.091 0.10106315 
58191 CXCL16 C-X-C motif chemokine ligand 
16 
593 0.085 0.11215416 
6774 STAT3 signal transducer and activator 
of transcription 3 (acute-phase 
response factor) 
626 0.083 0.124904655 
1147 CHUK conserved helix-loop-helix 
ubiquitous kinase 
633 0.083 0.13868468 
3576 CXCL8 C-X-C motif chemokine ligand 8 652 0.082 0.15178001 
3577 CXCR1 chemokine (C-X-C motif) 
receptor 1 
756 0.077 0.16056749 
5058 PAK1 p21 protein (Cdc42/Rac)-
activated kinase 1 
801 0.075 0.17142072 
1230 CCR1 chemokine (C-C motif) receptor 
1 
882 0.072 0.18030214 
5595 MAPK3 mitogen-activated protein kinase 
3 
938 0.070 0.18984975 
2185 PTK2B protein tyrosine kinase 2 beta 963 0.069 0.20055221 
2783 GNB2 G protein subunit beta 2 970 0.069 0.21195896 
57580 PREX1 phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac 
exchange factor 1 
983 0.068 0.2230366 
94235 GNG8 G protein subunit gamma 8 999 0.068 0.2338696 
5894 RAF1 Raf-1 proto-oncogene, 
serine/threonine kinase 
1185 0.062 0.23663521 
1794 DOCK2 dedicator of cytokinesis 2 1367 0.057 0.23871137 
7454 WAS Wiskott-Aldrich syndrome 1396 0.056 0.24701689 
54331 GNG2 G protein subunit gamma 2 1462 0.055 0.25356865 
10344 CCL26 C-C motif chemokine ligand 26 1501 0.054 0.26109427 
2870 GRK6 G protein-coupled receptor 
kinase 6 
1507 0.054 0.26997265 
6366 CCL21 C-C motif chemokine ligand 21 1557 0.053 0.27685428 
1237 CCR8 chemokine (C-C motif) receptor 
8 
1719 0.050 0.27857915 
4067 LYN LYN proto-oncogene, Src family 
tyrosine kinase 
1740 0.049 0.2860978 
156 ADRBK1 adrenergic, beta, receptor 
kinase 1 
1789 0.049 0.2923229 
5879 RAC1 ras-related C3 botulinum toxin 
substrate 1 (rho family, small 
GTP binding protein Rac1) 
1847 0.048 0.29801714 
2826 CCR10 chemokine (C-C motif) receptor 
10 
1873 0.047 0.30498856 
9844 ELMO1 engulfment and cell motility 1 1977 0.046 0.30849022 
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2932 GSK3B glycogen synthase kinase 3 beta 2042 0.045 0.31345806 
10850 CCL27 C-C motif chemokine ligand 27 2116 0.044 0.3178718 
59345 GNB4 G protein subunit beta 4 2172 0.043 0.3229155 
5330 PLCB2 phospholipase C beta 2 2209 0.043 0.32867756 
7852 CXCR4 chemokine (C-X-C motif) 
receptor 4 
2288 0.042 0.33254147 
5594 MAPK1 mitogen-activated protein kinase 
1 
2386 0.041 0.33540875 
207 AKT1 v-akt murine thymoma viral 
oncogene homolog 1 
2494 0.040 0.33765525 
2885 GRB2 growth factor receptor bound 
protein 2 
2495 0.040 0.34433612 
23236 PLCB1 phospholipase C beta 1 2637 0.038 0.34494045 
2919 CXCL1 C-X-C motif chemokine ligand 1 2688 0.038 0.34923044 
2784 GNB3 G protein subunit beta 3 2838 0.036 0.34912714 
1398 CRK v-crk avian sarcoma virus CT10 
oncogene homolog 
2855 0.036 0.35450387 
5290 PIK3CA phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic 
subunit alpha 
2875 0.036 0.35973102 
5294 PIK3CG phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic 
subunit gamma 
2905 0.035 0.3644924 
5829 PXN paxillin 2949 0.035 0.3686076 
2787 GNG5 G protein subunit gamma 5 2970 0.035 0.37363783 
2773 GNAI3 G protein subunit alpha i3 3027 0.034 0.3770849 
51764 GNG13 G protein subunit gamma 13 3062 0.034 0.38139 
2309 FOXO3 forkhead box O3 3194 0.033 0.38147116 
196883 ADCY4 adenylate cyclase 4 3284 0.032 0.38315174 
5291 PIK3CB phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic 
subunit beta 
3347 0.031 0.3858678 
23533 PIK3R5 phosphoinositide-3-kinase 
regulatory subunit 5 
3572 0.030 0.3815928 
6346 CCL1 C-C motif chemokine ligand 1 3577 0.030 0.38643363 
6093 ROCK1 Rho associated coiled-coil 
containing protein kinase 1 
3601 0.029 0.39046004 
4792 NFKBIA NFKB inhibitor alpha 3611 0.029 0.3950577 
2869 GRK5 G protein-coupled receptor 
kinase 5 
3673 0.029 0.3974369 
998 CDC42 cell division cycle 42 3976 0.027 0.3894948 
3579 CXCR2 chemokine (C-X-C motif) 
receptor 2 
4221 0.026 0.38372058 
6375 XCL1 X-C motif chemokine ligand 1 4311 0.025 0.38428256 
2920 CXCL2 C-X-C motif chemokine ligand 2 4392 0.025 0.38512826 
6357 CCL13 C-C motif chemokine ligand 13 4448 0.024 0.38696355 
5590 PRKCZ protein kinase C zeta 4520 0.024 0.3880743 
2793 GNGT2 G protein subunit gamma 
transducin 2 
4557 0.024 0.3906022 
6370 CCL25 C-C motif chemokine ligand 25 4647 0.023 0.39084518 
6369 CCL24 C-C motif chemokine ligand 24 4711 0.023 0.39210945 
5293 PIK3CD phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic 
subunit delta 
4877 0.022 0.3889987 
7410 VAV2 vav guanine nucleotide 
exchange factor 2 
4971 0.022 0.38880992 
6714 SRC SRC proto-oncogene, non-
receptor tyrosine kinase 
5039 0.021 0.3896404 
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2791 GNG11 G protein subunit gamma 11 5080 0.021 0.39155492 
729230 CCR2 chemokine (C-C motif) receptor 
2 
5156 0.021 0.39196363 
5566 PRKACA protein kinase cAMP-activated 
catalytic subunit alpha 
5305 0.020 0.3892242 
6773 STAT2 signal transducer and activator 
of transcription 2 
5357 0.020 0.3904689 
7074 TIAM1 T-cell lymphoma invasion and 
metastasis 1 
5382 0.020 0.3928156 
8517 IKBKG inhibitor of kappa light 
polypeptide gene enhancer in B-
cells, kinase gamma 
5925 0.018 0.3733217 
114 ADCY8 adenylate cyclase 8 (brain) 5980 0.017 0.3740253 
6367 CCL22 C-C motif chemokine ligand 22 6170 0.017 0.36899358 
10563 CXCL13 C-X-C motif chemokine ligand 
13 
6344 0.016 0.36452243 
5331 PLCB3 phospholipase C beta 3 6392 0.016 0.36523885 
3718 JAK3 Janus kinase 3 6470 0.015 0.36465907 
2770 GNAI1 G protein subunit alpha i1 6689 0.015 0.3581151 
3627 CXCL10 C-X-C motif chemokine ligand 
10 
6817 0.014 0.35527328 
6376 CX3CL1 C-X3-C motif chemokine ligand 
1 
7008 0.014 0.3497077 
53358 SHC3 SHC (Src homology 2 domain 
containing) transforming protein 
3 
7035 0.014 0.3509181 
6355 CCL8 C-C motif chemokine ligand 8 7050 0.013 0.35261673 
2931 GSK3A glycogen synthase kinase 3 
alpha 
7108 0.013 0.3525012 
6356 CCL11 C-C motif chemokine ligand 11 7316 0.013 0.34605935 
6363 CCL19 C-C motif chemokine ligand 19 7355 0.013 0.3466018 
111 ADCY5 adenylate cyclase 5 7380 0.012 0.34771082 
6372 CXCL6 C-X-C motif chemokine ligand 6 7790 0.011 0.332659 
131890 GRK7 G protein-coupled receptor 
kinase 7 
7843 0.011 0.33237827 
6351 CCL4 C-C motif chemokine ligand 4 7869 0.011 0.333206 
3845 KRAS Kirsten rat sarcoma viral 
oncogene homolog 
7881 0.011 0.33460745 
108 ADCY2 adenylate cyclase 2 (brain) 7906 0.011 0.3354586 
5579 PRKCB protein kinase C beta 8045 0.011 0.33151978 
5296 PIK3R2 phosphoinositide-3-kinase 
regulatory subunit 2 
8233 0.010 0.32545877 
2833 CXCR3 chemokine (C-X-C motif) 
receptor 3 
8555 0.009 0.31368193 
5604 MAP2K1 mitogen-activated protein kinase 
kinase 1 
8566 0.009 0.3147893 
5332 PLCB4 phospholipase C beta 4 8628 0.009 0.31375664 
2788 GNG7 G protein subunit gamma 7 8852 0.008 0.30589187 
25759 SHC2 SHC (Src homology 2 domain 
containing) transforming protein 
2 
8886 0.008 0.30588698 
4283 CXCL9 C-X-C motif chemokine ligand 9 9001 0.008 0.30247337 
2771 GNAI2 G protein subunit alpha i2 9066 0.008 0.3010968 
6011 GRK1 G protein-coupled receptor 
kinase 1 
9380 0.007 0.28925955 
9547 CXCL14 C-X-C motif chemokine ligand 
14 
9646 0.006 0.27929038 
6772 STAT1 signal transducer and activator 
of transcription 1 
9809 0.006 0.27352232 
5906 RAP1A RAP1A, member of RAS 9912 0.005 0.27019283 
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oncogene family 
387 RHOA ras homolog family member A 10036 0.005 0.26593232 
113 ADCY7 adenylate cyclase 7 10039 0.005 0.2666855 
6359 CCL15 C-C motif chemokine ligand 15 10219 0.004 0.26002115 
8976 WASL Wiskott-Aldrich syndrome-like 10581 0.004 0.24565682 
2786 GNG4 G protein subunit gamma 4 10726 0.003 0.24022906 
673 BRAF B-Raf proto-oncogene, 
serine/threonine kinase 
10732 0.003 0.24055928 
2782 GNB1 G protein subunit beta 1 10923 0.003 0.23313293 
409 ARRB2 arrestin, beta 2 11155 0.002 0.2239069 
6347 CCL2 C-C motif chemokine ligand 2 11281 0.002 0.21901819 
5970 RELA v-rel avian reticuloendotheliosis 
viral oncogene homolog A 
11324 0.002 0.21754967 
6361 CCL17 C-C motif chemokine ligand 17 11411 0.001 0.21422556 
5568 PRKACG protein kinase cAMP-activated 
catalytic subunit gamma 
11476 0.001 0.2117836 
6846 XCL2 X-C motif chemokine ligand 2 11557 0.001 0.20864157 
115 ADCY9 adenylate cyclase 9 11968 406000000000.000 0.19165644 
399694 SHC4 SHC (Src homology 2 domain 
containing) family member 4 
12309 -814000000000.000 0.17770317 
408 ARRB1 arrestin, beta 1 13040 -0.003 0.14790472 
1234 CCR5 chemokine (C-C motif) receptor 
5 (gene/pseudogene) 
13443 -0.004 0.13189231 
109 ADCY3 adenylate cyclase 3 13460 -0.004 0.13188377 
3551 IKBKB inhibitor of kappa light 
polypeptide gene enhancer in B-
cells, kinase beta 
13462 -0.004 0.1324989 
6374 CXCL5 C-X-C motif chemokine ligand 5 13672 -0.004 0.124585435 
2921 CXCL3 C-X-C motif chemokine ligand 3 13713 -0.005 0.12369324 
6354 CCL7 C-C motif chemokine ligand 7 14434 -0.006 0.09493738 
2785 GNG3 G protein subunit gamma 3 14542 -0.007 0.09163805 
643 CXCR5 chemokine (C-X-C motif) 
receptor 5 
14694 -0.007 0.086586766 
6387 CXCL12 C-X-C motif chemokine ligand 
12 
14804 -0.007 0.083330095 
6360 CCL16 C-C motif chemokine ligand 16 15905 -0.011 0.039571855 
2790 GNG10 G protein subunit gamma 10 15970 -0.011 0.03878284 
4893 NRAS neuroblastoma RAS viral (v-ras) 
oncogene homolog 
16097 -0.011 0.035487734 
56288 PARD3 par-3 family cell polarity 
regulator 
16112 -0.011 0.03684071 
4790 NFKB1 nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1 
16234 -0.012 0.033814088 
107 ADCY1 adenylate cyclase 1 (brain) 16333 -0.012 0.03179537 
5747 PTK2 protein tyrosine kinase 2 16352 -0.012 0.03310246 
208 AKT2 v-akt murine thymoma viral 
oncogene homolog 2 
16396 -0.012 0.033395663 
9475 ROCK2 Rho associated coiled-coil 
containing protein kinase 2 
16677 -0.013 0.024024887 
6464 SHC1 SHC (Src homology 2 domain 
containing) transforming protein 
1 
16835 -0.014 0.019848317 
9564 BCAR1 breast cancer anti-estrogen 
resistance 1 
17243 -0.015 0.005563962 
6364 CCL20 C-C motif chemokine ligand 20 17262 -0.015 0.0074141626 
2268 FGR FGR proto-oncogene, Src family 
tyrosine kinase 
17474 -0.016 0.0013939511 
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112 ADCY6 adenylate cyclase 6 17643 -0.017 -0.0027322304 
6373 CXCL11 C-X-C motif chemokine ligand 
11 
17720 -0.017 -0.0029982238 
4793 NFKBIB NFKB inhibitor beta 17845 -0.017 -0.0051811957 
5880 RAC2 ras-related C3 botulinum toxin 
substrate 2 (rho family, small 
GTP binding protein Rac2) 
18039 -0.018 -0.010106646 
2868 GRK4 G protein-coupled receptor 
kinase 4 
18178 -0.019 -0.012657629 
3265 HRAS Harvey rat sarcoma viral 
oncogene homolog 
18212 -0.019 -0.010830374 
56477 CCL28 C-C motif chemokine ligand 28 18321 -0.019 -0.012042116 
9560 CCL4L2 chemokine (C-C motif) ligand 4-
like 2 
18413 -0.020 -0.012476725 
10681 GNB5 G protein subunit beta 5 18422 -0.020 -0.009464691 
6362 CCL18 C-C motif chemokine ligand 18 19436 -0.024 -0.047339834 
2792 GNGT1 G protein subunit gamma 
transducin 1 
19444 -0.024 -0.043516282 
2829 XCR1 chemokine (C motif) receptor 1 19618 -0.025 -0.046407893 
6348 CCL3 C-C motif chemokine ligand 3 19870 -0.027 -0.052312125 
5473 PPBP pro-platelet basic protein 19878 -0.027 -0.048095997 
6654 SOS1 SOS Ras/Rac guanine 
nucleotide exchange factor 1 
20067 -0.028 -0.05123237 
1235 CCR6 chemokine (C-C motif) receptor 
6 
20479 -0.030 -0.063173026 
414062 CCL3L3 C-C motif chemokine ligand 3 
like 3 
20678 -0.032 -0.06605019 
8503 PIK3R3 phosphoinositide-3-kinase 
regulatory subunit 3 
20858 -0.033 -0.06793623 
55970 GNG12 G protein subunit gamma 12 20973 -0.033 -0.06699931 
157 ADRBK2 adrenergic, beta, receptor 
kinase 2 
21587 -0.038 -0.08592737 
1232 CCR3 chemokine (C-C motif) receptor 
3 
21687 -0.039 -0.083379544 
10803 CCR9 chemokine (C-C motif) receptor 
9 
21808 -0.040 -0.08151908 
5908 RAP1B RAP1B, member of RAS 
oncogene family 
21950 -0.042 -0.08033809 
1399 CRKL v-crk avian sarcoma virus CT10 
oncogene homolog-like 
22015 -0.042 -0.07585135 
5197 PF4V1 platelet factor 4 variant 1 22069 -0.043 -0.07082176 
6368 CCL23 C-C motif chemokine ligand 23 22305 -0.045 -0.07289121 
5196 PF4 platelet factor 4 22562 -0.049 -0.07526246 
5613 PRKX protein kinase, X-linked 22746 -0.051 -0.07418207 
10235 RASGRP2 RAS guanyl releasing protein 2 22764 -0.052 -0.06617448 
5295 PIK3R1 phosphoinositide-3-kinase 
regulatory subunit 1 
23370 -0.063 -0.080670804 
10663 CXCR6 chemokine (C-X-C motif) 
receptor 6 
23489 -0.066 -0.07445463 
1524 CX3CR1 chemokine (C-X3-C motif) 
receptor 1 
23618 -0.069 -0.06806984 
5567 PRKACB protein kinase cAMP-activated 
catalytic subunit beta 
23795 -0.076 -0.06248832 
1233 CCR4 chemokine (C-C motif) receptor 
4 
23964 -0.083 -0.055463944 
3702 ITK IL2 inducible T-cell kinase 24051 -0.089 -0.043997724 
10000 AKT3 v-akt murine thymoma viral 
oncogene homolog 3 
24179 -0.101 -0.032196235 
1236 CCR7 chemokine (C-C motif) receptor 
7 
24186 -0.103 -0.015113599 
6352 CCL5 C-C motif chemokine ligand 5 24257 -0.120 0.002279398 
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